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that CA IX-C-4.16 was more effective in inhibiting growth of A498 (WT and Ev-res) and to less 
extent (C) UOK262 (WT and Ev-res) RCC cell lines than sorafenib and Ev and support that C-
4.16 was more potent than FDA approved drugs (sorafenib and everolimus). (D) We summarized 
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1. CHAPTER 1: LITERATURE REVIEW 
1.1.Renal Cell Carcinoma (RCC) 
Urologic malignancies of the kidney are responsible for 1.62 % of all cancer deaths in the 
United States 2. Also, an age-adjusted incidence rates have elevated approximately 2-3% annually 
over the past 30 years 3–6.  In 2018, there will be an estimated 65,340 new cases of RCC and over 
14,970 deaths 7. Kidney cancer incidence increased from 1997 to 2008 before leveling off 8. The 
increase in incidence since late 1990s reflects a rapid increase in early stage disease that has been 
associated in part with incidental diagnosis during abdominal imaging and may not represent a real 
increase in cancer occurrence 9. The overall mortality rate has fallen an average of 0.6 percent each 
year since 2001 as shown in Figure 1.1. The expected RCC incidence and mortality rates in 2018 
are double as high in men (42,680 cases)  versus women ( 22,660 cases) 7. Kidney cancer is now 
the 6th highest occurring cancer in the US and has been continually increasing with over 14,970 
patients expected to die from this disease in 2018 7. The fivefold rise in incidence is because of 
many factors, such as smoking, obesity, exposure to some environmental agents, renal failure, and 
hypertension. The advances in detection technology are likely a result of the widespread utilization 
of sensitive imaging such as ultrasonography and computed tomography (CT) for diagnosis of 
abdominal or gastrointestinal complaints8. 
The most common cancer of the kidney with 72% of all cases is the renal cell carcinoma 
(RCC). RCC is heterogeneous in nature and progression of the disease has been difficult to monitor 
despite the existence of prognostic scoring systems based on conventional clinical and pathological 
indices 10. RCC is derived from renal tubular epithelial cells and considered as one of the ten 
highest common cancers worldwide 11,12.  RCC is lethal urologic malignancy as approximately 
third of patients would have developed visceral metastasis during the diagnosis and half of the 
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remaining patients would eventually progress to distant metastases 13. Survival data of a 
population-based cancer indicated that more than 40% of patients with RCC would die from the 
disease 14–16, in comparison with bladder and prostate cancers which have approximately half the 
mortality rates 17–20. 
 
Figure 1.1. US kidney cancer incidence and mortality. Estimated age-standardized rates of incidence for 
both sexes (per 100,000 people) between 1990-2011. Rates are generally higher in males with the higher 
mortality rates. Reproduced with permission from Surveillance, Epidemiology, and End Results (SEER) 
Program and the National Center for Health Statistics. 
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1.1.1. Histological Types of RCCs  
since 1990s, significant efforts from researchers and clinicians have been devoted to 
promoting the understanding of how molecular genetics drive RCC pathogenesis. The 
advancement of research in the histopathological and molecular characterization of RCC disease 
over the past few years have resulted into major revisions in its subtype classification 11,12,21,22. 
RCC is a heterogeneous malignancy and involves many different histological subtypes 23, each of 
which is distinguished from the other subtypes by the (i) location of the renal tubular epithelium 
from which it originates, (ii) the genetic mutations involved in its occurrence, and (iii) the 
particular clinical options and outcome of the disease 24,25 as shown in Table 1.1. As shown in 
Figure 1.2 , Primary RCC subtypes  with ≥5% incidence are clear cell RCC (ccRCC) , papillary 
RCC (pRCC), and Chromophobe RCC (chRCC) 26. Along with ccRCC, other recognized 
histological sub-classifications are Type 1 (5%) and Type 2 (10%) papillary RCC, chromophobe 
tumors (4-5%) and collecting duct/medullary cell tumors (<1%) as shown in Figure 1.2 21,27. The 
other subtypes are very rare (each with total incidence ≤1%) 22. Also, other known familial 
syndromes that might lead to renal tumors have been identified alongside RCC that arise 
sporadically. These hereditary subtypes of RCC have a meager rate (approximately 5%)  of 
occurrence and that involve: (i) Von Hippel-Lindau (VHL) disease; (ii) hereditary papillary renal 
cell carcinoma (HPRC); (iii) hereditary leiomyomatosis renal cancer (HLRC); and (iv) Birt-Hogg-
Dube (BHD) syndrome 28. Each genetic subtype has characteristic molecular changes, which are 
often indicated development of specific histopathological features 29. Molecular genetic 
understanding of hereditary cases contributes a significant insight into the molecular mechanisms 
causing cancer initiation and progression. This knowledge particularly would improve the 
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understanding of sporadic RCC and can possibly be converted into the more promising therapeutic 
approach for RCC.  
1.1.2. Clear Cell Renal Cell Carcinoma 
Clear cell RCC is the most common class, and the majority of deaths from kidney cancer 
are  from this type, and ccRCC will be the focus of this Dissertation 30. Indeed, considering the 
predominance of ccRCC histological manifestations in metastatic disease (83–88%) 31,32, tumors 
with non-clear cell histology have been named as non-clear renal cell carcinoma ‘nccRCC’ (Table 
1.1) 33–35. Likewise, recent cancer genome reports have explained an apparent complexity of intra-
tumor 36–38 and inter-tumor 27,39 heterogeneity in ccRCC, which could contribute to the 
heterogeneous clinical outcomes observed 21,28,40. Approximately 75% of all clear cell RCC is 
correlated with the inactivating VHL gene mutation. Papillary RCC often correlated with the 
activation of the Met proto-oncogene and chromosome trisomy while the other histological types 
do not have well-defined genetic mutation. Table 1.1 and Figure 1.2 provide a summary of tumor 
suppressor genes and oncogenes that might be the leading cause for development of familial and 
sporadic RCC 23,41–44. Recently, five new frequently mutated genes associated with the clear cell 
RCC were identified. These genes encode four other proteins; KDM6A/UTX, SETD2, 
KDM5C/JARID1C and MLL229 which are essential for the methylation and demethylation 
process of histone residues and consequently control gene transcription. 
Table 1.1. Classification of renal cell carcinoma (RCC) and their associated molecular alterations in 
hereditary syndromes associated with renal cell carcinoma. Adapted with permission from 8. 
 
Syndrome 
(phenotype 
OMIM 
reference)  
Gene 
(position)  
Protein  Incidence of 
developing a 
kidney tumor 
(%)  
Median age at 
diagnosis 
(years)  
Other phenotypic 
features  
Clear cell renal cell carcinoma*  
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von Hippel–
Lindau disease 
(193300)  
VHL (3p25–
26)  
pVHL  25–45  40   
Hemangioblastoma  
Pancreatic 
neuroendocrine 
tumors  
Pheochromocytoma  
Renal Cysts  
Pancreatic Cysts  
Ovary cystadenoma  
Epididymal 
cystadenoma  
 
BAP1 mutant 
disease (also 
known as tumor 
predisposition 
disease; 
614327)  
BAP1 
(3p21)  
BRCA-associated 
protein  
No data  No data   
Breast cancer  
Uveal melanoma  
Mesothelioma  
Other cutaneous 
melanocytic tumors  
 
SDH-associated 
kidney cancer 
(185470, 
602413, 602690 
and 115310)  
SDHB 
(1p36), 
SDHC 
(1q23) and 
SDHD 
(11q23)  
Succinate 
dehydrogenase 
subunits B, C and D  
5–15  30   
Paraganglioma  
Carotid body tumors  
Pheochromocytoma  
Gastrointestinal 
stromal tumor  
 
Papillary renal cell carcinoma  
Hereditary 
leiomyomatosis 
and renal cell 
cancer (150800) 
‡  
FH (1q43)  Fumarate 
hydratase  
2–21  46   
Uterine 
leiomyosarcomas  
Breast cancer  
Bladder cancer  
Cutaneous 
leiomyomas  
Uterine leiomyomas  
 
Hereditary 
papillary kidney 
cancer (605074) 
§  
MET (7q31)  Hepatocyte growth 
factor receptor  
No data  <60  No additional 
features  
Multiple tumor types  
Birt–Hogg–Dubé 
syndrome 
(135150)||  
FLCN 
(17p11.2)  
Folliculin  34  50   
Fibrofolliculomas 
and trichodiscomas  
Pulmonary cysts  
Pneumothorax  
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Tuberous 
sclerosis 
complex 
(191100 and 
191092) ¶  
TSC1 
(9q34) and 
TSC2 
(16p13)  
Hamartin and 
tuberin  
2–4  30   
Subependymal giant 
cell astrocytomas  
Angiomyolipomas  
Renal Cysts  
Facial angiofibroma  
Ungual and 
periungual fibromas  
Hypomelanotic 
macule  
Forehead plaque  
Cardiac 
rhabdomyomas  
Connective tissue 
naevus  
 
Cowden 
syndrome (also 
known as 
multiple 
hamartoma 
syndrome; 
158350) #  
PTEN 
(10q23)  
Phosphatase and 
tensin homologue  
34  40   
Breast cancer  
Endometrial cancer  
Thyroid cancer  
Prostate cancer  
Macrocephaly  
Intestinal 
hamartomatous 
polyps  
Benign skin tumors 
(multiple 
trichilemmomas, 
papillomatous 
papules, and acral 
keratoses)  
Dysplastic 
gangliocytoma of the 
cerebellum  
 
Hyperparathyroi
dism jaw tumor 
syndrome 
(145001) **  
HRPT2 
(1q31)  
Parafibromin  No data  No data   
Parathyroid 
carcinomas  
Uterine carcinomas  
Renal cysts and 
hamartomas  
Hyperparathyroidis
m  
Parathyroid gland 
tumors  
Jaw fibromas  
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Figure 1.2. Distinct subtypes and distribution of common histological subtypes of renal cell carcinoma 
(RCCs). Different types of RCC have different histology and clinical courses and caused by a different 
gene profiles. Tumors are accompanied with a significantly poorer prognosis. BHD=Birt-Hogg-Dubé; 
FH=fumarate hydratase; VHL=von Hippel-Lindau. Approximately 75% of RCCs are clear cell RCC. 
Papillary RCCs make up ~15% of all kidney Cancers and are divided into two types based on staining 
features: type 1 (basophilic) and type 2 (eosinophilic). Chromophobe RCCs make up ~5% of kidney tumors.  
Additional minor subtypes include medullary RCC, clear cell papillary RCC, acquired cystic disease-
associated RCC, tubulocystic RCC, mucinous tubular and spindle RCC, succinate dehydrogenase-deficient 
RCC, hereditary leiomyomatosis, RCC-associated RCC, and Oncocytoma. Tumors not fitting into any of 
these categories are designated as unclassified RCC. Adapted from 25.  
 
1.1.3.  Clear Cell-RCC and Von Hippel-Lindau (VHL) Gene Mutation 
The most common form of RCC (more than 95%) is clear cell RCC (ccRCC). The mutation 
and inactivation of tumor suppressor VHL gene is frequently presented in this malignancy. The 
VHL gene is positioned on chromosome 3p25-26 and composed of three exons 35,38,45. It yields 2 
transcripts that translate to three proteins (pVHL). The common product (VHL30) is made up of 
213 amino acids with a molecular weight of approximately 24 to 30 kDa 46. A second isoform of 
pVHL (VHL19) contains 160 amino acids and is approximately 19 kDa 47–50. The two isoforms 
show tumor suppressor activity. Exon 2 is not existed in the second mRNA transcript due to 
another splicing and has been recognized to encode a defective protein with no tumor suppressor 
activity 51. Studies had shown that pVHL locates between the nucleus and cytoplasm 52–55 and 
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VHL30 is located mainly in the cytoplasm; however, VHL19 is located mainly inside the nucleus, 
revealing that the activities of both isoforms might overlap but are not similar 48,55. 
1.1.3.1. Functions of VHL 
The function of VHL and the ability to regulate and control protein expression at the post-
transcriptional level has been studied extensively. VHL works as substrate recognition component 
of an E3 ubiquitin ligase complex and it forms a stable complex and functions as a binding and 
substrate recognition component 56,57 for the ubiquitination of targeted proteins. As a result, 
covalent binding of polyubiquitin residues onto the specific site of substrate protein promotes 
proteasomal degradation of the target protein 58. For example, ligase-E3 complex ubiquitylates 
HIF1α and HIF2α for proteasome-mediated degradation 59–61. As shown in Figure 1.3, both HIF-
1α and HIF-1β subunits which are the heterodimeric HIF-1 are a sequence-specific DNA-binding 
transcription factor 62,63. The modulation of the expression of HIF-1α regulates the transcription 
function of HIF-1 as the subunit HIF-1β is expressed genetically in cells 64. The HIF subunits 
respond to changes in oxygen in the cellular environment and are unstable in normoxic 
microenvironments. Under normoxic conditions, the highly conserved proline residues inside the 
oxygen-dependent degradation (ODD) domain of HIF-1α subunit are hydroxylated 65–68. The 
asparagine sites at the COOH-terminal transactivation domain (CAD) of HIF-1α are further 
hydroxylated by an enzyme called asparaginyl hydroxylase, Factor Inhibiting HIF1 (FIH-1) 69. 
Hydroxylation of HIF-1α by FIH-1 inhibits the association of HIFs with the transcriptional 
coactivator CREB-binding protein (CBP)/p300; therefore, suppressing transcription activation. 
Alternately, HIF-1 binds to the β domain of pVHL, goes through polyubiquitination and 
subsequent degradation by the proteasome 70–72. Under hypoxic conditions, the pVHL-HIF 
interaction is disordered due to the lack of oxygen-dependent hydroxylation of particular proline 
9 
 
 
 
and asparagine residues on HIF-1α; as a result, leading to active stabilization and translocation of 
HIF-1 to the nucleus. The HIF-1 complex binds to hypoxia response elements (HREs) in the target 
gene promoter origins and activates transcription as shown in Figure 1.3. 
 
 
 
Figure 1.3. Schematic role of pVHL in Hypoxia-inducible factors (HIF) pathway. pVHL is the crucial 
part of an ubiquitin ligase protein complex that involves elongin C (EloC) and other partners. Under 
normoxic conditions HIFα is hydroxylated on two proline residues by prolyl hydroxylase 2 (PHD2), then 
conjugates to pHVL that targets it for ubiquitylation and proteasomal degradation. Under hypoxic 
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condition, HIF 1α is stabilized, binds to HIF1β and lead to expression of several downstream genes 
including VEGF, PDGFβ, TGFα and EPO. pVHL/HIF oxygen sensing pathway. HIFs are transcription 
factors that are affected by the changes in available oxygen in the cellular microenvironment. In conditions 
of physiologic oxygen availability and normal VHL gene function, pVHL is the substrate recognition 
component of an ubiquitin ligase complex that targets HIFs for proteolysis. In conditions of cellular 
hypoxia, the pVHL-HIF interaction is disrupted due to the loss of oxygen-dependent hydroxylation of 
specific proline residues on HIF, thus leading to active stabilization and translocation of HIF to the nucleus. 
When the VHL gene is defective, this interaction is dysfunctional even in the presence of adequate oxygen. 
As such, HIF is not subjected to proteolysis and this leads to constitutive activation of the hypoxia response 
pathway and transcriptional activation of genes involved in tumor proliferation. Adapted with permission  
from 73. 
 
1.1.3.2. VHL Inactivation 
VHL has the mutations in α- and β- domain which is responsible for abrogation of protein 
binding and degradation because of malfunction in assembly of the VHL ubiquitin complex. In 
RCC, all familial VHL-related, and around 75% of occasional cases, harbor the biallelic VHL 
functional inactivation through lack of heterozygosity, promoter methylation or intragenic deletion 
74–76. Because of the malfunction of VHL gene, the interaction between VHL-HIF-1 becomes 
defective despite the presence of adequate oxygen. Intrinsically, HIF-1 is not required for 
proteolysis, and this induces consequent activation of the hypoxia responsive pathway and genes 
transcriptional activation associated with tumor proliferation. Genes linked to short-term hypoxic 
condition involve inducible nitric oxide synthase (iNOS) to amplify vasodilation, glycolytic 
enzymes to elevate glycolysis, glucose transporter-1 (GLUT-1) to have more glucose uptake, 
pyruvate dehydrogenase kinase (PDK1) to block mitochondrial respiration, and cyclin-dependent 
kinase inhibitors p21 and p27 to minimize cell proliferation. When cells lack functional VHL gene, 
chronic cellular adaption is attained via the help of hypoxic condition by promoting angiogenesis. 
These pro-angiogenic genes are majorly controlled by HIF and involve vascular endothelial 
growth factor (VEGF) and its receptors (VEGFR), platelet-derived growth factor (PDGF), and 
basic fibroblast growth factor (bFGF). 
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The tumor suppressor function of VHL regulates the activity of hypoxia-inducible factor 
(HIF). As a result, lack of VHL gene will lead to the abnormal accumulation of HIF proteins even 
insufficiently oxygenated tissue microenvironment, which consequently results in uncontrolled 
activation of HIF target genes that control angiogenesis, glycolysis and apoptosis (Figure. 1.3). 
Subsequently, human ccRCC tumors are rich in lipids and glycogens, and are greatly vascular 77,78 
which makes anticancer agents that primarily block VEGF and its receptor VEGFR therapeutically 
active for metastatic ccRCC 33,34,79. VHL loss alone however is inadequate to produce ccRCC, as 
demonstrated by the long latency (>30 years) in patients who harbor VHL mutations to develop 
ccRCC 80 and by the fact that lack of VHL in mice does not cause ccRCC 81. These outcomes 
indicate that additional genetic and epigenetic events are apparently required for ccRCC to occur 
82. To recognize these events, large-scale RCC genomic research has thus far indicated multiple 
new prevalent mutations in ccRCC. Complete molecular characterization of more than 400 clear 
cell RCC tumors identified more than 19 genes with extensive mutations, some of which changed 
cell metabolism and correlated with poor survival, suggesting new opportunities for therapeutic 
targets 83. 
1.1.4.  Therapy Models of RCCs  
RCC is tough to treat as the cells are largely resistant to many current therapies. Surgery 
continues to be  the best treatment choice 8, although 20-30% of patients progress to develop 
metastatic disease. In case of early diagnosis, there is a high chance of the cancer going into 
remission but if the cancer does not respond to first-line therapies there are very limited secondary 
options 8,32,35,84,85. The most important treatment for many years has been cytokine therapy with 
interferon alpha (IFN-αa) and interleukin-2 (IL-2). There has been a host of new FDA approved 
chemotherapeutic agents now approved for treatment of metastatic RCC including tyrosine kinase 
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inhibitors, mTOR inhibitors, and monoclonal antibodies 86.  Currently, FDA approved treatments 
for metastatic RCC include (i) tyrosine kinase inhibitors (TKIs) such as sorafenib, sunitinib, and 
cabozantinib; (ii) mammalian target of rapamycin (mTOR) inhibitors such as temsirolimus and 
everolimus; and (iii) immunotherapeutic agents as PD-1/PD-L1 inhibitors.  
1.1.4.1.Surgery 
In some early stages of RCC, surgery by radical nephrectomy remains the best treatment 
choice for localized RCC, provided tumors can be excised with an appropriate surgical margin. 
Under this stage, the prognosis is excellent and hence, it is considered as the “gold standard” 
among treatment models. The surgery involves early ligation of the renal vessels, removing the 
kidney outside the Gerota's fascia, with or without removing of the adrenal gland depending on 
tumor sites and invasiveness score 87,88. Data and reports indicated that  5-year survival rate of 
75% or more after radical nephrectomy for stage I tumors are achieved 89,90. Even though, about 
third of the RCC cases that were treated with radical nephrectomy eventually experience a local 
recurrence or distant metastasis 91, with the incidence based on tumor stage and grade 92,93. If the 
kidney cancer is contained within the kidney, the cancer can be surgically removed with robotic 
partial nephrectomy. This surgery cuts out the cancer, and saves 50-75% of the remaining kidney, 
which can function sufficiently to keep the patient off hemodialysis. As reported earlier, about 
third of cases exhibit visceral metastasis at diagnosis time 94. The overall clinical prognosis differs 
from less than 1 year for approximately half of the cases  to more than 5 years for 10% of the 
patients 95.  
1.1.4.2.Chemotherapy and Radiotherapy 
Treatment options for metastatic RCC are insufficient because it is unresponsive to usual 
chemotherapeutic agents and radiotherapies; therefore, it remains one of the most difficult tumors 
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to treat 96,97. Over 30% of people who are diagnosed with renal cancers will have cancer spread 
outside the kidney to the lymph nodes or distant metastases. With new FDA approved 
chemotherapeutic agents now approved for treatment of metastatic RCC, the survival has still been 
low. Unfortunately, renal cancers cells are usually resistant to chemotherapy; therefore, chemo 
drugs are not a standard treatment option for RCC. Some chemo drugs, such as vinblastine, 
floxuridine, 5-fluorouracil (5-FU), capecitabine, and gemcitabine have been utilized and shown to 
benefit a small population of patients. Importantly, chemo is often only used for kidney cancer 
after targeted drugs and/or immunotherapy have already been tried and failed.  In the last few 
years, cytokine-based immunotherapy using interleukin (IL)-2 or interferon (IFN)-α have been the 
only therapy that have shown efficacy for metastatic RCC cases. However, it is still unsatisfactory 
option as only a low percentage of patients (10-15%) respond to this treatment type but often with 
severe side effects 98–101. 
1.1.4.3. Molecular targeted therapy for RCC 
VHL inactivation leads to higher intracellular level of hypoxia-inducible factors 1α and 2α 
(HIF1α and HIF2α). The increased level of HIF-1α in RCC effectively regulates the tumorigenesis 
by secreting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), 
modifying the cellular metabolism, inhibiting apoptosis pathway, acclimatizing to acidic pH, and 
up-regulating metastasis associated proteins. All these factors promote RCC to develop resistance 
against radiotherapy and conventional chemotherapy 2,32,85,102. Several receptor tyrosine kinase 
inhibitors (RTKIs), mammalian target of rapamycin inhibitors (mTOR) and serine-threonine 
kinase (STK) inhibitors are clinically approved for treatment of RCC 2,32, although the benefit of 
overall progression-free survival continues to be very poor (5-year survival rate of <10%).Thus, 
there is an urgent  need for targeted combination therapies with novel mechanisms 85. RCC is 
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generally difficult to treat since the cancer cells are largely resistant to currently available 
therapies. When RCC fails to respond to first-line therapies there are very limited secondary 
options. For example, everolimus (inhibitor of mTOR) is the first drug that was recently developed 
as a secondary treatment option for resistant RCC. It is very clear that newer and more effective 
treatment strategies for RCC are needed. In patients with an advanced form of RCC, targeted 
therapies including the ones using Everolimus resulted in improved clinical outcomes. However, 
patients ultimately develop resistance to this targeted therapy as well 103.  
It is known that the pVHL/HIF molecular pathway is a crucial factor in the pathogenesis 
of  cc-RCC 104–106. As previously also reported, biallelic VHL mutation or inactivation by 
methylation occurs in majority of cases (~75%) of sporadic clear cell RCC 74,75. Importantly, 
multiple strategies are being investigated to target the various aspects of this hypoxic sensing 
pathway and its associated molecules and growth factors. One strategy which has proven to be 
highly effective is the activity of agents that specifically target angiogenesis. RCC is manifested 
with highly vascular nature in both the primary and metastatic origins of the disease. This is 
because of the continuous overexpression of pro-angiogenic factors, VEGF 107 and PDGF, which 
are the most important factor in RCC tumor angiogenesis. The molecular association between 
VHL, VEGF, and hypoxia signaling pathway in the biology of cc-RCC has revealed the 
angiogenesis pathway as an important therapeutic approach. Moreover, the introduction of agents 
that target angiogenesis has advanced the treatment strategies and effectively improvise the 
management of patients with metastatic RCC. Significant advantages to patients include 
management of the cancer, improvement in the quality of life and increase the overall duration of 
survival 101,108–110.  
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Now, there are more than six molecular targeted therapeutic agents that have been 
approved by the US Food and Drug Administration (FDA) for treatment of metastatic RCC. They 
are (i) tyrosine kinase inhibitors (TKIs); sunitinib, sorafenib, pazopanib, and cabozantinib which 
inhibit the tyrosine kinase activation domain of vascular endothelial growth factor receptor 
(VEGFR) and platelet-derived growth factor receptor (PDGFR), (ii) mammalian target of 
rapamycin (mTOR) inhibitors temsirolimus and everolimus, and (iii) a monoclonal VEGF 
antibody, bevacizumab in combination with IFN-α (Figure 1.4 and 1.5). A summary of the clinical 
efficacies of these approved therapeutic agents is listed in Table 1.3.  
 
Figure 1.4. VHL inactivation in clear cell RCC and its implication in targeted therapy. Loss of VHL 
(which encodes pVHL) is the most frequent genetic feature of ccRCC. Its loss relieves the cell of negative 
regulation of the hypoxia-inducible factors (HIFs), which results in increased HIF target gene expression 
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and ensuing changes in cellular metabolism and signaling that enhance cell survival. For example, increased 
vascular endothelial growth factor (VEGF) expression increases angiogenesis in concert with increased 
growth factor signaling in endothelial cells in the tumor microenvironment (including fibroblast growth 
factor (FGF) and hepatocyte growth factor (HGF)). Consequently, these changes provide the targets for 
therapeutic agents to impede tumor growth, as shown. The dashed inhibitory line indicates indirect 
inhibition shown in limited reports. EIF4EBP1, eukaryotic translation initiation factor 4E‑binding protein 
1; FGFR, FGF receptor; HRE, HIF response element; MET, hepatocyte growth factor receptor; mTORC, 
mechanistic target of rapamycin complex; PI3K, phosphoinositide 3‑kinase; PTEN, phosphatase and tensin 
homologue; RHEB, GTP-binding protein Rheb; S6K1, ribosomal protein S6 kinase; TSC, tuberous 
sclerosis complex; VEGFR, VEGF receptor. Adapted with permission from 8 
 
 
Figure 1.5. Selected current targeted therapies in metastatic RCC. Modified from 111. 
1.1.4.4.Anti-Angiogenesis therapy  
 Antiangiogenic drugs that block the vascular endothelial growth factor receptor (VEGFR) 
pathway are now standard first-line treatment in metastatic RCC. They are also used sequentially 
to prolong clinical benefit in patients with recurrent disease 8,112,113. However, resistance to therapy 
ultimately emerges in most patients, and further understanding of the underlying biology and 
potential therapeutic targets are urgently needed for clinical translation 8. Everolimus is one such 
drug that was recently developed as a secondary treatment option for resistant RCCs 85,96,114. 
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However, resistance to newer drugs (including Everolimus) continues to emerge. Therefore, newer 
drug molecules with a different mechanism of action and novel targeted drug delivery approaches 
are needed to address the safety and efficacy of newer therapies. In addition, the introduction of 
several anticancer small molecule drugs (e.g., sunitinib, pazopanib, axitinib, temsirolimus, and 
everolimus) has rapidly changed the treatment of metastatic RCC 8,96,113. Although the impact on 
RCC progression is encouraging, a substantial proportion of patients do not respond sufficiently, 
and resistance to therapy almost inevitably occurs 102. Possibly combination treatments aimed at 
different, non-related pathways may be advantageous 85,115,116. Due to their increase in vascular 
nature and high level of vascular permeability factor or vascular endothelial growth factor (VEGF) 
expression, ccRCC patients show promising success with anti-VEGF cancer therapy. 
Unfortunately, most of cancer patients ultimately develop a refractory response to anti-VEGFR 
treatment over time. 
1.1.4.5.Immunotherapy for RCC 
On November of 2015, the FDA approved Nivolumab (Opdivo®) for the treating of 
patients with advanced metastatic RCC and who already have received a specific prior anti-
angiogenic cancer treatment. The FDA approval was based in part on an open-label, randomized 
clinical trial including 821 cases with advanced metastatic RCC. The trial included  those whose 
disease status had deteriorated after or while on therapeutic plan with an anti-angiogenic 
medications. A certain percentage of cases received Nivolumab, while the rest took everolimus 
(Afinitor®). The Nivolumab group had an overall survival rate of more than 25 months compared 
to 19.6 months in Everolimus group. Furthermore, complete or partial tumor growth suppression 
lasting an average of 23 months was seen in 21.5% RCC patients of the Nivolumab treatment arm, 
compared to 13.7 months in 3.9% of the Everolimus treatment arm 117. 
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Table 1.2. (A) A summary of approved targeted therapies for metastatic RCC. Modified from Hutson et 
al., 2011. Adapted with permission. (B) Clinical trials leading to newly approved drugs for advanced renal 
cell carcinoma. 
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1.1.5. Disadvantages and Limitations of Current Targeted Therapy 
Despite the treatment advantages of agents targeting anti-angiogenic pathways, mostly 
60% of the cases are non-responsive to these medications. Anti-angiogenic targeted agents are 
estimated to have less toxicity than conventional chemo and radiotherapy approach due to the 
higher dependence of cancerous cells on this pathway as compared to healthy cells. Also, they 
might cause significant side effects that need to minimize the dose; therefore, restricting its clinical 
utility and efficacy 118,119. For instance, up to third of cancer patients on sorafenib needed dose 
reduction and of these, 50% stopped treatment because of the side effects. Another disadvantage 
of anti-angiogenic targeted therapy is that many active oncogenic pathways is mostly involved in 
oncogenesis. The utilization of a single treatment class will invariably stimulate tumor cell 
adaption by releasing higher amount of the many targeted growth factors. 120. In view of the 
existing limitations of the current molecular single targeted therapy, sequential treatment with 
various targeted medications is advanced to be the standard strategy for the treatment. The efficacy 
of combination treatment strategy thus urgently need a better understanding of the biology of the 
cancer disease development, and mechanisms of action of the anticancer agents for effective 
utilization in combination.  
1.1.6. Combinations and Sequential Treatment for RCC   
Anticancer agents that are synergistic or additive would ensure higher inhibition of 
abnormal molecular target and their related signaling pathways. Moreover, combination therapy 
can bypass or hinder the development of resistance. In addition to finding molecular targets for 
RCC and anticancer agents that can work on these targets, another important need is to find a 
molecular biomarker that can predict therapeutic outcomes in RCC. Currently, classical clinical 
and pathologic indices provide reasonable evaluations of cancer patient response and disease 
20 
 
 
 
development 10 but are inadequate for patients’ disease management given the heterogeneous 
nature of RCC. In essence, there is a crucial need for potential molecular biomarker which can be 
used to detect disease remission after therapeutic intervention and improve the accuracy of current 
prognostic indices. Also, the biomarkers will complement classical pathological and clinical 
indices utilized in monitoring tumor progression and the disease status. Therefore, the need for a 
suitable therapeutic target and an ideal molecular biomarker to predict responses of treatment in 
RCC remain critical and unmet need. Importantly, a patient-derived RCC xenograft or PDX model 
can be utilized for preclinical drug evaluation to find molecular targeted biomarkers capable of 
estimating therapeutic efficacy response to the new agents 121. This approach will save time for 
finding new strategy and further pave the way into clinical translation. 
1.2. Carbonic Anhydrase IX Targeting in Renal Cell Carcinoma 
Carbonic anhydrase IX (CA IX) is a membrane-bound protein overexpressed on the surface 
of many cancer cells in a hypoxic environment 122. Carbonic anhydrase enzymes tightly control 
the acid-base balance in the kidney 122. CA IX is involved in tumor cell survival and metastasis, 
and increased expression correlates with poor clinical outcome. As shown in Figure 1.6 the over-
expression of CA IX has been demonstrated in 93-97% of ccRCC with limited expression in 
normal tissues/organs 123. Numerous studies have confirmed the CA IX distribution in normal 
tissues and malignancies 124–129. For renal cancer, CA IX is almost homogeneously expressed in 
the ccRCC subtype 84,111,124–129. Given the favorable tissue distribution, the potential of CA IX 
targeting of RCC for diagnosis or therapy has been studied extensively 130,131. Due to the unique 
molecular basis of ccRCC, CA IX is regarded as an excellent target for diagnosis and possibly for 
therapy 111,126–128,132. Clinical trials have unambiguously demonstrated that CA IX can be targeted 
in RCC tissues without damage to normal tissues133,134 However, there are no approved therapies 
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against CA IX 135. Monoclonal antibodies have been used to target CA IX, but their large molecular 
weight limits penetration throughout a poorly vascularized tumor and their slow blood clearance 
minimize their utilization as tumor imaging agents or radiotherapeutics because of high 
background and toxicity 134,132. Finally, the new therapeutic options have led to investigations that 
examine whether small molecule CA IX-inhibitors can be used in serum assays or as an imaging 
target to study whether CA IX monitoring can be useful to predict responses 127–129. The future 
will show whether the conjugation of CA IX as a targeting moiety can be helpful in the treatment 
and clinical management of metastatic RCC. 
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Figure 1.6. CA IX Expression and its role in cancer. Carbonic anhydrase IX (CA IX) which is a zinc 
containing metalloproteinase is efficiently catalyzes the reversible hydration of carbon dioxide. It is up-
regulated in several cancer types. It has an important role in tumor progression, acidification and metastasis. 
Figures modified and adapted from many references as shown above 136. 
 
1.3. CARP-1 Functional Mimetics as a promising molecule to target Everolimus 
Resistant Renal Cell Carcinoma Therapy  
CARP-1 (Cell cycle and apoptosis regulator 1, aka CCAR1) is a peri-nuclear phospho-
protein and a regulator of cell growth and apoptosis signaling CARP-1 (Cell cycle and apoptosis 
regulator 1, CCAR1) is a peri-nuclear phospho-protein and a regulator of cell growth and apoptosis 
signaling 137–140. CARP-1 not only works as a transcriptional co-activator of steroid family of 
nuclear receptors and a regulator of adipogenesis through the glucocorticoid receptor (GR), it also 
regulates Adriamycin (ADR)-dependent apoptosis in part through co-activation of p53 141,142. 
CARP-1 expression is often elevated in cells experiencing stress due to growth factor withdrawal 
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or chemotherapy-induced cell cycle arrest and apoptosis 137,138,141. Knockdown of CARP-1 resulted 
in resistance to apoptosis by ADR or EGFR tyrosine kinase inhibitors demonstrating the 
requirement of CARP-1 in cell growth inhibitory and apoptosis signaling by these agents 137,138,141. 
CARP-1 as shown in Figure 1.7 also works as a co-activator of the APC/C E3 ligase 139. APC/C 
is a multi-subunit ubiquitin E3 ligase protein that plays a distinct role in cell cycle transitions, and 
misregulation of APC/C substrates such as securin, polo-like kinase (Plk) has been demonstrated 
to correlate with tumor progression 143,144. A chemical biology-based high-throughput screening 
of a chemical library resulted in the identification of some novel, small molecule inhibitors (SMIs) 
of CARP-1 binding with APC/C subunit APC2. These compounds, termed CARP-1 functional 
mimetic (CFMs), inhibit cell growth by inducing apoptosis in various cancer types as the NCI 60-
panel screening indicated including non-small cell lung cancers (NSCLC), triple negative breast 
cancers (TNBC) and RCC 145. Recently, a promising library of a novel class of anticancer 
compounds termed CARP-1 functional mimetics (CFMs) that inhibit cell growth by various 
mechanisms such as inducing apoptosis has been developed for resistant RCC. In the case of renal 
cell carcinoma (RCC), antiangiogenic drugs that block the vascular endothelial growth factor 
receptor (VEGFR) pathway are now standard first-line treatment in metastatic RCC. They are also 
used sequentially to prolong clinical benefit in patients with recurrent disease 30. However, 
resistance to therapy ultimately emerges in most patients, and further understanding of the 
underlying biology and potential therapeutic targets are urgently needed for clinical translation 102. 
Everolimus is one such drug that was recently developed as a secondary treatment option for 
resistant RCCs 96,114. However, resistance to Everolimus continues to emerge. Therefore, newer 
drug molecules with a different mechanism of action and novel targeted drug delivery approaches 
need to be developed to address the safety and efficacy of newer therapies. Also, the molecular 
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complications of cancer manifestations and therapy-associated adverse effects often hinder the 
effectiveness of many therapies and warrant discovery of effective alternative therapy for certain 
molecular targets while minimizing the off-target effects. Therefore, the objective of most research 
worldwide is to develop novel, safe and effective anti-cancer therapies and that is the focus of this 
dissertation. One of these targets for drug discovery is CARP-1 that is an inhibitor of cell growth 
and survival, as well as an inducer of apoptosis signaling.  
 
Figure 1.7. A Schematic representation of CARP-1/CCAR1 Apoptosis Signaling. Adapted from 140. 
1.3.1.  Combination therapy advantage of CARP-1 Functional Mimetics with TKIs 
The introduction of several anticancer small molecule drugs (e.g., sunitinib, pazopanib, 
axitinib, temsirolimus, and everolimus) has rapidly changed the treatment of metastatic RCCs 
112,113,146,147. Although the impact on disease progression is encouraging, a substantial proportion 
of patients do not respond adequately, and therapy resistance almost inevitably occurs 103. Possibly 
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combination treatment aimed at different, non-related pathways may be advantageous 112,113,146. 
Due to their increase in vascular nature and high level of vascular permeability factor or vascular 
endothelial growth factor (VEGF) expression, ccRCC patients show promising success with anti-
VEGF cancer therapy. Unfortunately, most of cancer patients ultimately develop a refractory 
response to anti-VEGF treatment over time. In this regard, novel therapeutic strategies for 
nonresponsive, highly aggressive tumor types to tackle the current clinical challenges are needed. 
Concurrently, we would like to perceive the molecular mechanism of these untreatable tumor types 
by using patient samples and utilizing different approaches. We speculate that the proposed 
experimental plan will be supportive to design new treatment options for lasting and sensitizing 
anti-angiogenic effects and better clinical management with the help of novel anticancer agents as 
CFMs. Also, we will work on different models of RCC, with a poor prognosis and because of their 
modest or non-response to systemic therapy. We will pursue different combination regimens, 
including drugs that work on the mTOR inhibition (everolimus), inhibit VEGFR (cabozantinib or 
sorafenib), because elevation in VEGF and CA IX levels are expected to happen in response to the 
hypoxic tumor environment. Escape from sorafenib and cabozantinib blockade of the VEGFR and 
mTOR inhibition of everolimus may also occur if levels of VEGF exceed a threshold that can 
circumvent the blockade. Toxicity was shown to be variable, and that will be taken into 
consideration. Even though in some combinations, both agents seem to be tolerable when utilized 
in full doses (Temsirolimus or everolimus with bevacizumab). In many instances the combination 
has shown not to be safe or feasible as a singular agent because combinations have required dose 
reductions (sorafenib with bevacizumab, Temsirolimus with sorafenib) or are not safe to be 
administered together (Temsirolimus with sunitinib, bevacizumab with sunitinib) 85,116,147–149. 
1.4. Can Nanotechnology help improve drug delivery for RCC? 
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When cancer metastasizes outside of the kidney, it becomes even more complicated to treat 
and control. One challenge to overcome is delivery of agents targeted to metastatic cancer. 
Nanotechnology can combine the drug delivery system with anticancer drugs to target cancer and 
augment the cellular kill with higher concentrations to deliver drugs to cancer will need to be 
tested. One challenge to overcome is the delivery of these medications to metastatic cancer which 
has spread outside the kidney. Nanotechnology is the engineering of novel small molecules to 
direct treatment. To let cancer agents interact with cells and molecules, these drugs and carriers 
should have uniform particle size. One property is the high surface area to volume ratio, meaning 
one can encapsulate drugs to the nanoparticle in high concentrations. Therefore, the concentration 
of the delivery of the drug to cancer can be increased many folds 150. 
One such solution is the use of nano-sized micelles as delivery vehicles for cancer 
therapeutics. Amphiphilic polymers self-assemble under aqueous conditions to form water-soluble 
micelles with a hydrophobic core. Hydrophobic drugs can then be chemically or physically 
incorporated into the micelle core for parenteral administration. This micelle drug delivery strategy 
has been applied to a variety of medical conditions, from hepatic fibrosis to knee osteoarthritis 
151,152. However, the micelle technique renders itself particularly relevant for the treatment of 
different types of solid tumor because of selective accumulation at the target site resulting from an 
enhanced permeability and retention (EPR) effect 153–156. EPR is a phenomenon by which 
macromolecules, notably nanoparticles (NPs) and micelles, are delivered to, and accumulate at the 
tumor site in higher concentrations than are observed in healthy tissue because of anatomical and 
pathophysiological abnormalities or the leaky tumor vasculature of the tumor tissues 153–155. 
However, angiogenesis is not always uniform throughout a tumor, leading to disproportional drug 
distribution by EPR; additionally, in some cases, tumors can exist with little or no evidence of EPR 
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153,155. Passive targeting by the EPR effect is a promising means of overcoming the specificity 
challenge of modern chemotherapeutic agents in many cases. Furthermore, newer active targeting 
strategies have been developed and can add to the selectivity of the EPR effect to overcome above 
noted limitations. 
Moreover, there is a critical need to develop safe and effective delivery vehicles that can 
carry the payload to the specific target tissue and cell. Different types of nanoparticles recently 
emerged as an excellent delivery system. The CFM compounds have poor aqueous solubility and 
consequently poor bioavailability for their use and development as potential anti-cancer agents157–
160. To address this issue, nanolipid formulations (NLFs) of CFM-4 and CFM-4.16 compounds 
were generated using chemically conjugated SMA-TPGS block polymer, then addition of DMSO 
contained the drug to the aqueous phase of polymer, followed by stirring, separation of 
unencapsulated drugs using Tangential Flow Filtration 161,162. The NLFs caused in a significant 
enhancement in overall bioavailabilities of CFM-4 and CFM-4.16 when compared with respective 
free compound. Nanoparticles that encapsulate CFMs also protect them from premature clearance 
and degradation. 
1.4.1.  Rationale Novel Designed Theranostics Nano-platforms Utilizing Multiple 
Linkers with Click chemistry  
In the proposed studies we will utilize a nanotechnology-based approach to address the 
poor aqueous solubility of a potent CFM compound (CFM-4.16) that has restricted its clinical 
development as a therapeutic agent. Our preliminary data thus far revealed that we have been 
successful in overcoming the solubility concerns of CFM-4.16 by encapsulating it in water-soluble 
vitamin E TPGS based nano-formulation that enabled high drug loading (up to 30% w/w of drug 
equivalent) and afforded its intravenous administration for animal testing.  Since there is a critical 
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need to develop safe and effective delivery vehicles that can carry the payload to the specific target 
tissue and cell, different types of nanoparticles have been developed to deliver a variety of 
therapeutic agents. They have recently emerged as an excellent delivery system. Nanoparticles 
need to encapsulate CFMs and protect them from premature clearance and degradation. Ideally, 
they need to be loaded and functionalized with targeting ligands such as CA IX, which may 
potentially improve the delivery, specificity, and efficacy. 
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2. CHAPTER 2. RESEARCH OBJECTIVES 
2.1.Introduction 
Cancer remains the second cause of mortality worldwide. Throughout the last decade, cancer 
incidence has constantly and sharply increased all over the world.  The molecular complications 
of cancer manifestations and therapy-associated adverse effects often hinder effectiveness of many 
therapies and warrant discovery of alternative effective therapy for certain molecular targets while 
minimizing the off-target effects. Therefore, the objective of most research worldwide is to 
develop novel, safer and more effective anti-cancer therapies. One of these targets for drug 
discovery works based on cell growth and survival inhibiting functions of an apoptosis regulatory 
protein, termed CARP-1. CARP-1 (Cell cycle and apoptosis regulator 1, aka CCAR1) is a peri-
nuclear phospho-protein and a regulator of cell growth and apoptosis signaling 137–140 CARP-1 not 
only functions as a transcriptional co-activator of steroid family of nuclear receptors and a 
regulator of adipogenesis through the glucocorticoid receptor (GR), it also regulates Adriamycin 
(ADR)-dependent apoptosis in part through co-activation of p53 141,142. CARP-1 expression is 
often elevated in cells experiencing stress due to growth factor withdrawal or chemotherapy-
induced cell cycle arrest and apoptosis 137,138,141. Knockdown of CARP-1 resulted in resistance to 
apoptosis by ADR or EGFR tyrosine kinase inhibitors, demonstrating requirement of CARP-1 in 
cell growth inhibitory and apoptosis signaling by these agents 137,138,141.  
2.2.Significance 
Renal cell carcinoma (RCC) is one of the most common and lethal of all kidney cancers. RCC 
is tough to treat as the cells are largely resistant to many current therapies. In patients with an 
advanced form of RCC, targeted therapies including the ones using the new drug, Everolimus 
resulted in improved clinical outcomes. However, patients ultimately develop resistance to 
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targeted therapies as well. Thus, newer therapies including better ways of delivery system such as 
by targeting CA IX and using novel approaches are urgently needed to effectively fight this 
malignant disease. Our current project for uses a nanotechnology-based approach as well as 
clinically relevant RCC tumor model and directed address the current challenges of treating 
resistant RCCs. This project will be an important step forward in the development of novel drug 
delivery technologies and therapies for treating clinically relevant RCC. Besides that, identifying 
TKIs such as sorafenib or cabozantinib that can work synergistically in combination with CFMs 
using targeted nano-formulation will have a huge impact on kidney cancer treatment options. Our 
robust and positive preliminary studies provide a rational approach to investigate our hypothesis 
that CFMs and kinase inhibitors loaded in CA IX-PLNPs/OMs alone or combination will offer 
better prospects for inhibiting resistant RCCs. In the research strategy as outlined before, we will 
design experiments to maximize the success in overcoming naive and everolimus resistant RCC 
in animal models. 
2.3. Specific Aims 
 
In the light of the preceding literature review, it is apparent that CARP-1 (CCAR-1) is a 
potential molecular target whose functional mimetic analogs may lead to the suppression of tumor 
growth, that of resistant ccRCC. It may also be useful to integrate a combination strategy with CA 
IX targeted molecule as a predictive biomarker for patient survivability and treatment modalities, 
as suggested in preliminary studies. To validate this hypothesis, the small molecule mimetic of 
CARP-1 CFM-4.16, has been deployed. In this study, the initial step would be to elucidate the 
effect of CFM-4.16 on RCC cell growth and survival. This would provide insight into the 
molecular mechanisms by which CARP-1 is regulated in RCC.  Once established, the next step 
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would be to investigate the effect of CFM-4.16 on a panel of RCC cells and to determine if it is 
inhibiting RCC cell lines growth.  
In the specific aim 1, the CFM compounds will be investigated for (i) the molecular 
mechanisms of RCC cell growth inhibition, and (ii) to the extent these compounds inhibit growth 
of RCC cells. Collectively, these data would establish that CFMs inhibit growth of parental, wild-
type RCC in part by promoting apoptosis signaling. However, CFM compounds suffer from an 
inherent drawback of poor aqueous solubility and its dose escalation for systemic administration 
and in vivo testing is highly challenging. 
In Specific Aim 2, we will perform confirmatory studies to validate that the in vitro 
anticancer activity of CFM-4.16 is maintained when loaded in vitamin E-TPGS based micellar 
nano-formulation. Specifically, samples consisting of free CFM-4.16 and CFM-4.16 loaded in 
vitamin E-TPG based micellar nano-formulation (abbreviated as SMA-TPGS-CFM) will be tested 
in vitro and in vivo using parental, wild-type RCC cells as well as Everolimus-resistant RCC. The 
objective for SA2 is to test the safety of intravenous administration of SMA-TPGS-CFM micellar 
nano-formulation and the antitumor response in RCC mouse model. Our preliminary data thus far 
revealed that we have been successful in overcoming the solubility concerns of CFM-4.16 by 
encapsulating it in water-soluble vitamin E TPGS based nano-formulation that enabled high drug 
loading and affords its intravenous administration for animal testing. Studies will be performed  (i) 
to test the in vitro efficacy of the CFM 4.16 loaded in vitamin E TPGS based nano-formulation in 
parental, wild-type RCC and Everolimus-resistant RCC cells as well as (ii) perform proof-of-
concept studies to explore their antitumor response in a clinically relevant RCC mouse model. 
Specifically, we aim to achieve (1) an increased serum bioavailability of CFM-4.16 nano-
formulation following i.v administration; (2) increased nano-formulation accumulation and 
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retention within the tumor (by the EPR effect) and therefore (3) an increased localized CFM-4.16 
concentration in tumor tissues relative to free drug, thus producing a marked antitumor response. 
In this regard, it is worthwhile to note that in an earlier study a polymeric nano-lipid formulation 
resulted in enhanced serum bioavailability of CFM-4.16 when compared with the free CFM-4. 
Oral administration of CFM-4 NLF resulted in reduced weights and volume of the xenograft 
tumors derived from A549 NSCLC and MDA-MB-231 TNBC cells 160.  
In Specific Aim 3, CA IX expression on the cell surface is associated with the induction 
of tumor hypoxia through regulation of HIF1α. The clinicopathological analysis has supported the 
fact that overexpression of CA IX in RCC is linked to poor disease prognosis and resistance to 
therapy. The accumulated literature and clinical trial data indicate that CA IX expression is 95-
99% for both primary and metastatic RCC 129,132,133,163,164, whereas it has restricted expression in 
healthy tissues (including non-cancerous renal tissue). Thus, CA IX is significantly overexpressed 
in RCC tumor. These results signify that CA IX is an excellent target for site specific delivery of 
therapeutic payloads to renal tumors. As reported earlier, a small molecule, Acetazolamide (ATZ), 
has high affinity (Kd 8.3 nM) to CA IX 133,164 and ATZ-conjugated nanoformulations can deliver 
the payload into the inner core (more than the periphery) of the tumor. Along these lines, for the 
first time, development of an ATZ-conjugated polymeric lipid nanoformulations library for the 
selective delivery of a drug cocktail to the hypoxic region of therapy resistant RCC was proposed. 
It is well established that the hypoxic tumor (core) harbors aggressive and drug resistant stem-like 
cells that can persist after initial drug therapy and have the ability to invade normal tissues and 
metastasize to distant sites forming secondary tumors. Authenticated RCC cell lines such as WT 
(A498, UOK262) and Evr-res (A498, UOK262) will be utilized as RCC cells, as well as Raw 
264.7 (macrophage) for macrophage phenotyping studies. The following will be established (i) a 
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synergistic anticancer effect of CFM-4.16 with TKIs, (ii) the role of M2-macrophages in tumor 
immune evasion, and (iii) the mechanism of inhibiting tumorigenic cross-talk between RCC 
epithelial cells and M2-macrophages using NPs. The tumor environment mimetic advance 
spheroid and Transwell cell culture models will be used to establish efficacy.  
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3. CHAPTER 3. A CARP-1 FUNCTIONAL MIMETIC AS A PROMISING 
THERAPEUTIC ANTICANCER AGENT FOR EV-RESISTANT RENAL CELL 
CARCINOMA 
Results from the following studies have been published: Oncotarget Journal, Cheriyan, V. T. *, 
Alsaab, H. O., *, et al., (2017). A CARP-1 functional mimetic loaded vitamin E-TPGS micellar 
nano-formulation for inhibition of renal cell carcinoma. Oncotarget, 8(62), 104928. *Equal contribution. 
3.1.Objectives: 
In this chapter we investigated: (i) the molecular mechanisms of RCC cell growth 
inhibition by the CFM compounds, (ii) the extent to which these compounds inhibit growth of drug 
(Everolimus)-resistant RCC cells, and (iii) whether CFMs inhibit growth of parental as well as 
Everolimus-resistant RCC cells. 
3.2.Introduction 
RCCs comprise of different types of renal epithelial tumors that include most commonly 
occurring conventional (clear cell) renal cell carcinomas (ccRCCs) followed by the papillary renal 
cell carcinomas, Chromophobe renal carcinoma, Oncocytoma, and Collecting-duct carcinoma 165. 
Most RCCs seem to occur sporadically while 1-4% of the cases have an inherited predisposition. 
Mutations in the Von Hippel-Lindau (VHL) tumor suppressor occur frequently in RCCs. RCC is 
generally very difficult to treat as the cells are largely resistant to many conventional therapies. 
Currently, surgery remains the best treatment option 165, although 20-30% of the patients progress 
to develop metastatic disease. If diagnosed early, there is a better chance of the cancer going into 
remission but if the cancer does not respond to first-line therapies there are very limited secondary 
options 30,97. FDA approved agents for treatment of metastatic RCC include tyrosine kinase 
inhibitors (TKIs) such as sorafenib and sunitinib, and mammalian target of rapamycin (mTOR) 
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inhibitors temsirolimus and everolimus 8,112,113,147. These targeted therapies result in improved 
clinical outcomes, and although everolimus is the first drug used as a secondary treatment option 
for resistant RCCs, patients ultimately develop resistance to targeted therapies that correlates with 
poor overall prognosis 96,166. Dr. Rishi’s group at Wayne State University previously discovered 
that CARP-1 also functions as a co-activator of the APC/C E3 ligase 139. APC/C is a multi-subunit 
ubiquitin E3 ligase protein that plays a distinct role in cell cycle transitions. Misregulation of 
APC/C substrates such as Securin, Polo-like kinase (Plk) correlate with tumor progression 143,167. 
A chemical biology-based high-throughput screening of a chemical library as shown in Figure 3.1 
resulted in identification of a number of novel, small molecule inhibitors (SMIs) of CARP-1 
binding with APC/C subunit APC2 139. These compounds, termed CARP-1 functional mimetics 
(CFMs)159. CFMs bind with CARP-1 and block its interaction with APC2, cause G2M cell cycle 
arrest, and inhibit cell growth by inducing apoptosis in various cancer types 139,140.  
 
Figure 3.1 CFMs (Top Row) and CFM-4 analogs (Bottom Row) that inhibit CARP-1 binding with 
APC-2. IC50 value for each compound was derived by conducting dose response assays. Adapted 
from 1. 
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CARP-1 (Cell cycle and apoptosis regulator 1, aka CCAR1) is a peri-nuclear phospho-
protein and a regulator of cell growth and apoptosis signaling 137,138,140. CARP-1 not only functions 
as a transcriptional co-activator of steroid family of nuclear receptors and a regulator of 
adipogenesis through the glucocorticoid receptor (GR), it also regulates Adriamycin (ADR)-
dependent apoptosis in part through co-activation of p53 140–142. CARP-1 expression is often 
elevated in cells experiencing stress due to growth factor withdrawal or chemotherapy-induced 
cell cycle arrest and apoptosis. Knockdown of CARP-1 resulted in resistance to apoptosis by ADR 
or EGFR tyrosine kinase inhibitors demonstrating requirement of CARP-1 in cell growth 
inhibitory and apoptosis signaling by these agents 137,140.  
3.3.Material and methods: 
3.3.1.  Chemicals and Reagents 
Structure and synthesis of CFM compounds (CFM-4, -4.16, and -4.17) have been recently 
described and their structures are shown in Figure 3.1. A stock solution of 50mM of each CFM 
was prepared in dimethyl sulfoxide (DMSO) and stored at –20°C. 3-[4,5-Dimethylthiazol-2-yl]-
2,5diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich, St Louis, MO. 
Everolimus was purchased from SelleckChem, Boston, MA and a 50mM stock solution was 
prepared in DMSO and stored at –20°C, while clinical grade Adriamycin (ADR) was obtained 
from Karmanos Cancer Institute pharmacy, Detroit, MI. We purchased all other analytical grade 
reagents from Sigma-Aldrich (St Louis, MO) and used them without further purification. 
3.3.2. Cell culture conditions and cell lines 
DMEM, EMEM medium and antibiotics (penicillin and streptomycin) used in this study 
were purchased from Invitrogen Co. (Carlsbad, CA). Fetal bovine serum (FBS) and DMSO were 
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obtained from Denville Scientific Inc. (Metuchen, NJ), and Fisher Scientific (Fair Lawn, NJ), 
respectively. The Protein Assay Kit was obtained from Bio-Rad Laboratories (Hercules, CA). The 
mouse monoclonal antibodies for –actin was acquired from Sigma-Aldrich (St. Louis, MO). We 
purchased rabbit polyclonal antibodies for α-tubulin, Cyclin B1, Cleaved Caspase-8, PARP, 
phospho and total p38/, phospho- and total JNK1/2 SAPKs from Cell Signaling Technology 
(Beverly, MA). We have previously described generation and characterization of the anti-CARP-
1 rabbit polyclonal antibodies 159,160,168,169. 
The human RCC A498, CAKI-1, CAKI-2, and ACHN cells were from ATCC and kindly 
provided by Dr. Rajvir Dahiya from Department of Urology, San Francisco Veterans Affairs 
Medical Center and University of California San Francisco, San Francisco, CA (UCSF). The 
HLRCC (UOK 268 and UOK 262) cells were kindly provided by Dr. Marston Linehan Urologic 
Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of 
Health, and Bethesda, MD. (NCI). All the cells were routinely maintained as described before. 
All the cell culture media were containing 10% FBS, 100 units/ml of penicillin, and 100 μg/ml 
of streptomycin, and the cells were kept at 37°C and 5% CO2. For cell growth and MTT studies, 
the cells were cultured in fresh media with 10% FBS prior to their treatments with various agents. 
The Caki-1 and Caki-2 were grown in RPMI 1640 medium, and UOK 262, UOK 268, and Huh7 
were routinely cultured in DMEM medium. 
3.3.3. Generation of Everolimus-resistant RCC cells 
 The human RCC A498, UOK262, and UOK268 cells were cultured in the chronic 
presence (>6 months) of Everolimus. The parental A498 cells were initially treated with 500nM 
Everolimus for 3-4 weeks, followed by escalation to 1.0, 2.0, 4.0 and 10.0μM doses for a period 
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of three to four months till the resistant subline emerged. The cells were cultured in continuous 
presence of each of the dose for 3-4 weeks till resistance developed and cells adapted to growth 
in 2μM Everolimus. In the case of UOK262 and 268 RCC cells, the parental cells were initially 
cultured in 10nM Everolimus for 3-4 weeks. For selection of the resistant cells, everolimus dose 
was escalated to 20, 50, 100, 200, 500, 1000, and 2000nM. The UOK cells were cultured in 
continuous presence of each of the dose for 2-3 weeks till resistance developed and cells adapted 
to growth in 2μM Everolimus. Subsequent, routine maintenance of the resistant cells in the 
presence of 2μM Everolimus was continued and multiple, resistant sublines for each of the RCC 
cells were isolated and characterized for their growth inhibitory (GI50) dose of Everolimus by 
the MTT-based viability assays as detailed below. Several resistant sublines of each cell line 
were then isolated and maintained in respective culture media containing 2.0 µM everolimus. 
3.3.4.  Generation of CARP-1 knock-down RCC cells 
 The human RCC UOK262 parental cells were transfected with vector plasmid 
pcDNA3/hygro or plasmid expressing CARP-1 anti-sense (Clone 1.6, ref 8). Multiple, stable 
sublines for hygromycin resistance were selected in the presence of 400μg/ml hygromycin 
(#10687010, Invitrogen Inc) following methods described before 159,160,168,169. We determined 
the levels of CARP-1 in the parental, and vector or CARP-1 antisense plasmid-transfected RCC 
cells and their viabilities in the presence of CFM compounds by western blot and MTT assays, 
respectively, as described below.  
3.3.5. Cell viability assays (MTT assay) 
The cell growth inhibition was assessed by using MTT assay. The cytotoxicity of CFM-4, 
-4.6, -4.16, -4.17, Everolimus, and ADR in the RCC cells (A498, UOK262, and UOK268) was 
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assessed by MTT assay.  First, we seeded 5 X 103 cells in the 96-well plate in triplicate, allowed 
the cells to grow in fresh culture media for another 24h, and treated them with respective agents 
for the noted dose and time. Control cells were treated with 0.1% DMSO in culture medium. After 
treatment, we performed an MTT assay. Briefly, 20 μl of 1mg/ml of MTT was added to each well 
and cells were incubated for 2-4h at 370C. MTT was removed, and the resulting formazan products 
were dissolved by adding 50μl DMSO/well followed by colorimetric analysis using a multi-label 
plate reader at 570 nm (Victor3; PerkinElmer, Wellesley, MA). 
3.3.6.  Western Blot and protein expression analysis  
For protein expression analysis, we conducted western blot experiments. The RCC cells 
were treated with DMSO/Vehicle (Control) or indicated dose and time of the noted compound and 
were lysed to prepare protein extracts. Cells were harvested and lysed in RIPA buffer (50mM Tris-
HCI, pH 8.0, 150mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulfate (SDS), and 0.1% of protease inhibitor cocktail) for 20 min at 40C. The lysates were 
then centrifuged at 14,000 rpm at 40C for 15 min to get rid of debris. We then determined the 
protein concentrations of whole cell lysates utilizing the Protein Assay Kit. 50μg from each sample 
of supernatant proteins were separated by SDS-10% polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA) 
by company standard protocol. The membranes were hybridized with primary antibodies followed 
by incubation with appropriate secondary antibodies. The antibody-bound proteins were visualized 
by treatment with the chemiluminescence detection reagent (Amersham Biosciences) according to 
the manufacturer’s instructions, followed by exposure to X-ray film (Kodak X-Omat). The same 
membranes were then re-probed with either the anti-β actin or anti-α tubulin antibody, which was 
utilized as an internal control for protein loading. 
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3.4.Results 
3.4.1.  Novel Analogs of CFM-4 Suppress Growth of Human NSCLC, TNBC, and RCC 
Cells 
We first tested the growth-inhibitory effects of CFM-4 and 4.16 on human RCC, NSCLC, 
and liver cancer cell lines. CFM-4 and 4.16 inhibited the viability of all cell lines in a dose and 
time-dependent manner (Figure. 3.2A and B). Generally, most of cell lines were more sensitive 
towards all the CFM, showing at least 50% reduced proliferation in the presence of 20 µM CFM-
4 and 4.16 (Figure 3.2). Doses of 1 µM and 2 µM of CFM-4 over a 24 h treatment elicited more 
than 40% reduced viability of HepG2 and UOK262 cell lines. Also, doses of 5 µM and 10 µM of 
CFM-4 showed at least 40% growth cells viability in Huh7, H1299, UOK268, and UOK 262 
(Figure 3.2.A). The HepG2, A549, UOK262 cells were relatively less sensitive to CFM4 since a 
10 µM dose of CFM-4 caused little more than 20% reduction in their viability (Figure 3.2.A). 
However, in case of CFM-4.16, there is an approximately 50% attenuation of the viability of all 
cells was indicated when treated with a lower dose of CFM-4.16 over a 24 h period which indicates 
its stronger activity against these cell lines (Figure 3.2.B). 
 In addition, since the RCC, NSCLC, and liver cancer cell lines were relatively more 
sensitive to CFM-4.16, these cells were separately treated with various doses of CFM-4 for a 
period of 24 h to evaluate the lowest effective dose for these agents. Despite 500 nM dose of both 
compounds failed to affect RCC, NSCLC, and liver cancer cells viability, a 1 µM and 5 µM dose 
of the CFM-4.16 agent elicited more than 60% loss in the viability of all the cell lines. These data 
suggest that the viabilities of the RCC, NSCLC, TNBC, and liver cancer cells were affected 
properly by the 1 µM or higher doses of free drug (CFM-4.16) and CFM-4.16 nanoformulation.  
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Figure 3.2.  Liver cancer cells (Huh-7 and Hep G2), lung cancer cells (H1299 and A549) and renal cancer 
cells (UOK 268 and UOK 262) were treated with the indicated doses of (A) CFM-4 and (B) CFM-4.16 for 
24 hours.  The number of viable cells was then determined by MTT assay as described. Adapted from 1. 
A 
B 
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3.4.2.  CFMs inhibit viabilities of RCC cells 
  Our prior findings had indicated anti-cancer properties of a novel class of CFM compounds 
169, and our recent medicinal chemistry-based structure-activity relationship (SAR) studies 
reported identification of CFM analogs, in particular CFM-4.16, that was a superior inhibitor of 
parental and drug-resistant human and murine triple-negative breast cancer cells in vitro and in 
vivo 169. Since emergence of resistance to current therapeutics remains a formidable problem in 
effective treatment and management of RCCs in clinic 2,96,97, we speculated whether CFM class of 
compounds would be effective inhibitors of RCC cells and to the extent, these compounds would 
be suitable to inhibit the resistant RCCs. We tested this possibility by conducting studies as 
detailed below. First, we evaluated potencies of the parent compound CFM-4 and its analogs CFM-
4.6, and CFM-4.16 in cell culture studies utilizing RCC cell lines of ccRCC (CAKI-1, A498), 
papillary RCC (ACHN, CAKI-2), and HLRCC (UOK 262 and UOK 268) origins 83,170 by MTT 
based assays. As shown in Figure 3.3, CFM-4.16 dose of 1.0 and 2.0 μM over a period of 12h 
caused a greater loss of viability of all the RCC cells when compared to the RCC cells treated with 
similar doses of CFM-4 compound. Since Everolimus is one of the currently used targeted therapy 
for RCCs, we tested whether Everolimus treatments also provoked loss of viabilities of the RCC 
cells and to the extent anti-RCC effects of Everolimus were different from the CFM-4.16 
treatments. The Everolimus doses of 0.2, 0.5, 1.0, and 2.0μM caused a moderate 20-40% loss in 
the viabilities of RCC cells, the doses of 5.0, and 10.0μM however provoked a greater than 60-
70% reduction in the viabilities of the RCC cells (Figure 3.3 C). Given that the molecular masses 
of Everolimus, Doxorubicin, and CFM-4.16 are 958.22, 543.5, and 440.35, respectively, a 1μM 
dose of Everolimus will have an approximate molar equivalence to a 2.0μM dose of either 
Doxorubicin or CFM-4.16. Thus, although treatments with 5.0 or 10.0μM doses of Everolimus, 
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CFM-4, and CFM-4.16 provoked a similar 60-80% reduction in viabilities of the RCC cells, a 
2.0μM dose of CFM-4.16 induced a 40-60% loss of RCC cell viabilities (Figure 3.3 B) while a 
1μM dose of Everolimus caused a moderate 20-40% reduction in RCC cell viabilities (Figure 3.3 
C). These data in Figure 3.3 and Figure 7.1. in Appendix suggest that the RCC cells are likely 
more sensitive to inhibition by CFM-4.16 when compared with CFM-4 or Everolimus at the 
equivalent doses of up to 2μM of each compound. Additional dose response studies with reference 
to A498, CAKI-1, and ACHN RCC cells revealed that CFM-4.16 dose for inhibition of the cell 
growth by 50% (GI50) was ~1.5-1.8μM, its dose for inducing a 50% cytotoxic effects (LC50) was 
5.5-5.7 μM.  
 
Figure 3.3. CFMs inhibit RCC cell growth. We treated noted cell lines either with DMSO (Control), with 
various CFMs (A, B, D-F), Everolimus (C), or ADR (D) for indicated dose and time. We determined cell 
viability by MTT assay. The data in the histograms represent means of three independent experiments with 
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4-6 replicates for each treatment; bars, S.E. A-D, @,#,&,*, E-F, α,β,γ,δ, statistically significant inhibition 
(p = <0.05) relative to DMSO-treated respective controls. Adapted from 1. 
 
3.4.3. CFMs inhibit viabilities of the resistant RCC cells 
To test whether CFM class of compounds are also effective inhibitors of the resistant 
RCCs, as a proof-of-concept strategy, we first generated and characterized several RCC sublines 
that were resistant to Everolimus. We cultured A498, UOK 262, and UOK 268 RCC cells in the 
chronic presence of escalating doses of Everolimus until the resistance emerged. As shown in 
Figure 3.4 A, the GI50 doses for Everolimus were 1.2, 0.02, and 0.02μM for the parental A498, 
UOK 262 and UOK 268 RCC cells, respectively. These data in Figure 3.4 A strongly suggest that 
all the RCC cells developed a robust level of resistance to Everolimus. We next investigated 
whether the CFM compounds inhibited viabilities of the Everolimus resistant RCC cells by 
conducting MTT based assays as in Figure 3.3. and 7.1. Appendix. As shown in Figure 3.4 B-D, 
a 4.0μM dose of CFM-4 caused ~50% loss of viability of the Everolimus resistant A498 cells while 
a moderate ~20% reduction in the viability of the Everolimus resistant UOK 262 and UOK 268 
cells was noted. A 4.0μM dose of CFM-4.16 on the other hand provoked ~80% reduction in the 
viabilities of all the Everolimus-resistant RCC cells. These data corroborate our current findings 
in Figure 3.3 and our recent studies demonstrating increased effectiveness of CFM-4.16 in 
attenuating viabilities of the parental RCC cells as well as drug-resistant RCC (Figure 3.4) and 
TNBC cells 159.   
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Figure 3.4. CFM-4. 16 inhibits Everolimus-resistant RCC cell growth. (A) GI50 values of parental and 
drug-resistant RCC cells. In the case of Everolimus-resistant cells, the respective parental and resistant 
sublines were treated with 0.02, 0.1, 0.2, 1.0, 2.0, 4.0, and 10.0 μM dose of Everolimus. Percent cell 
viabilities were determined relative to respective DMSO-treated controls. The data in the GI50 columns 
represent means of three independent experiments. (B-D) Indicated parental and their respective drug 
resistant RCC cells were either untreated (Control) or treated with noted doses of Everolimus, CFM-4, or 
CFM-4.16 for 12h. We determined cell viability by MTT assay. The histogram columns represent means 
of three independent experiments with 4-6 replicates for each treatment; bars, S.E. B-D, α, β, γ, δ, 
statistically significant inhibition (p = <0.05) relative to DMSO-treated respective controls. Adapted from 
1. 
 
3.4.4. CFM-4.16 Stimulates apoptosis by activating p38 MAP kinase, c-Jun N-terminal 
kinase (JNK) enhancing expression of CCAR-1/CARP-1 
CARP-1 is a key transducer of apoptosis signaling by therapeutics such as Doxorubicin, 
Etoposide, and Gefitinib 137, and CARP-1 expression was necessary for transduction of 
apoptotic/inhibitory signaling by these therapeutics as well as by our experimental CFM class of 
compounds in parental and drug-resistant TNBC cells 159. Since CFM-4.16 was more effective in 
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reducing viabilities of parental as well as Everolimus resistant RCC cells (Figure 3.4), we next 
investigated molecular mechanisms of apoptosis by CFM compounds and to the extent CARP-1 
was required for inhibition of RCC cells by CFMs. Our western blot (WB) analyses revealed that 
equimolar (10μM) dose of CFM-4 or CFM-4.16 stimulated CARP-1 expression and activation of 
pro-apoptotic, stress-activated protein kinases (SAPKs) in the RCC cells in a time-dependent 
manner (Appendix Figure 7.2. A, B). Although activation of both the p38α/β and JNK1/2 SAPKs 
occurred as early as 1h of treatment with CFMs, CFM-4.16 caused a rather robust activation of 
these SAPKs at 6h treatment period (Appendix Figure 7.2. A, B). Co-incident with the SAPK 
activation, treatments with CFMs over a 6h period stimulated activation of PARP and caspase 8, 
while causing a significant decline in levels of mitotic cyclin B1 in the RCC cells. Since CFMs 
inhibited viabilities of Everolimus-resistant RCC cells, we then determined whether CFMs 
provoked apoptosis in the Everolimus-resistant RCC cells as well. As shown in Figure 7.2. C, both 
the compounds stimulated CARP-1 expression, activation of SAPKs, PARP cleavage, and loss of 
cyclin B1 in the Everolimus-resistant UOK262 RCC cells. Here again, CFM-4.16 caused a 
generally higher increase in CARP-1 levels, activation of SAPKs, PARP-1 cleavage in parental or 
Everolimus-resistant RCC cells when compared with the cells that were treated with CFM-4. 
CFM-4.16 treatments also provoked a greater loss of cyclin B1 in both the parental and 
Everolimus-resistant RCC cells when compared with their CFM-4-treated counterparts. These data 
suggest that CFMs inhibit RCC cell viabilities in part by promoting apoptosis.  
3.4.5. CFM-4.16 Stimulates apoptosis in parental and resistant RCC cells by enhancing 
expression of CCAR-1/CARP-1 
We next clarified whether the CFM compounds required CARP-1 to inhibit variabilities of 
the RCC cells. For this purpose, we first generated and characterized multiple, independent 
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hygromycin-resistant stable sublines of UOK262 cells that express reduced CARP-1 as detailed in 
methods. The parental UOK262 cells were transfected with a plasmid encoding CARP-1 antisense 
or its vector counterpart, and transfected cells were cultured in chronic presence of hygromycin 
over a period of 6-8 weeks to obtain resistant sublines essentially following our previously 
described methods 159. As shown in Appendix Figure 7.3 A, stable expression of CARP-1 antisense 
plasmid caused reduced levels of CARP-1 in two sublines when compared with the levels of 
CARP-1 noted in two, vector-expressing sublines or the parental UOK262 cells. We then 
determined whether knock-down of CARP-1 expression interfered with loss of viabilities induced 
by treatments with CFM compounds. Our data in Appendix Figure 7.3 B demonstrate that 
depletion of CARP-1 in the UOK262 cells resulted in a significant abrogation of inhibitory effects 
of both the CFM compounds when compared with their vector-expressing counterparts. Taken 
together, our findings in Appendix Figures 7.2 and 7.3 suggest that CFMs stimulate apoptosis in 
parental and resistant RCC cells and CARP-1 expression is required in transduction of inhibitory 
effects of the CFM compounds.  
3.4.6. CFM-4.16 suppresses three-dimensional growth of the parental and Everolimus-
resistant RCC cells 
Recent studies have revealed culture of the RCC cells in a three-dimensional (3D) system 
as spheroids, and that the overall gene expression patterns of RCC spheroids in 3D more closely 
mimicked those observed in RCC tumors in vivo 171. These studies further suggested suitability of 
3D RCC spheroids from established cell lines as well as patient-derived, primary RCC tumors for 
pharmacological testing and investigating molecular mechanisms of RCC metastasis. Since CFM-
4.16 inhibited growth of mammospheres derived from parental and drug-resistant human TNBC 
cells, we tested whether CFM-4.16 will inhibit growth of the RCC spheroids in 3D culture 
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conditions. As shown in Figure 3.5, the parental A498, UOK262, and UOK268 RCC cells as well 
as their respective, Everolimus-resistant sublines formed RCC spheres in 3D culture conditions 
that are detailed in methods. Consistent with our observations with the human TNBC 
mammospheres, CFM-4.16 caused marked disintegration of spheres of parental and Everolimus 
resistant human RCC cells (Figure 3.5.).  
Figure 3.5. CFM-4.16 inhibits growth of RCC spheres derived from parental and 
Everolimus-resistant cells. Parental and Everolimus-resistant RCC cells were grown as spheres 
as detailed in Methods. The sphere cultures were either untreated (Control) or treated with CFM-
4.16 for noted dose and time. The untreated and treated spheres were then photographed as in 
methods. Representative photomicrographs of untreated and CFM-4.16 treated spheres are shown. 
Adapted from 1.  
 
3.5. Discussion 
In this chapter, we initiated further studies to determine whether the CFM-4 and its analogs 
inhibit growth of RCC cells; and further explored molecular mechanism(s) of RCC cell death by 
these compounds. CFM-4.16 exposure resulted in a somewhat higher loss of RCC cell viability 
when compared with their loss of viabilities noted following treatments with CFM-4. It is therefore 
feasible that further rational medicinal chemistry modifications of these promising anticancer 
agents could yield additional novel small molecule compounds that may have greater potency and 
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selectivity in inhibiting RCCs. In an attempt to elucidate apoptosis signaling by chemotherapy, 
CARP-1 was identified as a perinuclear protein that was required for apoptosis by EGFR targeted 
therapeutics as well as DNA damaging agents such as Adriamycin (ADR) and etoposide 159,160. 
Although CARP-1 is a coactivator of steroid-thyroid receptor superfamily, we focused our efforts 
to exploit apoptosis signaling of CARP-1 for development of novel anti-cancer agents. 
Approximately one third of RCC patients present metastases at diagnosis, and 30-70% of patients 
relapse within five years of surgery 31. During the last decade, several targeted therapies have been 
developed and approved for treatment of metastatic RCC. These second-line targeted therapies for 
the metastatic RCCs include mechanistic target of rapamycin (mTOR) inhibitors such as 
Temsirolimus and Everolimus, and tyrosine kinase inhibitors such as Sunitinib and Sorafenib 166. 
Although most of these therapies have substantially improved patient outcomes, none of these 
drugs are curative and resistance eventually develops. Here we utilized ccRCC cells and hereditary 
non-ccRCC subtypes to generate laboratory models of drug resistance by exposing them to chronic 
presence of Everolimus over an extended period. Several Everolimus-resistant sublines of A498 
(representative of cc-RCC subtype), and UOK262 and UOK268 (representative of non-cc-RCC 
subtype) were obtained and characterized for their resistance to Everolimus. In this proof-of-
concept investigation, we find that CFM compounds are potent inhibitors of parental as well as 
Everolimus-resistant RCC cells. In fact, the compound CFM-4.16 seemed to be generally more 
effective inhibitor of these cells when compared with the parent compound CFM-4. Nevertheless, 
both the compounds function in part by stimulating apoptosis. Since CFMs function in part by 
binding with CARP-1 and interfere with activity of the Anaphase Promoting Complex/Cyclosome 
(APC/C) E3 ligase, our studies also revealed a CARP-1 requirement in transduction of growth 
inhibitory effects of CFM-4.16 in the RCC cells.  At the molecular levels, CFMs target mitotic 
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cyclin B1 and cause apoptosis in the parental and resistant RCC cells. This loss of cyclin B1 and 
stimulation of apoptosis by CFMs in RCC cells would be consistent with our prior findings 
demonstrating promotion of G2M cell cycle arrest, loss of mitotic cyclin B1, and apoptosis 
stimulation by CFMs in other cancer cell models 158–160,168.  In this regard, the novel class of CFM 
scaffold that stimulate G2M arrest as well as cause apoptosis hold potential for therapeutic use for 
targeting drug-resistant cancers especially in RCC.  
3.6. Conclusion  
The CFM compounds have been investigated for (i) the molecular mechanisms of RCC 
cell growth inhibition, and (ii) to the extent these compounds inhibit growth of drug (Everolimus)-
resistant RCC cells. Conclusively, the current in vitro data is highly encouraging, and indicate that 
CFMs inhibit growth of parental, wild-type as well as Everolimus-resistant RCC cells in part by 
promoting apoptosis signaling. Clearly, there is a need for further in vivo testing of these 
compounds in animal tumor models of RCC. However, CFM compounds suffer from an inherent 
drawback of poor aqueous solubility and its dose escalation for systemic administration remains 
highly challenging. 
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4. CHAPTER 4: A CARP-1 FUNCTIONAL MIMETIC LOADED IN VITAMIN E-
TPGS MICELLAR NANO-FORMULATION FOR INHIBITION OF RENAL 
CELL CARCINOMA UTILIZING EPR EFFECT 
 
Some results from the following studies have been published: Oncotarget Journal, Cheriyan, V. T. 
*, Alsaab, H. O., *, et al., (2017). A CARP-1 functional mimetic loaded vitamin E-TPGS micellar 
nano-formulation for inhibition of renal cell carcinoma. Oncotarget, 8(62), 104928. *Equal contribution. 
4.1.Objectives 
Studies will be performed (i) to test the in vitro efficacy of the CFM 4.16 loaded in vitamin E 
TPGS based nano-formulation in parental, wild-type RCC and Everolimus-resistant RCC cells as 
well as (ii) perform proof-of-concept studies to explore their antitumor response in a clinically 
relevant RCC mouse model. Specifically, we aim to achieve (1) an increased serum bioavailability 
of CFM-4.16 nano-formulation following i.v administration; (2) increased nano-formulation 
accumulation and retention within the tumor (by the EPR effect) and therefore (3) an increased 
localized CFM-4.16 concentration in tumor tissues relative to free drug, thus producing a marked 
antitumor response. 
4.2. Introduction 
Recent studies reported development of various strategies to circumvent the poor aqueous 
solubility of many compounds in order to improve the outcomes of anticancer therapy. In this 
study, we will thus employ a nanotechnology advanced technique to tackle the poor aqueous 
solubility of a potent CFM compound (CFM-4.16) that has restricted its clinical utility as a 
therapeutic anticancer agent. Additionally, in order to improve the outcomes of anticancer agents, 
strategies to circumvent the poor aqueous solubility have been studied extensively in recent years. 
One of these strategies is to utilize D-alpha-tocopheryl polyethylene glycol succinate (Vitamin E 
TPGS) which is a water-soluble derivative of a PEGylated vitamin E (Vitamin E conjugated with 
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PEG). TPGS has an amphiphilic structure comprised of a hydrophobic alkyl tail and a hydrophilic 
polar head. The amphiphilic nature of TPGS confers it an excellent ability to encapsulate 
hydrophobic drugs, forming nano-micelles172–175. The nano-micelles with low critical micellar 
concentrations thereby improve the solubility, stability and bioavailability of the loaded lipophilic 
drug. Other groups previously have demonstrated that TPGS features such as bulky structure and 
large surface area makes it as an excellent solubilizer and enhancer for hydrophobic drug 
bioavailability. In addition, TPGS delivery system by itself could inhibit P-glycoprotein MDR and 
promote a synergistic anticancer effect. We also chose styrene-maleic acid (SMA) polymer with a 
relatively low molecular weight of 1.6 kDa for generation of SMA-TPGS block copolymer that 
could enhance the formation of nano-micelles. It was selected as a block copolymer with TPGS 
based on its favorable properties as reported earlier. The critical reason for choosing SMA for 
polymeric nano micelles is due to their favorable properties for in vivo delivery such as high drug 
loading, good water solubility, nontoxicity, and biosafety. These nano-micelles have high drug 
loading, good water solubility, nontoxicity, and biosafety profiles for use in vivo delivery of drug 
payload. In this regard, the native SMA polymer conjugated to neocarzinostatin (SMANCS) was 
approved for human use 176–178. 
In the current study, we investigated the efficiency of drug delivery of novel CFMs analog 
nano-formulation and their effects on circumventing the water solubility obstacle to permit 
intravenous administration. Furthermore, we aimed to test the in vitro efficacy of the CFM 4.16 
loaded in vitamin E TPGS based nano-formulation in different cancer cell lines as well as 
performed proof-of-concept studies to explore the mechanism of action of these newly developed 
small molecules inhibitors. Also, we investigated (i) the extent to which these CFM 
nanoformulations inhibit growth of drug (Everolimus)-resistant RCC cells, and (ii) whether the 
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SMA-TPGS nano-formulation of CFM-4.16 circumvents the solubility concerns of CFM 
compounds to permit its intravenous administration in conducting in vivo studies. Our data indicate 
that CFMs inhibit growth of parental as well as Everolimus-resistant RCC cells in part by 
promoting apoptosis. The TPGS-based nano-formulation of CFM-4.16 inhibits viability of RCC 
cells in vitro and their growth as xenografted tumors in immunocompromised mice. 
4.3. Materials and Methods 
4.3.1. Chemicals and Reagents  
CFM-4.16 was synthesized by Dr. Scott Larsen (University of Michigan) and provided to 
Dr. Rishi (KCI) and has been recently described. All the CFMs were dissolved in DMSO at a stock 
solution of 10-50 mM and stored at –20°C. Everolimus was purchased from SelleckChem, Boston, 
MA. Styrene maleic anhydride (SMA, MWt 1600) and D-alpha-tocopheryl polyethylene glycol 
succinate (Vitamin E TPGS) were obtained from Sigma Aldrich, St Louis, MO). All other reagents 
will be purchased at analytical reagent grade from Sigma Aldrich (St Louis, MO) and used without 
further purification. 
4.3.2. Cell Lines and Cell culture supplies  
RCC cell lines Caki-1, Caki-2, ACHN, and A-498 were kindly provided by and Dr. Rajvir 
Dahiya, Department of Urology, San Francisco Veterans Affairs Medical Center and University 
of California San Francisco, San Francisco, CA. The RCC UOK262 and UOK268 cells were 
kindly provided by Dr. WM Linehan, Urologic Oncology Branch, Center for Cancer Research, 
National Cancer Institute, National Institutes of Health, Bethesda, MD. The Caki-1 and Caki-2 
were grown in RPMI 1640 medium, and UOK 262, UOK 268, and Huh7 were routinely cultured 
in DMEM medium. All the cell culture media were also supplemented with 10% FBS, 100 units/ml 
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of penicillin, and 100 μg/ml of streptomycin, and the cells were maintained at 37 °C and 5% CO2. 
For cell growth and MTT studies, the cells were cultured in fresh media with 5% FBS prior to their 
treatments with various agents.   
DMEM, EMEM medium and antibiotics (penicillin and streptomycin) were purchased 
from Invitrogen Co. (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from Denville 
Scientific Inc. (Metuchen, NJ), and DMSO was purchased from Fisher Scientific (Fair Lawn, NJ). 
Enhanced Chemiluminescence Reagent kit was purchased from Amersham Biosciences 
(Piscataway, NJ) and the Protein Assay Kit was purchased from Bio-Rad Laboratories (Hercules, 
CA). The affinity purified, anti-CARP-1 polyclonal antibodies were described before 160,168. The 
mouse monoclonal antibody for b–actin and 3-[4, 5-Dimethylthiazol-2-yl]-2,5diphenyltetrazolium 
bromide (MTT) were obtained from Sigma-Aldrich (St. Louis, MO). Rabbit polyclonal antibodies 
for Cyclin B1, Cleaved Caspase-8, PARP, phospho and total p38a/b, phospho and total JNK1/2 
SAPKs were obtained from Cell Signaling Technology (Beverly, MA).  
4.3.3. SMA-TPGS Synthesis and micellar nano-formulation fabrication and characterization 
The block copolymer (SMA-TPGS) was first synthesized by adding known amounts of 
TPGS in NaHCO3 buffer at pH 8.9 with fixed amounts of anhydrous SMA to afford the anhydride 
ring opening reaction of SMA with the alcohol group of TPGS. All unconjugated reagents were 
removed by ultrafiltration (Millipore TFF, Milford, MA) of the SMA-TPGS conjugate prior to 
its lyophilization. We characterized nano-micelles by proton nuclear magnetic resonance 
spectroscopy (1H NMR) and Fourier transform infrared spectroscopy (FTIR). The structure of 
the synthesized SMA-TPGS copolymer was detected by 1H NMR in D2O. The -CH protons and 
methyl protons of SMA segment had signals at 5.2 and 1.69 ppm, respectively. The -CH2 protons 
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of PEO part of TPGS had the peak at 3.65 ppm. We noted the lower peaks in the aliphatic region 
that belong to various moieties of vitamin E tails 179,180. The proper synthesis of the SMA-TPGS 
copolymer was also confirmed by the FTIR analysis and was not found to be a physical mixture 
of TPGS with SMA as all measurements indicated the absence of any free crystalline particles 
in nano-micelles preparation. Both SMA and TPGS inhibited crystallization of CFM-4.16 during 
nano-micelles formulation. We then fabricated the CFM loaded micelles according to our earlier 
published protocols 155,161,162,181–187, followed by characterization of micelles for size, charge, 
critical micelles concentration (CMC), and drug loading as below. For Morphology, 
Transmission Electron Microscopy (TEM) of the nanoparticles was assessed using JEOL JEM-
1000 instrument (JEOL Ltd, Tokyo, Japan). Then, the products obtained were stored in the 
freezer until further use. 
4.3.4. Particle size, and zeta potentials  
The particle size and surface charge (zeta potential, ), measurements were performed 
using a Beckman Coulter Delsa Nano-C-DLS Particle analyzer (Miami, FL) equipped with a 658 
nm He-Ne laser. For particle size, we suspended the nano-micelles in de-ionized (DI) water and 
detected the scattered light at 165° angle. We then obtained the peak average histograms from the 
intensity, volume and number from 70 scans to calculate the average diameter of the particles. The 
zeta potentials were evaluated by measuring the electrophoretic mobility of the charged particles 
under an applied electric field.   
4.3.5. The Loading efficiency of SMA-TPGS-CFM nano-micelles 
We evaluated the CFM-4.16 loading content percentage in SMA-TPGS nano-micelles by 
High-Performance Liquid Chromatography (HPLC). First, a method for analyzing drug content 
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was developed and validated according to ICH guidelines 188. We measured the standard curve of 
CFM-4.16 in DMSO and its successive dilutions with mobile phase at 309 nm (λ max). The 
calibration curve was linear in the range of 50–50,000 ng/ml with a correlation coefficient (R2) = 
0.9999. The loading efficiency of micelles was calculated by dissolving a known amount of nano-
micelles directly in DMSO and further dilution of drugs with the mobile phase followed by 
determination of the absorbance at 309 nm with respect to the standard curve as described 
previously 169.  
4.3.6. Drug Encapsulation Efficiency (EE) 
Free drug (non-incorporated in the SMA-TPGS) was separated by ultrafiltration 
centrifugation technique. Briefly, 1 mL of CFM-4.16 and SMA-TPGS-CFM 4.16 colloidal 
solution were placed in the upper chamber of a centrifuge tube matched with an ultrafilter and 
centrifuged for 15 min at 4000 rpm. The total drug content in CFM-4.16 nano-formulation was 
determined as follows. Aliquots of 1mL formulation dispersion were diluted appropriately by 
ethanol to dissolve the TPGS-SMA ingredient, and the resulting suspension was then filtrated 
through 0.45µm membrane filters. The filtered solution was analyzed by Waters® Alliance e2695 
HPLC using Symmetry® C18 column (250mm × 4.6mm, 5µm). The mobile phase was a mixture 
of Acetonitrile, Methanol, 10mM KH2PO4 buffer (65:20:15 v/v) with pH adjusted to 2, and the 
flow rate was maintained at 1.0mL/min. All the samples were analyzed at 309nm using empower 
PDA software. We then calculated the encapsulation efficiency (EE) and drug loading content 
(DLC) by the following equations:  
𝐃𝐫𝐮𝐠 𝐥𝐨𝐚𝐝𝐢𝐧𝐠 𝐜𝐨𝐧𝐭𝐞𝐧𝐭 (𝐃𝐋𝐂) =
𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐂𝐅𝐌−𝟒.𝟏𝟔
 𝐞𝐧𝐜𝐚𝐩𝐬𝐮𝐥𝐚𝐭𝐞𝐝 𝐢𝐧 𝐦𝐢𝐜𝐞𝐥𝐥𝐞𝐬
𝐓𝐨𝐭𝐚𝐥 𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐂𝐅𝐌−𝟒.𝟏𝟔
 𝐥𝐨𝐚𝐝𝐞𝐝 𝐢𝐧 𝐦𝐢𝐜𝐞𝐥𝐥𝐞𝐬
 𝐱𝟏𝟎𝟎                      Equation (1)           
𝐄𝐧𝐜𝐚𝐩𝐬𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐄𝐟𝐟𝐞𝐜𝐢𝐞𝐧𝐜𝐲  (𝐄𝐄) =
𝐌𝐚𝐬𝐬  𝐨𝐟 𝐂𝐅𝐌−𝟒.𝟏𝟔
 𝐞𝐧𝐜𝐚𝐩𝐬𝐮𝐥𝐚𝐭𝐞𝐝 𝐢𝐧 𝐦𝐢𝐜𝐞𝐥𝐥𝐞𝐬
𝐓𝐨𝐭𝐚𝐥 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐂𝐅𝐌−𝟒.𝟏𝟔
𝐢𝐧𝐢𝐭𝐢𝐚𝐥𝐥𝐲  𝐥𝐨𝐚𝐝𝐞𝐝 𝐢𝐧 𝐦𝐢𝐜𝐞𝐥𝐥𝐞𝐬
 𝐱𝟏𝟎𝟎             Equation (2) 
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4.3.7. Cell viability assays (MTT) 
The cytotoxicity of CFM-4.16, SMA-TPGS copolymer, SMA-CFM-4.16, SMA-TPGS-
CFM-4.16 in the RCC cells (A498, UOK262, and UOK268) was assessed by MTT assay.  First, 
we seeded 5 X 103 cells in the 96-well plate in triplicate, allowed the cells to grow in fresh culture 
media for another 24h, and treated them with respective agents for the noted dose and time. Control 
cells were treated with 0.1% DMSO in culture medium. After treatment, we performed an MTT 
assay. Briefly, 20 μl of 1mg/ml of MTT was added to each well and cells were incubated for 2-4h 
at 370C. MTT was removed, and the resulting formazan products were dissolved by adding 50μl 
DMSO/well followed by colorimetric analysis using a multi-label plate reader at 570 nm (Victor3; 
PerkinElmer, Wellesley, MA). 
4.3.8. Protein expression (WB) Assays 
For protein expression analysis, the cells will be either untreated or treated with CFM-4.16 
or SMA-TPGS-CFM-4.16 nano-formulation for various times. Cells will be lysed in cell lysis 
(10X) buffer containing 0.1% of protease and phosphatase inhibitor cocktail (Sigma) for 20 min 
at 4ºC. The cell lysates will be centrifuged at 14,000 rpm at 4ºC for 15-20 min to remove debris. 
Protein concentrations of the clarified cell lysates will be determined using the Protein Assay Kits. 
The cell lysates (50-100µg from each sample) will be separated by SDS-PAGE and transferred to 
PVDF membrane (Bio-rad, Hercules, CA) by standard procedures. The membranes will be then 
hybridized with primary antibodies followed by incubation with appropriate secondary antibodies. 
The antibody-bound proteins were pictured by treatment with the chemiluminescence detection 
reagent based on manufacturer’s instructions, followed by exposure to X-ray film (Denville 
Scientific Inc.). The same membranes will be re-probed with the anti--actin antibody, which will 
be used as an internal control for protein loading. 
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4.3.9. Three-dimensional Renal sphere assays 
The RCC cells were obtained from xenograft tumors derived from parental cells (see 
below) or from the parental and Everolimus-resistant RCC cells from a two-dimensional culture 
plate with ~70-80% confluence. We performed the three-dimensional renal sphere cultures by 
essentially following the methods described by us before 169. Briefly, the cells were washed twice 
in 1 x PBS and trypsinized following established protocols. We then pelleted the cells at 200 x g 
at room temperature and re-suspended them in 5ml of sphere media (DMEM/F12 supplemented 
with 2mM L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, 1 x B27 supplement, 
20ng/ml recombinant human epidermal growth factor (EGF; Sigma), and 10ng/ml recombinant 
human basic fibroblast growth factor (bFGF; R&D Systems). We seeded ~5000 viable cells per 
ml in an ultra-low adherent 60mm plate and incubated them at 37°C and 5% CO2 for two weeks 
without disturbing the plates. After the spheres formed, we added fresh media with or without 
10µM CFM-4.16 and continued incubating cells for additional 24h at 37°C and 5% CO2. At the 
end of the incubation period, we photographed the spheres in the untreated and treated plates as 
described [45].   
4.3.10. Maximum tolerated dose (MTD) analysis and experimental design 
 Healthy non-tumor mice will be used to establish the MTD of the CFM-4.16. The MTD 
of CFM-4.16 is 30 mg/kg 159, thus the tolerance study will be find. The dose-limiting toxicity 
(DLT) is weight loss ≥10%. The study will begin at dose 30 mg/kg for CFM-4.16 and 60 mg/kg. 
If there are any DLTs, the level of CFM-4.16 will be reduced to 25 mg/kg and another cohort 
evaluated. If there are any DLT in this cohort, then CFM4.16 will be reduced by 20%. 
4.3.11. Establishment of RCC cell-derived xenografts in immunocompromised mice 
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The experiments involving generation of RCC cell-derived sub-cutaneous xenografts were 
performed according to our previously published methods and protocols approved by the 
Institutional Laboratory Animal Care & Use Committee (IACUC) at the Wayne State University 
160,169. Female, 5-weeks old NCR SCID mice with Lc Background were purchased from Charles 
River Laboratories (Horsham, PA). For subcutaneous (sc) tumor xenograft studies, we first 
determined maximal tolerated doses for CFM-4.16 (prepared in 10% DMSO/Cremophor + 
distilled, sterile water, and pH adjusted to 4.5), SMA-TPGS copolymer, SMA-TPGS-CFM-4.16, 
and SMA-CFM-4.16 preparations. The MTD for free CFM-4.16 (prepared in DMSO/Cremophor) 
have been described before, and a 30mg/kg/day iv injection was judged safe a total dose of 
482mg/kg provoked a mild ataxia with some tail and leg twitching that resolved within 1-2 
minutes. This dose/schedule of free CFM-4.16 produced a mild weight loss of 1.6% body weight 
by day 7(recovery by day 18). No other histological abnormalities were noted 160,169. A 
30mg/kg/day dose of SMA-TPGS, was injected (iv) while a 30mg/kg/day of SMA-TPGS-CFM-
4.16 was administered by oral gavage in two female, NCR SCID mice for 10 days. The animals 
did not show any signs of toxicity, discomfort, or any histological abnormalities. These 
observations indicate suitable toxicity profile of SMA-TPGS copolymer and its CFM-4.16 
formulation. However, the iv injections of a 30mg/kg were best tolerated when administered on 
alternate days. Accordingly, for the efficacy studies we chose to administer daily the block 
copolymer by iv route while the micellar formulation with CFM-4.16 was administered by oral 
gavage. The iv administration of the CFM-4.16 micellar formulation was conducted on every 
alternate day. 
For efficacy studies, after a suitable period of acclimation, we subcutaneously implanted a 
suspension of 1 x 106 A498 RCC cells in 200µl of serum-free Hank’s balanced salt solution in 
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flanks of each animal using a 27-gauge needle. Tumors were allowed to grow unperturbed for 10-
14 days. When tumors became palpable (200 mm3), the mice were randomly assigned to treatment 
or control groups of eight animals each. Mice were treated with Control, PBS only, SMA-TPGS 
copolymer (30mg/kg; iv), SMA-TPGS-CFM-4.16 formulation (30mg/kg/day) by oral gavage for 
10 days. In the case of the group of mice treated with iv administration of SMA-TPGS-CFM-4.16 
formulation (30mg/kg), only two injections were administered where the first dose was followed 
by the second dose on the alternate day. The tumor weight and volume were measured daily, and 
mice were observed for changes in weight and side effects. The endpoints for assessing antitumor 
activity consisted of tumor weight, tumor growth inhibition (%T/C), and tumor cell kill Log10. 
Tumor weight (mg) = (A X B2)/2 where A and B are the tumor length and width (in mm), 
respectively. Tumor growth inhibition (T/C) was the median tumor weight in the treated group (T) 
when the median tumor weight in the control group reached 750mg. Results were expressed as 
percentage. According to NCI-accepted criteria, a treatment is considered effective if T/C is < 
42%. Tumor growth delay (T-C) is the difference between the median time (in days) required for 
the treatment group tumors (T) to reach 1000 mg and the median time (days) for the control group 
tumors to reach the same weight. The animals were sacrificed on day 10 and tumor tissues were 
collected immediately after tumor volume measurement. Tumor volumes were calculated by the 
modified ellipsoidal formula. Tumor volume = 1/2(length × width2). Representative tumor 
samples were stored at –80°C for subsequent analysis.  
4.3.12. Statistical analysis 
The Data will be presented as mean ± SD for the absolute values for all experiments. The 
cell growth inhibition after treatments will be statistically evaluated using Graph Pad Prism 6.0 
software (Graph Pad Software Inc., San Diego, CA Comparisons will be made between control 
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and treatment groups. P<0.05 will be used to indicate statistical significance. For in vivo 
experiments, the statistical significance of differential findings between all formulations and 
control mice will be determined by Student's t-test. The p-values smaller than 0.05 will be 
considered statistically significant.  The data were expressed as mean ± SEM and analyzed using 
a two-tailed Student t-test or one-way ANOVA followed by a post hoc test. A p value of <0.05 
was considered statistically significant. 
4.4. Results 
4.4.1. Nanomicellar formulation Synthesis and characterization 
The block copolymer (SMA-TPGS) was first synthesized and well characterized. The so-
formed SMA-TPGS conjugate was purified by ultrafiltration to remove all unconjugated 
molecules before lyophilizing. Figure 4.1 illustrates the schematic representation of the 
Nanocarrier synthesis by using EDC/NHS coupling chemistry. 
4.4.1.1. H-NMR and FTIR 
 Nanomicelles were characterized by proton nuclear magnetic resonance spectroscopy (1H 
NMR) and Fourier transform infrared spectroscopy (FTIR). The structure of the synthesized SMA-
TPG copolymer was detected by 1H NMR in D2O. Figure 4.2(A) shows a typical 1H NMR 
spectroscopy of the SMA-TPGS copolymer and monomers. The signals at 5.2 and 1.69 ppm were 
assigned to the -CH protons and methyl protons -CH3 of SMA segment, respectively. The peak at 
3.65 ppm was assigned to the -CH2 protons of PEO part of TPGS. The lower peaks in the aliphatic 
region belong to various moieties of vitamin E tails 173,179,189.  In FTIR analysis, we confirmed that 
the SMA-TPGS copolymer was synthesized by the EDC/NHS coupling chemistry as it is shown 
in Figure 4.2(B). The product was not a physical mixture of TPGS with SMA and all measurements 
indicated the absence of any free crystalline particles in nanomicelles preparation and both SMA 
and TPGS could inhibit crystallization of CFM4.16 during nanomicelles formulation. 
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Figure 4.1. (A) The pictorial representation of SMA-TPGS copolymer synthesis with 
encapsulation of CFM-4.16 and (B) accumulation of nano-micelles (SMA-TPGS-CFM-4.16) and 
internalization at tumor site by endocytosis due to EPR effect. Then, a schematic representation 
for mechanism of action of CFM-4.16. It is works on inhibition of CARP-1 binding with APC/C 
subunit APC2. Also, it inhibits the growth of tumor cells in part by inducing CARP-1 expression, 
promoting PARP cleavage, activating pro-apoptotic stress-activated protein kinases (SAPK) p38 
and JNK, and apoptosis. 
B. 
CFM 4.16  
mechanism  
of action 
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Figure 4.2. (A) 1H NMR profile for polymers used (SMA and TPGS) and the conjugated polymer 
(SMA-TPGS). The structure of the synthesized SMA-TPGS copolymer was detected by 1 H NMR 
in D2O. The -CH protons and ring protons of SMA segment had signals at 1.69 ppm and 7.3 ppm, 
respectively. The-CH2 protons of PEO part of TPGS had the peak at 3.65 ppm. We noted the lower 
peaks in the aliphatic region that belong to various moieties of vitamin E tails. These peaks have 
been identified as well in the conjugated polymer as indicated by arrows. (B) FTIR data for 
polymers used (SMA and TPGS) and the conjugated polymer (SMA-TPGS). The arrows indicated 
(A) 
(B) 
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forming an amide bond between the conjugated polymer (SMA-TPGS). Peaks were identified for 
C-N bond, C=O stretching, and N-H stretching at around 1100, 1640-1690, and 3100-3500 cm−1, 
respectively. Adapted from 1. 
4.4.1.2.Particle size distribution and zeta potential  
Using dynamic light scattering (DLS), the average size and size distribution of the micelles 
was shown in Figure 4.3 and Table 1 (mean ± SD, n=3). The mean diameter, the polydispersity 
index, and the Zeta potential of SMA-TPGS-CFM-4.16 were 144.6nm±20nm, 0.275, and -7.86Mv, 
respectively. The drug-loaded nanoparticles can be prepared with or without TPGS added as a 
copolymer in the fabrication process. This is because the TPGS component in the copolymer has 
a self-emulsifying function. This is an advantage of the SMA-TPGS copolymer in nanoparticle 
formulation, which circumvents the side effects of the traditional formulation vehicle Cremophor 
EL®, which has been used for various poorly-water soluble drugs. 
The particle size for all samples was found around 146 nm with narrow size distribution of 
less than 0.275 polydispersity. The obtained results, of particle size of CFM4-16 loaded 
nanomicelles was ~145 nm and surface charge were -7.86 mV Figure 4.3 (A).  It can be observed 
from Table 4.1 that addition of TPGS in the process as emulsifier slightly increased the particle 
size. This is because the coating effects of TPGS on the particle surface and extra TPGS on the 
particle surface may cause aggregation of the formed nanoparticles. Zeta potential determines the 
particle stability in dispersion. High absolute value of the zeta potential defines high surface charge 
of the nanoparticles, which leads to strong repellent interactions among the nanoparticles in 
dispersion and thus high stability. The zeta potential of the TPGS emulsified, CFM-4.16-loaded 
SMA-TPGS nanoparticles was found to be about -7.86 mV. Similar results were found for the 
SMA-CFM-4.16 loaded nanoparticles.  
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Figure 4.3. (A) Particle size and Zeta potential characterization of SMA-CFM and FA-SMA-CFM 
using Dynamic light scattering (DLS) technique; (B) Transmission Electron Microscopy for 
optimized SMA-TPGS Nano micelles. 
4.4.1.3. Critical Micellar Concentration (CMC) and TEM (Morphology) 
Additionally, Surface morphology of the drug-loaded SMA-TPGS nanoparticles was 
examined by Transmission Electron Microscopy (TEM). It showed in Figure 4.3 (B) the particle 
(A) 
(B) 
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size (160nm) little bigger than the one tested by DLS. It also showed the micelles nanoparticles 
were spherical or quasi-circular and homogenous with no aggregates were existed. The particles 
seemed to have smooth surface within the TEM resolution level. The smooth surface may 
contribute to a slower drug release from the nanomicelles than that from those of rough surface. 
No difference was noticed between CFM-4.16 loaded and unloaded nanomicelles in term of 
morphology. The loading of CFM-4.16 has no significant effect in nanomicellar mean diameter, 
polydispersity index, and Zeta potential in comparison to unloaded nanomicelles. These results 
indicate that the size and surface properties are optimal and safe for intravenous injection as well 
as ideal for tumor delivery by passive targeting (by the EPR-effect153,155,190,191). The micelles were 
also characterized for critical micelles concentration (CMC) and it was identified as 0.01 mg/ml 
Figure 4.3(A).         
   
Figure 4.4. (A) Critical micellar concentration (CMC)  for SMA-TPGS nanomicelles.(B) HPLC 
method validation and chromatogram. 
 
4.4.1.4. Drug Loading and Encapsulation efficiency 
It has been known that the polymer used in the fabrication process and the drug loading 
level are important factors to influence the particle size and size distribution and the drug 
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encapsulation efficiency in the polymeric nanoparticles 192; as results, it will determine the drug 
release kinetics, cellular uptake and then the therapeutic efficacy of the drug-loaded nanoparticles 
189,193,194. Table 4.1 also shows the drug loading and TPGS effects on size and size distribution and 
the drug loading efficiency. It can be identified that the SMA-TPGS nanoparticles prepared with 
no emulsifier (TPGS) added can result in satisfactory drug EE, which was found to be 77% for 
17% drug loading and with TPGS to be 85.5% for 29% drug loading found by HPLC as shown in 
Figure 4.4 (B). This is normal since the higher the drug loading is because there will be more space 
for drug encapsulation with taking the advantage of TPGS amphiphilic structure. For the less drug 
loading of 17% in case of SMA-CFM-4.16; however, the EE of the CFM-4.16-loaded SMA-TPGS 
nanoparticles can be improved by adding TPGS in the process as emulsifier. Nevertheless, the 
amount of TPGS to be added should be carefully figured out. The amphipathic surfactants align 
themselves at the oil–water interface to promote the stability of the particles by lowering the 
surface energy and thus resist coalescence and flocculation of the particles. 
Table 4.1. Characterization of SMA-TPGS nano-micelles 
Sample CMC 
(mg/ml) 
Hydrodynamic 
size (nm) 
PDI Zeta 
potential 
(mV) 
EE (%) 
SMA-TPGS-
CFM-4.16 
0.010 144.6±20nm 0.275±0.05 -7.86 ±4 85.5±12 
SMA-CFM-4.16 0.023 123±31nm 0.163±0.07 -18±5 77±9 
Abbreviations: SMA, styrene maleic acid; TPGS, d-α-tocopheryl polyethylene glycol succinate; 
CMC, critical micelle concentration; PDI, polydispersity index; EE, encapsulation efficiency. 
 
4.4.1.5. Stability indication characterization 
Storage conditions of 4 °C, 25 °C, and 35°C with light protection for 2 months as shown 
in Table 4.2 indicated that the CFM-4.16 remains encapsulated in the nano-micelles, indicating 
that SMA-TPGS-CFM-4.16 nanoformulations were very stable with a recovery percentage of 
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99.73±1.10 at 4 °C, 94.9±7.2 % at 25 °C, and 92.88 ±1.78 at 35°C. These results indicated that 
both conditions (4 °C and 25 °C) would be more appropriate for storing the nanoformulations.  
  
4.4.2. Nanomicellar formulation of CFM-4.16 improve its release kinetics characteristics   
The CFM compounds have poor aqueous solubility and consequent poor bioavailability 
for their use and development as potential anti-cancer agents. To address this issue, we previously 
generated and tested nano-lipid formulations (NLFs) of CFM-4 and CFM-4.16 compounds. These 
NLFs resulted in significant improvements in overall bioavailabilities of CFM-4 and CFM-4.16 
when compared with the respective free compound 160,169. Here we generated nano-micellar 
formulations of CFM-4.16 and tested their abilities to inhibit growth of parental and resistant RCC 
cells in vitro and in vivo. As a first step, we synthesized, purified, and characterized a block 
copolymer (SMA-TPGS) as detailed in methods. The proton nuclear magnetic resonance 
spectroscopy (1H NMR) and Fourier transform infrared spectroscopy (FTIR) analysis revealed that 
the SMA-TPGS copolymer was a conjugate and not a physical mixture of TPGS with SMA Next, 
we generated and characterized SMA-CFM-4.16 and SMA-TPGS-CFM-4.16 formulations. The 
mean diameter, the polydispersity index, and the Zeta potential of SMA-TPGS-CFM-4.16 
formulation were 144.6nm ±20nm, 0.275 ±0.05, and -7.86 ±4 mV, respectively. The mean 
diameter, the polydispersity index, and the Zeta potential of SMA-CFM-4.16 formulation however 
Table 4.2.  Percent drug content of nanomicellar formulations after 60 days (n=3). Values 
expressed as mean ± standard deviation (SD) 
Formulation Temperature  
4ºC 25ºC 35ºC 
SMA-TPGS-CFM4.16 
(% drug content) 
99.73±1.10 94.9±7.2 % 92.88 ±1.78 
SMA-CFM4.16 
 (% drug content) 
101.41± 0.53 96.42±0.42 90.81±1.32 
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were 123nm ±31nm, 0.163 ±0.07, and -18 ±5 mV, respectively.  The slight increase in the particle 
size of the TPGS containing formulations is understandable, due to the hydrophilic PEG chains 
protruding out thereby increasing the hydrodynamic diameter. The critical micelles concentration 
(CMC) of the formulations was 0.010 and 0.023 mg/ml for SMA-TPGS-CFM-4.16 and SMA-
CFM-4.16, respectively indicating high stability even on dilution of the sample. The Transmission 
Electron Microscopic (TEM) analyses did not indicate any morphological differences between 
CFM-4.16 loaded and unloaded nano-micelles (appendix). The loading of CFM-4.16 also had 
insignificant effect on the nano-micellar mean diameter, polydispersity index, or Zeta potential in 
comparison to the unloaded nano-micelles.  
 The type of polymer and the drug loading levels are critical factors that often influence 
drug release kinetics, cellular uptake and the therapeutic efficacy of the drug-loaded nanoparticles 
192,195,196. We then determined the encapsulation efficiency (EE) and drug loading content (DLC) 
for our formulations as detailed in methods. The EE and DLC for the SMA-CFM-4.16 was 77% 
and 17% respectively. The EE and DLC parameters for SMA-TPGS-CFM-4.16 preparation were 
85.55 and 29%, respectively, suggesting improved loading due to the inclusion of emulsifier, 
TPGS. We next determined the stability of the formulations by their extended (2 months) storage 
at 4°C, 25°C, or 35°C with light protection. CFM-4.16 remained encapsulated in the SMA-TPGS 
nano-micelles with a recovery percentage of 99.73 ±1.10 at 4°C, 94.9 ±7.2 at 25°C, and 92.88 
±1.78 at 35°C. The recovery percentage of CFM-4.16 in SMA encapsulated formulation was 
101.41 ±0.53 at 4°C, 96.42 ±0.42 at 25°C, and 90.81 ±1.32 at 35°C. Altogether, our results indicate 
that the CFM-4.16 micellar formulations have suitable drug loading and particle characteristics 
and can be stored at 4°C or at room temperature (25°C). Based on this information, we proceeded 
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to determine whether the CFM-4.16 nano-micellar formulations inhibit growth and viability of 
parental and drug-resistant RCC cells in vitro and in vivo as detailed below. 
4.4.3. Nanomicellar formulation of CFM-4.16 inhibits growth of parental and Everolimus-
resistant RCC cells in vitro and in vivo in part by stimulating apoptosis   
Next, we treated the parental RCC cells and their respective, Everolimus-resistant sublines 
with various doses of block copolymer (SMA-TPGS), free CFM-4.16, SMA-CFM-4.16, and 
SMA-TPGS-CFM-4.16 for 24h. The RCC cell viabilities were determined as described in 
methods. As shown in Figure 4.5 A and B, the treatments of cells with various doses of block 
copolymer alone elicited a very modest to no loss of their viabilities when compared with their 
untreated counterparts. The free CFM-4.16 or its nano-micellar formulations, on the other hand, 
inflicted a significant loss of viabilities of the parental as well as Everolimus-resistant RCC cells 
when compared with their respective, untreated counterparts. Of note is the fact that the free 
compound or its formulations at the three respective doses of each provoked a generally similar 
degree of reduction in RCC cell viabilities that ranged between 40-80%. A498 parental and 
resistant RCC cells albeit were more sensitive to the 10μM dose of either of the micellar 
formulations when compared with their CFM-4.16 treated counterparts, overall a similar range of 
reduction in the viabilities of cells that were treated with free compound or its micellar 
formulations would suggest for an excellent in vitro activity of CFM-4.16 formulations. Consistent 
with our data in Chapter 3, the western blot analysis further revealed that treatments of parental or 
Everolimus-resistant RCC cells with 10μM dose of respective micellar formulations of CFM-4.16 
also caused activation of pro-apoptotic SAPKs, P38α/β and JNK1/2, CARP-1 expression, and 
PARP cleavage when compared with their respective block copolymer (SMA-TPGS)-treated cells 
(Figure 4.5. C, D).  
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Figure 4.5. Nano-micellar formulations of CFM-4. 16 inhibits growth and stimulates apoptosis in 
parental and Everolimus-resistant RCC cells. (A, B) Indicated RCC cells were either untreated 
(Control), treated with SMA-TPGS, CFM-4.16, SMA-CFM-4.16, or SMA-TPGS-CFM-4.16 for 
noted dose and time. (A, B) Cell viability was determined by MTT assay. The histogram columns 
represent means of three independent experiments with 4-6 replicates for each treatment; bars, S.E. 
(C, D) Cell lysates were analyzed by Western blotting (WB) as noted in Methods for levels of 
CARP-1, cleaved PARP and activation (phosphorylation) of pro-apoptotic p38, and JNK1/2 
SAPKs essentially. Adapted from 1. 
 
 
  C   
Cell Line CFM-4.16, 72h, IC50 (uM) 
A498 Wild type ≈0.90 
UOK262 Wild type ≈0.85 
HEK 293 Wild type ≈9.2 
HK2 Wild type ≈3.8 
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Figure 4.6. RCC cells are more sensitive to inhibition by CFM-4.16 when compared with non-
cancer renal epithelial cells. (A, B) Indicated cells were treated with 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, and 
10.0 uM dose of CFM-4.16. Percent cell viabilities were determined relative to respective DMSO-
treated controls. The histogram (Lines in A or Columns in B) represent means of two independent 
experiments with 4-6 replicates of each dose for the respective cell type (C) IC50 values of RCC 
and Renal epithelial cells treated with CFM-4.16 as in panels A and B.  
 
 
4.4.4. Nanomicellar formulation of CFM-4.16 inhibits growth of parental and Everolimus-
resistant RCC cells in vivo  
We next examined the in vivo antitumor efficacy of nano-micellar formulation of CFM-
4.16 (SMA-TPGS-CFM-4.16) in a highly aggressive RCC A498 orthotropic xenograft tumor 
bearing SCID mice as described in methods and our published protocols 157,159.  In our previous 
studies, we prepared CFM-4.16 by dissolving it in 10% DMSO/Cremophor plus sterile, distilled 
water with a pH of 4.5. We administered a dose of 30mg/kg/day of this preparation by intravenous 
(tail vein) injections for a total dose of 482mg/kg in SCID mice bearing human TNBC cell-derived 
xenografts. With the exception of a mild, <2% loss in body weight, the preparation did not cause 
any histological abnormalities in the treated animals and lacked a therapeutic T/C values 159. On 
this basis, we chose a 30mg/kg/day dose of CFM-4.16 (free compound as DMSO/Cremophor 
preparation or nano-micellar formulation) for use in current in vivo experiments. As shown in 
Figure 4.7A, intravenous (iv) administration of vehicle (Control) SMA-TPGS (total dose of 
120mg/animal), DMSO/Cremophor preparation of CFM-4.16 (total dose of 240mg/animal), or 
administration of SMA-TPGS-CFM-4.16 (total dose of 210mg/animal) by oral gavage failed to 
inhibit tumor growth. However, only two i.v. injections of 30mg/kg/day of SMA-TPGS-CFM-
4.16 (total dose of 60mg/animal) caused a significant reduction in tumor size when compared with 
the tumor sizes noted in the other treatment groups (Figure 4.7A). The HPLC analysis of the tumors 
from animals treated with i.v. injections of SMA-TPGS-CFM-4.16 revealed presence of CFM-
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4.16 in tumors. In addition, after the completion of the animal experiment, tumors from treatment 
and control groups were dissected, and cryosectioned for imaging of apoptotic signs using TUNEL 
(Terminal deoxynucleotidyl transferase dUTP nick end labeling) and CARP-1. The immuno-
histological analysis of tumors from animals treated with i.v. injections of SMA-TPGS-CFM-4.16 
showed elevated levels of CARP-1 and TUNEL-positive cells when compared with the tumors 
derived from the animals of control group (Figure 4.7B). Thus, the data suggest that nano-micellar 
formulation of CFM-4.16 enhance anti-tumor efficacy of CFM-4.16 when administered i.v. but 
not orally, at a significantly lower total dose when compared with the free compound. 
 
Figure 4.7. Nano-micellar formulation of CFM-4. 16 inhibits growth of RCC cell-derived 
xenografts. (A) Histogram showing tumor size in the vehicle-treated (indicated as Control), CFM-
4.16, or SMA-TPGS-CFM-4.16 (p.o. or i.v.) treated, RCC (A498) xenograft-bearing animals. The 
xenograft establishment, treatment and analysis procedures were carried out essentially as detailed 
in Methods. The columns represent average values from a total of eight animals in respective 
group, bars, SE, significant where *p = 0.05 vs Control. (B) SMA-TPGS-CFM-4.16 treatments 
(iv) induce CARP-1 expression and apoptosis in RCC tumor xenografts. Representative tumor 
tissues from two animals each from the vehicle-treated (noted as Control) or SMA TPGS-CFM-
4.16 treated groups were fixed in formalin, paraffin embedded, processed, and subjected to 
immuno-staining as detailed in Methods. Photomicrographs (400 x magnification) are shown for 
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apoptosis (by TUNEL assay), and levels CARP-1 protein as noted in methods. Elevated apoptosis 
is indicated by increased brown staining or dark-brown spots in SMA-TPGS-CFM-4.16 panels 
stained with anti-CARP-1 antibodies or TUNEL, respectively. Adapted from 1. 
 
 
 
                
 
Figure 4.8. (A) Body weight changes of mice during treatment course. The lines represent average body 
weight from a total of eight animals in respective group that were measured on the indicated days; bars, SE. 
(B) Tumor size of mice during treatment. The line represents average values from a total of eight animals 
in respective group, bars, SE. (C) Amount of CFM4.16 remaining in the blood after the last injection of 
drug. The histogram columns represent means of CFM-4.16 concentrations from three animals from the 
indicated treatment group; bars, S.E. 
 
(A) (B) 
(C) 
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4.5. Discussion 
CFM-4 and its analog CFM-4.16 have poor aqueous solubility of <1mg/ml. This attribute 
contributes to poor dissolution with consequent poor absorption and bioavailability. Recent 
advances in nano-formulation-based technology have allowed optimization of poorly soluble 
compounds for preclinical as well as clinical testing and use. In our prior proof-of-concept studies, 
nano-lipid formulations of CFM-4 and CFM-4.16 compounds were prepared by combining high-
melting solid lipid carriers and vitamin E TPGS co-surfactant. These formulations were 
demonstrated to not only enhance solubility and oral bioavailability of the CFMs, but also were 
effective in suppressing NSCLC and TNBC cell-derived tumor growth in pre-clinical animal 
models when administered orally 159,160. Here we prepared a polymeric micelle based nano-drug 
delivery system of CFM-4.16 to improve its dissolution and bioavailability. A nanomicellar 
formulation of SMA-TPGS and CFM-4.16 resulted in improved dissolution and consequent 
enhanced absorption, which was also evident by the improved pharmacokinetic profile as 
previously reported 159,160. Vitamin E-TPGS is FDA approved co-surfactant that acted as stabilizer 
and permeation enhancer while SMA contributed to good micellar property 172,197,198. Thus, 
chemical conjugation of SMA and TPGS, namely SMA-TPGS creates more hydrophobic space, 
which provides higher CFM-4.16 encapsulation efficacy. Due to the crystalline nature of matrix 
lipids in solid particles, the space for the drug loading is often limited. Size and surface coating 
also play an important role in determining the mechanism and efficiency of nanoparticle. The 
particle size of ~145 nm and surface charge is -7.86 mV of the CFM-4.16 loaded nanomicelles are 
optimal and safe for systemic (intravenous or oral) drug administration as well as competent for 
tumor delivery by passive targeting EPR-effect 178,190,199.  
78 
 
 
 
Our preliminary studies here indicate that both free and SMA-TPGS formulation of CFM-
4.16 inhibit growth of RCC cells in vitro, in part by stimulating apoptosis. Consistent with our 
prior findings, CFM-4 or CFM-4.16 caused loss of cyclin B1, and upregulation of CARP-1, 
activation of p38 and JNK1/2 SAPKs, and cleavage of PARP in the RCC cells. Intravenous 
administration of the nano-micellar formulation of CFM-4.16 inhibited growth of RCC cell-
derived tumor xenografts in vivo in part by stimulating CARP-1 levels and apoptosis. Taken 
together, our current data provide us with a further rationale to develop CFM compounds and their 
formulations for targeting parental and resistant RCCs. 
4.6. Conclusions 
CARP-1 functional mimetics (CFMs) are novel small molecule inhibitors of RCC. In 
addition, CFMs induce apoptosis by activating SAPKs and elevating CARP-1. In this study, we 
employed a nanotechnology to tackle the poor aqueous solubility of a potent CFM compound 
(CFM-4.16) which restricts its in vivo therapeutic efficacy. This SMA-TPGS-CFM-4.16 
formulation maintained its nanoparticulate nature, homogenous polydispersity and high drug 
encapsulation efficacy. Since free CFM-4.16 or SMA-TPGS-CFM-4.16 elicited similar effects on 
cell viability, and levels of apoptosis would indicate that the anti-cancer effects of CFM-4.16 are 
retained in nanoformulation. Moreover, the physicochemical analyses indicate an optimum release 
of CFM-4.16 from nanoformulation. Together the physicochemical characteristics and biological 
activity of SMA-TPGS-CFM-4.16 seem promising for their use in future pre-clinical in vivo 
studies for the RCC tumor models. 
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5. CHAPTER 5. TUMOR HYPOXIA DIRECTED MULTIMODAL 
NANOTHERAPY FOR OVERCOMING DRUG RESISTANCE IN RENAL CELL 
CARCINOMA AND REPROGRAMMING MACROPHAGES 
 
Results from the following studies have been submitted to Biomaterials Journal: CA-IX as a 
selective approach for targeting RCC and overcoming resistance with combining drugs 
approach 
5.1. Objectives 
Studies conducted includes: (i) Development of an ATZ-conjugated polymeric lipid 
nanoformulations library for the selective delivery of a drug cocktail to the hypoxic region of 
therapy resistant RCC. (ii) Also, to alleviate the RCC drug resistance, we have used Sorafenib 
(Sor) in combination with tumor hypoxia directed nanoparticle (NP) loaded with a new class of 
apoptosis inducer, CFM 4.16 (C4.16), namely CA IX-C4.16. (iii) Authenticated RCC cell lines 
such as WT (A498, UOK262) and Evr-res (A498, UOK262) will be utilized as RCC cells, as well 
as Raw 264.7 (macrophage) for macrophage phenotyping studies. The following will be 
investigated (1) a synergistic anticancer effect of CFM-4.16 with TKIs, (2) the role of M2-
macrophages in tumor immune evasion, and (3) the mechanism of inhibiting tumorigenic cross-
talk between RCC epithelial cells and M2-macrophages using NPs. The tumor environment 
mimetic advance spheroid and Transwell cell culture models will be used to establish efficacy.  
5.2. Introduction 
Renal Cell Carcinoma (RCC) contributes to >90% of the most common form of kidney 
cancer and remains one of the ten leading causes of cancer deaths. It has been estimated 
that each year around 60,000 new patients are diagnosed with, and about 13,500 succumb 
to RCC 8. Thus, RCC represents one of the most lethal malignant urological tumor 200. The 
common form of RCC (more than 95%) is clear cell renal cell carcinoma (ccRCC) 83. The 
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mutation and inactivation of tumor suppressor Von Hippel-Lindau (VHL) gene is 
frequently observed in this malignancy that leads to a higher intracellular level of hypoxia-
inducible factors 1α and 2α (HIF1α and HIF2α). The increased level of HIF-1α in RCC 
effectively regulates the tumorigenesis by upmodulating the function of AKT and VEGFR 
kinases that play an essential role in cellular metabolism, apoptosis inhibition, and hypoxia 
induction 201. All these factors promote RCC to develop resistance to radiotherapy and 
conventional chemotherapy 202,203. Several receptor tyrosine kinase inhibitors (TKIs), 
mammalian target of rapamycin inhibitors (mTOR) and serine-threonine kinase (STK) 
inhibitors are clinically approved for the treatment of RCC 166, although the benefit of 
overall progression-free survival remains poor (5-year survival rate of <10%). Thus, there 
is an urgent unmet need for targeted combination therapies with novel cell killing 
mechanisms 102,204. Although, TKIs and mTOR inhibitors have increased therapeutic 
possibilities for treating RCC, a substantial proportion of patients do not respond 
adequately, and therapy resistance almost inevitably occurs. Recently, new strategies have 
also emerged that include immunotherapy such as PD-1 inhibitor (Nivolumab) 117 and the 
combination of chemo-immune therapy 103. These developments suggest that combination 
treatments aimed at different, non-related pathways could be advantageous 112,113,146. In 
addition, due to the increase in vascular nature and high level of vascular permeability 
factor, ccRCC patients have benefited from anti-VEGFR cancer therapy. Over a period of 
time, the majority of the  RCC patients ultimately develop a refractory response to anti-
VEGFR treatment that is due to poor vascularization at the tumor core associated with 
tumor hypoxia 205. In this regard, delivery of the therapeutic payload to the tumor hypoxic 
(core) is a rational approach for improving the current therapy. Additionally, development 
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of novel synergistic therapeutic strategies, such as the resurrection of apoptosis, inhibition 
of AKT, and suppression of tumorigenic macrophages are desirable to tackle the current 
clinical challenges of drug-resistant and highly aggressive RCC 157. We have developed 
Evr-res RCC cell model to evaluate the reversal of drug resistance using nano-combination 
therapy. We pursued different combination regimens, including drugs Evr (mTOR 
inhibitor) and Sorafenib or Cabozantinib (both VEGFR and MET inhibitors).  
The hypoxic tumor environment, highly prevalent in poorly vascularized and necrotic tumor 
core is well known to stimulate expression of VEGF and CA IX. CA IX is a membrane-
bound protein that is overexpressed on the surface of many cancer cells in a hypoxic 
environment 122. CA IX  tightly controls the acid-base balance in the kidney 122,  whereas 
during malignancy CA IX is involved in tumor cell survival and metastasis, and its 
increased expression correlates with poor clinical outcome. More than 7-clinical trials are 
underway to target CA IX in RCC and other solid tumors [NCT00059735, NCT00884520] 
that fortifies CA IX as an excellent biomarker for selective hypoxia mediated payload 
delivery. Numerous studies have investigated CA IX distribution in normal tissues and 
malignancies 124–129. Over-expression of CA IX has been documented in 93-97% of 
ccRCCs with rather low to limited expression in normal tissues/organs making it a selective 
biomarker for RCC 123. Indeed, CA IX is almost homogeneously over-expressed in the 
ccRCC subtype 84,111,124–129. Given the favorable tissue distribution, the potential of CA IX 
targeting of RCC for diagnosis or therapy has also been studied 130,131. Due to the unique 
molecular attribute of RCC, CA IX is regarded as an excellent target for diagnosis and 
possibly for targeted therapy 111,126–128,132. Clinical trials have unambiguously demonstrated 
that CA IX can be targeted to RCC tissues with minimal damage to normal tissues, further 
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highlighting suitable toxicity profiles of CA IX targeting 133,134. However, there are no 
currently approved therapies against CA IX 164. Monoclonal antibodies have been used to 
target CA IX, but their large molecular weight limits penetration through the poorly 
vascularized tumor and their slow blood clearance minimize their utilization as tumor 
imaging agents or radiotherapeutics because of high background and toxicity 134. Finally, 
some recent studies have investigated whether small molecule CA IX-inhibitors can be 
used in serum assays or as an imaging target to monitor therapy responses 127–129. 
Importantly, there is a critical need to develop safe and effective delivery vehicles that can 
carry the payload to the desired target tissue and cells 157,185,206–209.  
Toward this end, we developed a simple and efficient multistage nanoplatform for 
systemically targeted polypharmacy payload delivery to induce the combination of 
chemotherapeutic and immunotherapeutic effect in RCC. The oligomer we developed 
comprised of Vitamin-E- α-D-Tocopherol (TPGS) and styrene maleic anhydride (SMA) 
ligated with Acetazolamide (ATZ), namely CA IX-SMA-TPGS. The CA IX-SMA-TPGS 
oligomer was further encapsulated with C4.16 to obtain highly potent therapeutic payload 
containing nanoparticle CA IX-C4.16, respectively. The CA IX-C4.16 NPs have 
homogenous nanoparticle nature with narrow polydispersity index that is suitable for in 
vivo delivery. For ease of chemical synthesis of oligomers, we utilized copper free ‘click’ 
chemistry. We have discovered and demonstrated CCAR1/CARP-1 protein as an inducer 
of apoptosis in RCC and other types of cancer. Upregulation of CARP-1 activates 
“apoptosis hallmarks”, such as caspase mediated PARP cleavage, downregulation of 
PI3K/AKT signaling and loss of cyclin B1 in RCC157. Our collaborator recently identified 
the potent activators of CARP-1, a library of small molecule CARP-1 functional mimetic 
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(CFM) compounds. CFM-4.16 (namely C4.16), is highly efficient in RCC cell killing as 
noted from NCI-60 screen 157. Our data revealed that C4.16 is a superior inhibitor of both 
WT and Evr-resistant RCC cells with 4-5-fold improvement in IC50 value as compared to 
FDA approved Evr or Sor. In 2007, Sorafenib (Sor), a potent multi-kinase inhibitor of 
tumor-cell proliferation and angiogenesis, was clinically approved for oral treatment of 
advanced RCC with the median progression-free survival of 5.5 months 210. Along with 
this encouraging clinical outcome, there are a few reports on durable responses of Sor or 
the other VEGFR pathway blockers. However, the majority of patients develop resistance 
to Sor within a median of 5–9 months 211. Thus, more efficient and divergent combination 
therapy for inhibiting multiple tumorigenic pathways in RCC is required. Toward this, we 
found the combination of Sor and CA IX-C4.16 showed remarkable synergy in killing WT 
and Evr-res RCC cells. This combination treatment caused a complete wipeout of activated 
AKT (P-AKT) level, upregulated apoptosis hallmarks, such as caspase 3/7 and annexin V. 
The CA IX-C4.16+Sor is promising in upmodulating tumoricidal function of M-1 
macrophage, while downmodulating tumorigenic M-2 macrophage-associated biomarkers, 
such as CD206, arginase-1. Further, NIR imaging of CA IX-SMA-TPGS-S0456 confirmed 
the selective tumor accumulation of the vehicle with ~6-fold higher tumor/liver as 
compared to control. The high intensity of NIR-dye in tumor core indicates selectivity of 
CA IX-SMA-TPGS-S0456 in tumor hypoxia targeting. Finally, the significant tumor 
growth inhibition by CA IX-C4.16+Sor in Evr-res A498 model underscores the rationale 
of using Sor in combination nanotherapy as a promising platform in reversing drug 
resistance with untraceable liver and kidney toxicity (Scheme 1). 
5.3. Materials and methods 
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5.3.1. Cell culture, reagents, and chemicals  
Structure and synthesis of the C4.16 compound have been previously described 
157,159. A stock solution of 50mM of C4.16 was solubilized in dimethyl sulfoxide (DMSO) 
and stored at –20°C for further use. Sor was obtained from LC Laboratories, Woburn, MA, 
and a 10mM stock solution was prepared in DMSO and stored at –20°C. Everolimus (Evr) 
was obtained from selleckchem, Boston, MA, and a 10mM stock solution were prepared in 
DMSO and stored at –20°C. Acetazolamide (ATZ), ‘click’ chemistry reagents, Styrene 
maleic anhydride (SMA, MW 1600), D-alpha-tocopheryl polyethylene glycol succinate 
(Vitamin E-TPGS), and 3-[4, 5-Dimethylthiazol-2-yl]-2, 5 diphenyltetrazolium bromide 
(MTT) were purchased from Sigma-Aldrich (St Louis, MO). NIR dye, S0456 was obtained 
from FEW Chemicals GmbH, Germany. We obtained all other analytical grade reagents 
from Fisher Scientific (Hampton, NH) and Sigma-Aldrich (St Louis, MO) and used them 
without further purification. DMEM, RPMI medium and antibiotics (penicillin and 
streptomycin) utilized in this work were purchased from Invitrogen Co. (Carlsbad, CA). 
Fetal bovine serum (FBS) and DMSO were purchased from Fisher Scientific (Fair Lawn, 
NJ). The Protein Assay Kit was obtained from Bio-Rad Laboratories (Hercules, CA). The 
rabbit monoclonal antibodies for –actin was acquired from Sigma-Aldrich (St. Louis, 
MO). We purchased rabbit monoclonal antibodies to phospho- and total AKT, and 
Carbonic Anhydrase-IX (CA IX) from Cell Signaling Technology (Beverly, MA). 
5.3.2. Cell lines development and culturing condition  
The human RCC A498 cells were from ATCC and kindly provided by Dr. Rajvir 
Dahiya (UCSF). All the cells were regularly maintained following procedures published 
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before 212,213. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
with GlutaMAX that was supplemented with 10% FBS, 100 units/ml of penicillin, and 
100 μg/ml of streptomycin, and the cells were cultured at 37°C and 5% CO2. For cell 
viability and MTT studies, the cells were cultured in fresh media supplemented with 10% 
FBS before their treatments with various agents 214,215. Resistant RCC cell-lines, including 
Evr-res A498, have been already established and validated in our previous work 157. For 
inducing hypoxia, cells were treated with 200 M Cobalt Chloride (CoCl2) in standard 
growth media for 72 h before experiment 216,217. RCC 3D-spheroid cell lines were grown 
in low density with 2% FBS containing culture media and before treatment they were 
induced with the hypoxic condition. 
5.3.3. General procedure for synthesis of compound SMA-TPGS and ATZ-SMA-TPGS by 
Copper-free 'click' chemistry  
As illustrated in Figure 1 (Scheme 1), we first synthesized acetazolamide-amine (ATZ-
NH2) from acetazolamide (ATZ) by acid hydrolysis as previously described 218. Subsequently, 
ATZ-NH2 was being reacted with DBCO-NHS-ester to finally arrive at ATZ-DBCO (compound 
a) which is CA IX (hypoxia) targeting ligand. Secondly, in scheme 2, we synthesized SMA-TPGS 
oligomer (SMA-TPGS) by adding known amounts of TPGS in NaHCo3 buffer at pH 8.9 with 
fixed amounts of anhydrous SMA to permit its anhydride ring opening reaction with the alcohol 
group of TPGS. Then, we conjugated the oligomer with azido functional compound (NH2-PEG8-
N3) by acid-amine coupling (EDC/NHS) reaction to finally get (compound b). Finally, the Cupper 
free click chemistry reaction will occur by reacting (compound a) with (compound b) to form 
triazole ring. All unconjugated reagents were removed prior lyophilization.  
5.3.4. Preparation and Characterization of C-4.16-loaded NPs  
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After ‘click’ reaction, we obtained CA IX-SMA-TPGS (CA IX-targeted oligomer), and in 
parallel, we generated SMA-TPGS (non-targeted oligomer). Both, (SMA-TPGS and CA IX-SMA-
TPGS-C4.16) NPs were developed using our previously reported methods with slight modification 
157. In brief, 100 mg of conjugated polymer was dissolved in 100 ml of deionized (DI) water under 
stirring. Then C4.16 (30 mg) was dissolved in 1 ml of DMSO and mixed with the polymer solution. 
Subsequently, 40 mg of EDC was added dropwise into solution and pH was kept at 5.0 to stir for 
30 min. Then, the pH was raised to 11 and kept for other 30 min. Finally, pH was adjusted to 7.8 
– 8.0 and the free drug C4.16 were removed by dialysis for 4-5 h in a bag with a cut-off of MW 2 
kDa. Then, the products obtained were lyophilized to obtain the final powder and stored in the 
freezer until further use. Subsequently, the particle size and surface charge (zeta potential) 
measurements were performed using a Beckman Coulter Delsa Nano-C-DLS Particle analyzer 
(Miami, FL) equipped with a 658 nm He-Ne laser. For particle size, we suspended the NPs in DI 
water and detected the scattered light at 165° angle. We then obtained the peak average histograms 
of intensity, volume and number from 70 scans to calculate the average diameter of the particles. 
The zeta potentials were evaluated by measuring the electrophoretic mobility of the charged 
particles under an applied electric field. For Morphology, Transmission Electron Microscopy 
(TEM) of the NP was evaluated using JEOL-JEM-1000 instrument (JEOL Ltd, Tokyo, Japan). We 
also characterized oligomer by proton nuclear magnetic resonance spectroscopy (1H NMR) and 
Fourier transform infrared spectroscopy (FTIR). The structure of the synthesized SMA-TPGS and 
CA IX-SMA-TPGS copolymer was detected by 1H NMR in D2O as previously described 
157209. 
The proper synthesis of the SMA-TPGS and CA IX-SMA-TPGS oligomer was also confirmed by 
the MALDI/MS and was found not to be a physical mixture of TPGS with SMA as all 
measurements indicated the absence of any free crystalline particles before NPs preparation. 
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5.3.5. The Drug Loading (DLC) and Encapsulation efficiency (EE) of C4.16 loaded-
nanoparticles                
We evaluated the C4.16 loading content percentage and the encapsulation efficiency (EE 
%) in NPs by High-Performance Liquid Chromatography (HPLC, Waters, Milford, MA). Samples 
of the C4.16 NPs preparations were taken, and the unentrapped C4.16 was quantified using our 
previously published HPLC method 157. The loading efficiency of micelles was calculated by 
dissolving a known quantity of NPs directly in DMSO and further dilution of drugs with the mobile 
phase followed by determination of the absorbance at 309 nm (λ max) with respect to the standard 
curve. Free drug (unentrapped C4.16 in the SMA-TPGS or CA IX-SMA-TPGS) was separated by 
ultrafiltration centrifugation technique. Briefly, 1 mL of CA IX-SMA-TPGS-C4.16 (targeted CA 
IX-C4.16 NPs) and SMA-TPGS-C4.16 (non-targeted) colloidal solutions were placed in the upper 
chamber of a centrifuge tube matched with an ultrafilter and centrifuged for 15 min at 4000 rpm. 
The total drug content in C4.16 NPs was determined as follows. Aliquots of 1mL formulation 
dispersion were diluted accordingly by ethanol to dissolve the ingredient, and the resulting 
suspension was then filtrated through 0.45µm membrane filters. The filtered solution was analyzed 
by Waters® Alliance e2695 HPLC using Symmetry® C18 column (250mm × 4.6mm, 5µm). The 
mobile phase was a mixture of Acetonitrile, Methanol, 10mM KH2PO4 buffer (65:20:15 v/v) with 
pH adjusted to 2, and the flow rate was maintained at 1.0mL/min. All the samples were analyzed 
using empower PDA software. We then calculated the encapsulation efficiency (EE) and drug 
loading content (DLC) by the following equations:  
Drug loading content (DLC) =
The weight of C−4.16
 encapsulated in micelles
Total weight of C−4.16
 loaded in micelles
 x100                         Equation (1)                                                  
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 Encapsulation Effeciency  (EE) =
Mass  of C−4.16
 encapsulated in micelles
Total mass of C−4.16
initially  loaded in micelles
 x100                 Equation (2) 
                                                                         
5.3.6. Expression of CA IX by A498 RCC cells and A498 RCC tumor models 
The expression of CA IX on the surface of A498 and Evr-A498 cells was investigated 
under a normoxic or hypoxic condition by exposing cells to normoxia (no treatment) or hypoxia 
(cobalt chloride, CoCl2 treatment) for 72 h, followed by CA IX detection using 
immunofluorescence analysis or western blot. Proteins from tumor tissues were extracted using 
RIPA buffer with the Halt Protease and Phosphatase Inhibitor Cocktail. A498 cells or tumors were 
fixed with 4% cold paraformaldehyde for 15 min after incubation for 24 h under normoxic or 
hypoxic condition. Cells were washed three times with DPBS and blocked with 10% bovine serum 
albumin for 1 h at room temperature, then incubated with primary rabbit monoclonal anti-CA IX 
antibody (20 μg/mL) overnight at 4 °C. Cells were subsequently washed three times followed by 
incubation with FITC-conjugated rabbit anti-mouse secondary antibody for 1 h at room 
temperature. A498 cells under the normoxic or hypoxic condition, only treated with FITC-
conjugated goat anti-mouse secondary antibody served as controls to avoid interference of cell 
auto-fluorescence. Cells were observed using a Confocal Laser Scanning Microscope (CLSM). 
For tumor tissues, mice were implanted with A498 cells using the technique previously reported 
157. Briefly, A498 cell suspensions were prepared in PBS and mice were injected with 1 × 106 cells 
subcutaneously by syringes with 29-gauge needles. On day 14 after tumor cell implantation, mice 
were sacrificed, and RCC tumor tissue was collected for histology performed by Biobank core 
facility.  
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5.3.7. Hypoxic core penetration of CA IX-SMA-TPGS oligomer in hypoxic A498 3D tumor 
spheroid 
Cancer cell specific uptake of CA IX-SMA-TPGS oligomer was performed in tumor 
spheroids by immunofluorescence. Cells were cultured with ~70-80% confluence. We cultured 
Evr-res A498 cells to form 3D spheroid structure based on previously published methods 157,159. 
Briefly, the cells were washed twice in 1 x PBS, trypsinized and pelleted the cells with 200 x g 
centrifugation at room temperature. It was re-suspended in 5ml of sphere media (DMEM/F12 
supplemented with 2mM L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin, 1 x B27 
supplement, 20ng/ml recombinant human epidermal growth factor (EGF; Sigma), and 10ng/ml 
recombinant human basic fibroblast growth factor (bFGF; R&D Systems). Cells were seeded 
approximately 5000 cells per ml on an ultra-low adherent 60mm plate and incubated at normal cell 
culturing conditions for two weeks without disturbing the plates. Seventy-two h prior to treatment, 
media was replaced with the hypoxic condition. Once the sphere was formed, spheres were treated 
with 1µM Rhodamine B conjugated CA IX-SMA-TPGS oligomer (CA IX-Rhoda-B) for 4 h or 
kept untreated at 37°C and 5% CO2. At the end of the incubation period, the spheroids were washed 
with cold DPBS and scanned beginning from the top of the equatorial plane to obtain the Z-stack 
images by CLSM for the spheres of untreated and treated plates as described as reported before 
196. 
5.3.8. In vitro cytotoxicity assay  
MTT assay was used to evaluate the anti-cancer effects of targeted CA IX-C4.16 NP and 
free anticancer drugs (C4.16, Evr, and Sor) in CA IX-positive (A498 RCC cells). First, the cells 
were seeded in a 96-well plate at a density of 5x103 cells per well and allowed to grow in fresh 
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culture media overnight. Cells were subjected to parallel treatments under hypoxic and normoxic 
conditions as described above. After 20 h, the medium was removed, and the cells were washed 
twice with PBS.  Cells were then treated with various concentrations of respective agents for the 
noted dose and time. Control cells were treated with 0.1% DMSO in the culture medium219–221. 
After treatment, cell viabilities were measured by the MTT assay. Briefly, 20 μl of 1mg/ml of 
MTT was added to each well and cells were incubated for 2-4 h at 370C. MTT was removed, and 
the resulting formazan products were dissolved by adding 50μl DMSO/well followed by 
colorimetric analysis at 595nm using a multi-label plate reader (Victor3; PerkinElmer, Wellesley, 
MA).  
5.3.9. Apoptosis analysis by flow cytometry and Caspase 3/7 Glo assay  
 We determined apoptosis induction in A498 RCC cells that were treated with free C.4.16 
or CA IX-C4.16 NP by flow cytometry with Annexin V/7-AAD dual staining. The percentage of 
Annexin V-/7-AAD - (R5), Annexin V+/7-AAD - (R6) and Annexin V-/7-AAD + (R4) and Annexin 
V-/7-AAD + (R3) cells were obtained to determine the number of live, as well as early and late 
apoptotic, and necrotic cells. To evaluate caspase-3/7 activities, cells were cultured and treated 
with DMEM medium (Free oligomer or control), C4.16, Sor, or C4.16+Sor for 24 h and were 
tested by Caspase-Glo 3/7 Assay (Promega) according to the manufacturer’s recommendations.  
5.3.10. Western Blot analysis 
The RCC cells were treated with DMSO/Vehicle (Control) or indicated dose and time of 
the noted compound. Cells were harvested and lysed in RIPA buffer (50mM Tris-HCI, pH 8.0, 
150mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate 
(SDS), and 0.1% of protease inhibitor cocktail) for 20 min at 40C. The lysates were then 
centrifuged at 14,000 rpm at 40C for 15 min to get rid of debris. We then determined the protein 
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concentrations of whole cell lysates using the Bradford Protein Assay Kit. Supernatant proteins, 
50μg from each sample, were separated by SDS-10% polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA) 
by standard procedures. The membranes were hybridized with primary antibodies followed by 
incubation with appropriate secondary antibodies. The antibody-bound proteins were visualized 
by treatment with the chemiluminescence detection reagent (Amersham Biosciences) according to 
the manufacturer’s instructions, followed by exposure to X-ray film (Kodak X-Omat). The same 
membranes were then re-probed with the anti-β actin antibody, which was used as an internal 
control for protein loading. 
5.3.11. Reprogramming macrophages with (CA IX-C4.16+Sor) 
Transwell inserts 0.4 μM Corning, Falcon®, catalog number: 353493 and Corning® 6 well cell 
culture plates were used. Figure 6 A shows a diagram representing a brief outline of the steps of 
the protocol and a timeline indicating the order of events that were all carried out under sterile 
conditions following protocol published by Smith et al. Briefly, Raw264.7 cells were placed into 
the Transwell inserts. Raw-264.7 cells were first polarized to M1-macrophage using IFN- and 
LPS, and to M2-macrophage using IL-4 recombinant protein. Then, A498 RCC cell lines were 
cocultured with activated macrophages followed by treatment of Sor, C4.16, and CA IX-
C4.16+Sor for 24 h. Caspase 3/7 assay was performed in Evr-res A498 cells treated with Sor, 
C4.16, and CA IX-C4.16+Sor while co-culturing with Raw-264.7 macrophage to demonstrate 
whether combination treatment can reeducate macrophage to induce apoptosis mediated A498 cell 
death.     
5.3.12. A-498 Three-dimensional RCC tumor spheroids uptake 
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  CA IX expression of tumor spheroids was checked by immunofluorescence. The RCC cells 
were obtained from xenograft tumors derived from WT cells and Everolimus-resistant RCC cells 
from a two-dimensional culture plate with ~70-80% confluence. We performed the three-
dimensional renal sphere cultures by mostly following the methods described before [14,36]. 
Briefly, the cells were washed twice in 1 x PBS and trypsinized following established protocols. 
We then pelleted the cells at 200 x g at room temperature and re-suspended them in 5ml of sphere 
media (DMEM/F12 supplemented with 2mM L-glutamine, 100 U/ml penicillin, 100 U/ml 
streptomycin, 1 x B27 supplement, 20ng/ml recombinant human epidermal growth factor (EGF; 
Sigma), and 10ng/ml recombinant human basic fibroblast growth factor (bFGF; R&D Systems). 
We seeded approximately 5000 cells per ml in an ultra-low adherent 60mm plate and incubated 
them at normal cell culturing conditions for two weeks without disturbing the plates. After the 
spheres formed, we added fresh media with or without 1µM Rhodamine B conjugated CA IX 
targeted-OMs and continued incubating cells for additional 4h at 37°C and 5% CO2. At the end of 
the incubation period, the spheroids were washed with cold DPBS and scanned began from the top 
to the equatorial plane to obtain the Z-stack images by CLSM for the spheres in the untreated and 
treated plates as described as reported before by another group [42]. 
5.3.13.  Antitumor therapy study in highly aggressive Evr-res A498 tumor in nu/nu xenograft 
model 
The generation of RCC cell-derived subcutaneous tumor was done according to our 
previously published protocols approved by the Institutional Laboratory Animal Care & Use 
Committee (IACUC) at the Wayne State University 157,159. Female, 5-6 weeks old nu/nu mice were 
obtained from Jackson Laboratory, Bar Harbor, ME.  For therapy studies, after an appropriate 
period of acclimation, a suspension of 1 x 106 Evr-res A498 cells in 150µl PBS was subcutaneously 
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implanted in flanks of each animal using a 27-gauge needle. Tumors were allowed to grow for 10 
days. When tumors became palpable (200 mm3), the mice were randomly assigned for treatment 
or control groups of five animals each. Mice were treated with Vehicle (Control), CA IX-C4.16 
NP (24mg/kg/day), Sor (10mg/kg/day) via intravenous (i.v) administration. Sor was formulated 
with 10% Kolliphor EL in PBS with DMSO concentration is <5%. In case of CA IX-C4.16 and 
Sor combination, only two doses were administered where the first dose was on day 1 was followed 
by the second dose on the third day. The tumor volume was measured, and mice were monitored 
for body weight changes. Antitumor activity was measured by using NIH formula, tumor volume 
(mm3) = 1/2(length × width2). The tumor volume of the last day of therapy study was represented 
to demonstrate the endpoint outcome of combination therapy as described before 157. The animals 
were sacrificed, and tumor tissues were collected. Representative tumor samples were stored at –
80°C for subsequent analysis. The histology of normal organs (Kidney and Liver) was performed 
by Biobank core facility.  
5.3.14. NIR imaging and bio-distribution of CA IX-SMA-TPGS-S0456 oligomer  
A CA IX-targeted oligomer was conjugated with Near-infrared (NIR) dye CA IX-SMA-
TPGS-S0456, namely CA IX-S0456 (CA IX-oligomer) and administered via i.v route to 5-6 weeks 
old nu/nu mice, and the bio-distribution of NIR dye was monitored after 24 h of the single dose 
with 10 nmole NIR dye per mouse. Fluorescence images were collected in Bruker Carestream 
Xtreme in vivo imaging system at excitation (750 nm) and emission (830 nm) wavelength. The 
bio-distribution and tumor-targeting properties of CA IX-S0456 was evaluated after euthanizing 
the mice after 24 h post i.v injection. The instrument has dual fluorescence and X-ray imaging 
modalities with light source: 400 W Xenon illuminator. Both fluorescence and X-ray images of 
the mouse were merged to demonstrate the localization of NIR dye. We obtained PDx tumor mice 
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from Jackson laboratory, and tumor slice was passaged to mice using trocar and imaging was 
performed as similar with nu/nu mice.  
5.3.15. Statistical analysis  
The statistical analysis was done using Prism 7.0 software (Graph Pad Software Inc., San 
Diego, CA). The data were expressed as mean ± SEM and analyzed using a two-tailed Student t-
test or one-way ANOVA followed by a post hoc test unless specified otherwise. A p value of <0.05 
was considered statistically significant. 
5.4. Results and discussion 
5.4.1. General procedure for synthesis of compound SMA-TPGS and ATZ-SMA-TPGS by 
Copper-free 'click' chemistry 
The current work aims to synthesize and formulate nanosystems targeting hypoxia in 
tumors. CA IX enzyme on the surface of kidney cancer cells was targeted by ATZ-containing 
oligomers using a modular copper-free 'click' chemistry-based approach. As illustrated in Scheme 
1 of Figure 5.1, we first synthesized acetazolamide-amine (ATZ-NH2) from acetazolamide (ATZ) 
by acid hydrolysis as previously described 218. Subsequently, ATZ-NH2 was reacted with DBCO-
NHS-ester to arrive at ATZ-DBCO (compound a) which functions as a CA IX targeting ligand. 
Second, in Scheme 2 of Figure 5.1, we synthesized SMA-TPGS oligomer (SMA-TPGS-Cys) by 
adding known amounts of TPGS and Cysteine in dichloromethane at pH 8 with fixed amounts of 
anhydrous SMA to permit its anhydride ring opening reaction with the alcohol group of TPGS and 
amine group of cystine. Then, we conjugated the SMA-TPGS-Cys with azido (N3) group of (NH2-
PEG8-N3) compound by acid-amine coupling (EDC/NHS) reaction to finally get (compound b). 
Finally, the Copper-free ‘click’ reaction was carried out by reacting compound ‘a’ with compound 
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‘b’ to form triazole ring, compound ‘c’. All unconjugated reactants were removed by dialysis prior 
to lyophilization. The compound ‘c’ was reacted with Rhodamine B NCS to obtain “CA IX-
Rhoda” for in vitro 3D spheroid uptake study 222 and reacted with S0456 to get “CA IX-S0456” 
for in vivo tumor imaging 163.  S0456 is a near-infrared (NIR) fluorescent dye used in phase III 
clinical trials for image guided tumor surgery 223. The final compounds were characterized by 
MALDI-MS, 1H-NMR (Supplementary, S1 A-C) to assure chemical identity. 1H-NMR results 
confirmed the triazole ring formation in CA IX-SMA-TPGS (Supplementary, S1 A, C) as the 
characteristic peaks were found for the -NH group of-triazole ring around 7.9 ppm, O-CH2 of 
triazole ring around 5.2, and CH2-N3 peak around 4.2 respectively. The molecules were analyzed 
by MALDI-MS spectroscopy to confirm the chemical conjugation. This work expands upon our 
previous success in the design, synthesis, and development of SMA-TPGS-C4.16 and SMA-C4.16 
nanomicellar formulation 157. 
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Figure 5.1. Scheme 1 and 2 indicate the general procedure for acetazolamide-oligomer fragment 
synthesis. Scheme 3 indicates the preparation of OMs with C-4.16 and mechanism of CA IX 
receptor mediated internalization of OMs in RCC. Summary of tumor hypoxia directed 
nanotherapy in combination with Sorafenib for achieving multiple benefits against cancer, such as 
reversing drug resistance, inducing apoptosis and reprogramming macrophages. 
5.4.2. Preparation and characterization of CA IX targeting NP 
The oligomers (SMA-TPGS and CA IX-SMA-TPGS) conjugate was purified by 
ultrafiltration (Millipore TFF, Milford, MA) and then lyophilized. The NPs were prepared with 
different methods, such as solvent evaporation, and oil-in-water emulsion method to formulate 
spherical micelles with SMA-TPGS and CA IX-SMA-TPGS. Both, CA IX targeted NP and non-
targeted NP were loaded with water-insoluble C4.16 to produce CA IX-C4.16 NPs and SMA-
TPGS-C4.16. The NPs were characterized for size, charge and drug loading and these parameters 
are presented in Table 1.  The particle size of non-targeted C4.16 loaded NPs were ~105.2 nm with 
a Polydispersity index (PDI=0.165) (Figure 5.2A). Morphology of the NP was also assessed using 
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Transmission Electron Microscopy (TEM) instrument (Figure 5.2 B) and the particle size 
resembled with DLS data and a favorable negative surface charge of NPs was noted (Figure 5.2C). 
After incorporation of targeting ligand (ATZ) to NPs, the particle size slightly increased compared 
to that of the non-targeted NPs suggesting the presence of ATZ on the surface of NPs. These results 
indicate that both the size and surface properties are optimal and safe for intravenous injection as 
well as ideal for tumor delivery. The Figure 5.2 C show histograms of comparative analyses of the 
particle size and zeta potential of the NPs.  Figure 5.2 D indicates the results of MALDI-MS 
analysis of CA IX-SMA-TPGS and SMA-TPGS. The increment of molecular weight in CA IX-
SMA-TPGS (m/z 3126) compared to SMA-TPGS (m/z 2399) and their corresponding fragmented 
peaks indicates the successful conjugation of ATZ to the SMA-TPGS polymers. Also, The C4.16 
loading content and encapsulation efficiency in both NPs were evaluated by High-Performance 
Liquid Chromatography (HPLC). First, a method for analyzing drug content was developed and 
validated according to ICH guidelines 188. The loading efficiency of micelles was then calculated 
by dissolving known quantity of NPs directly in DMSO followed by determination of the 
absorbance at 309 nm with respect to the standard curve performed by HPLC method. The 
encapsulation efficiency was 85 % and 75.5 % for SMA-TPGS NPs and CA IX-C-4.16 NPs, 
respectively. 
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Figure 5.2. Oligomicelles formulation and characterization. (A) Hydrodynamic size of targeted 
CA IX-C4.16 OMs and non-targeted SMA-TPGS-C-4.16 OMs and (B) Zeta potential by Dynamic 
Light Scattering (DLS) are shown. (C) The morphology of representative OMs is characterized by 
TEM as shown. Scale bar = 100 nm. (D and E) MALDI-MS analysis of ATZ-SMA-TPGS and 
SMA-TPGS are shown. The increment of m/z value in ATZ-SMA-TPGS (m/z 2239.1) compared 
to SMA-TPGS(m/z1565.6) oligomers indicates the successful conjugation of ATZ to the SMA-
TPGS polymers.  
Table 5.1. Characterization of Oligomicelles.  
Sample CMC 
(mg/ml) 
Hydrodynamic 
size (nm) 
PDI Zeta 
potential 
(mV) 
EE (%) 
ATZ-SMA-
TPGS-C-4.16 
(Targeted) 
0.021 159.5±20nm 0.094±0.05 -10.21 ±4 75.5±12 
SMA-TPGS-C-
4.16 (non-
targeted) 
0.010 105.2±31nm 0.165±0.07 -7.86 ±4 85±9.8 
Abbreviations: C-4.16, CARP-1 Functional Mimetics; SMA, styrene maleic acid; TPGS, d-α-
tocopheryl polyethylene glycol succinate; ATZ, Acetazolamide; CMC, critical micelle 
concentration; PDI, polydispersity index; EE, encapsulation efficiency. 
 
5.4.4. Rationale for choosing CA IX protein for RCC therapy 
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In this study, we have shown that CA IX was overexpressed in A498 and Evr-res A498 RCC cells 
and tumor. In Figure 5.3A, immunohistochemistry of CA IX-positive A498 RCC tumor xenografts 
collected from tumor tissue section is shown. The intense bright green fluorescence indicates the 
presence of CA IX. In Figure 5.3B, Western blot data show levels of CA IX   protein in A498 and 
Evr-res A498 RCC cells that were cultured under normoxic (no cobalt chloride treatment) or 
hypoxic conditions (treated with cobalt chloride for 72 hrs.). Together with immunohistological 
localization of CA IX in RCC tumor, the up-regulation of CA IX expression in hypoxic WT and 
Evr-res A498 RCC cells in comparison to their respective, normoxic counterparts provides a 
rational strategy for delivering the payload into the hypoxic core of RCC tumor. Moreover, CA IX 
has been shown to be specifically overexpressed in 93 to 97% of both ccRCC and some papillary 
RCCs, with limited expression in normal tissues 224. CA IX is also an important biomarker for 
RCC, and it plays a pivotal role in tumor progression, acidification, metastasis, and the intra-
tumoral hypoxic condition. CA IX expression on the cell surface is associated with induction of 
tumor hypoxia through regulation of HIF1 The clinicopathological analysis have supported the 
fact that overexpression of CA IX in RCC is linked to poor disease prognosis and resistance to 
chemo and immunotherapy. Many clinical trials are evaluating CA IX linked inhibitors or 
antibodies for monotherapy or diagnostic imaging. Recently,  a small molecule, acetazolamide 
(ATZ), with high affinity (Kd~ 8.3 nM) to CA IX 225 has been reported to deliver the payload into 
the inner core (more than the periphery) of a tumor 163,218. These results signify that CA IX is an 
excellent target for site-specific delivery of therapeutic payloads to renal tumors 226,227. Along these 
lines, we developed ATZ-conjugated NPs for selective delivery of drug cocktail to the hypoxic 
region including the tumor core of therapy resistant RCC. It is well established that the hypoxic 
tumor core harbors aggressive and drug-resistant stem-like cells can persist after initial drug 
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therapy, which can invade normal tissues and metastasize to distant sites forming secondary 
tumors. Targeting the hypoxic core using CA IX is thus a highly innovative approach needing 
immediate attention. 
 
                                 
Figure 5.3. Overexpression of CA IX protein in A498 RCC cells and xenograft model. (A) 
Immunohistochemistry of CA IX positive A498 renal cell carcinoma tumor xenografts collected 
from tumor tissue section is shown. The intense bright green fluorescence indicates the rationale 
of choosing CA IX as an excellent RCC targeted therapy. (B) Western blot detection of CA IX 
protein in A498 and EV-A498 RCC cells lysates after normoxia (no cobalt chloride treatment) and 
hypoxia (treated with cobalt chloride for 72 hrs. to induce hypoxia) are shown. The fold up-
regulation of CA IX   expression in hypoxic WT and EV-res A498 RCC cells than normoxia 
provides a solid foundation for delivering the payload into oxygen deprived regions and hypoxic 
core of RCC tumor.  
5.4.5. Selective uptake and tumor spheroid core penetration of CA IX oligomers to RCC. 
The 3 D spheroid cell culture model is an in vivo mimetic study for testing NPs deep tumor core 
penetration ability. Thus, culturing A498 RCC cell lines with a spheroid model in hypoxic 
condition could be predictive of the tumor permeability of CA IX targeted NPs. In Figure 5.4 C, 
we found that the rhodamine-conjugated ATZ oligomer (CA IX-Rhoda) has deep tumor matrix 
penetration and superior uptake in hypoxic Evr-res A498 spheroid model. The cell uptake study 
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of CA IX targeted NPs was performed using Evr- res A498 spheroid model followed by imaging 
of spheroid using confocal microscopy. Interestingly, Z-stacking from 10, 40, 60, and 100 µm in 
confocal microscopy of CA IX targeted oligomer-treated cells indicate that rhodamine-signal is 
significantly higher in the core of the spheroid than the periphery (Figure 5.4. C-D). This is a strong 
indication that CA IX targeted oligomer can  penetrate deep into the tumor spheroid and likely 
reached the hypoxic regions very efficiently. The highest fluorescence intensity at the center (as 
indicated by arrow) of 3D- plot (Figure 5.4 C) suggests that CA IX targeted oligomer efficiently 
reached the core of tumor spheroid. Also, in Figure 5.4 C, with the lower range of Z-stacking from 
40-60 m section (which is the core) has more fluorescence intensity than the periphery. Z-
stacking of the spheroid at different sections from 10-100m with CA IX targeted formulations 
also shows superior fluorescence intensity from 40-60 µm sections representing organoid core. 
Figure 5.4. E showed the overall merged view of CA IX-Rhod-B oligomer with bright field and 
compared with untreated control. Figure 5.4 F shows the overall shape of the spheroid from along 
the three dimensions (x, y, and z) as another way of representation to demonstrate spheroid core 
penetration.  
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Figure 5.4. 3D spheroid uptake studies of hypoxia targeted-oligomer. Confocal microscope 
images of ATZ-oligomer conjugated with rhodamine B and treated with hypoxic A498 RCC cells 
-spheroid indicates tumor matrix penetration of CA IX targeted Oligomicelles. The untreated and 
treated spheres were then photographed as noted in methods section. Z-stacking of the spheroid 
(A-D) clearly indicates that fluorescence intensity is superior in 40-60 µm section. The highest 
fluorescence intensity at the center (as indicated by arrow) of 3D- plot (E) suggests that CA IX-
Rhoda oligomer is highly efficient to reach deep into the core of the tumor spheroid. (F) Z-stacking 
of the spheroid at different sections from 10-100 m with CA IX targeted formulations also reveals 
similar findings as noted for the 40-60 µm that had superior fluorescence intensity. Figure (G) 
shows the untreated control experiments in comparison with CA IX-Rhoda oligomer and Figure 
(H) shows the overall shape of the spheroid from along the three dimensions (x, y, and z). 
 
5.4.6. C4.16 anti-cancer effect and Hypoxia targeting ability of CA IX NP  
RCC is very difficult to treat as the cells are mostly resistant to many current therapies. Therefore, 
newer treatments including better ways of drug delivery are urgently needed to fight this malignant 
disease efficiently. Our previous work has demonstrated generation and characterization of RCC 
cells that are resistant to Evr, a frontline mTOR-targeted therapy, and revealed that a class of 
CARP-1 functional mimetic (CFM) compounds especially C-4.16 inhibited parental (WT) and 
Evr-res RCCs157. In this study, we utilized C-4.16 and current clinical anti-RCC therapeutics Sor 
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and Evr.  First, we determined cytotoxicity of individual drugs C4.16, Sor, and Evr in both A498 
as shown in Figure 5.5. Our results from Figure 5.5. A, B indicated that C4.16 was more effective 
in inhibiting growth of WT and Evr-res A498 compared with Sor. Evr, however, did not inhibit 
growth of Evr-res A498 RCC cells as previously published [14]. We then clarified whether a 
combination of C4.16 and Sor were more effective when compared with individual treatment. In 
vitro cytotoxicity assay of C4.16 and Sor on Figure 4 A, B indicates C4.16 was more potent than 
FDA approved drug (Sor) and combining both drugs showed significantly lower the IC50 value. 
All the results indicate C4.16 and Sor inhibited viabilities of WT and Evr-res RCC cells, and C4.16 
when combined with sor was more effective than C4.16 or Sor alone. However, C4.16's poor water 
solubility limits it’s in vivo testing and clinical translation. We addressed the solubility and 
delivery concerns of C4.16 by utilizing a nanotechnology-based approach. Thus, encapsulation of 
C4.16 in NP and conjugating them with CA IX targeting oligomer was considered as a functional 
approach for resolving the challenges to deliver the compounds selectively to resistant RCC. The 
results as noted in Figure 5.5 C show that CA IX-C4.16 was more effective in inhibiting growth 
of A498 (WT and Evr-res) compared to Sor and Evr and supported that CA IX-C4.16 nano-
formulation was more potent compared to FDA approved drugs. The table in Figure 5.5. D 
summarizes IC50 values for all drugs with the WT and Evr-res RCC cell lines. The data in Figure 
5.5. C, D showed that CA IX-C4.16 was more effective in inhibiting growth of A498 (WT and 
Evr-res) compared to Sor and Evr and collectively indicate that CA IX-C4.16 was more potent 
compared to other drug options. Furthermore, to confirm the synergism, we utilized CompoSyn® 
software to evaluate the combination index (CI) value of C4.16 and Sor. As shown in Figure 5.5. 
E, C4.16 and Sor had CI value (less than 1) of 0.531 for A498 WT and 0.654 for Evr-Res, which 
indicated synergism between the two compounds. Figure 5.5. F also demonstrated a combination 
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of CA IX-C4.16 with Sor is synergistic in RCC cell killing as obtained from isobologram analysis. 
Thus, low dose of CA IX-C4.16 NP could potentially sensitize RCC cells for inhibition by Sor. 
Moreover, as shown in Appendix Figure, a combination of 500 nM dose of CA IX-C4.16 with 
various doses of Sor further support their synergistic inhibition of RCC cells. A 500 nM dose of 
CA IX-C4.16 caused greater inhibition of RCC cell growth when combined with low doses of Sor 
(100, 200, 500 nM).  
 
Figure 5.5. C-4.16 inhibits growth of RCC cell lines derived from WT and Everolimus-
resistant cells. Cell cultures studies and in vitro cytotoxicity assay of C-4.16, sorafenib, 
Everolimus on (WT and Evr-Res) A498 and UOK-262 RCC cell lines. (A, B, and C) Cytotoxicity 
data indicates C-4.16 was more potent than FDA approved drugs (sorafenib and everolimus) in 
WT A498 and (D, E, and F) WT UOK262. Also, cell cultures studies result on EV-res A498 RCC 
cell lines (G and H) indicates that C-4.16 was more effective in inhibiting growth of Evr-res A498 
RCC cell lines than sorafenib; however, Everolimus is not inhibiting the growth of Evr-res A498 
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and UOK262 RCC cell lines as previously published. The data in the GI50 columns represent mean 
of three independent experiments. Indicated parental and their respective drug resistant RCC cells 
were either untreated (Control) or treated with noted doses of C-4.16 and sorafenib for 48h.  
 
Figure 5.6. High synergistic CI value of C-4.16 with sorafenib combination supports the 
hypothesis of selecting the combination to RCC treatment using hypoxia targeting OMs. (A) 
Combining very low doses of both drugs will lower the IC50 value significantly as in (D) which 
shows the combination index plot for C-4.16 plus sorafenib in the cells for both types A498 RCC 
cell lines indicates very strong synergism between sorafenib and C-4.16. (B) The results also show 
that CA IX-C-4.16 was more effective in inhibiting growth of A498 (WT and Ev-res) and to less 
extent (C) UOK262 (WT and Ev-res) RCC cell lines than sorafenib and Ev and support that C-
4.16 was more potent than FDA approved drugs (sorafenib and everolimus). (D) We summarized 
IC50 value table for all drugs with all the above mentioned RCC cell lines. (E) In vitro cytotoxicity 
assay of CA IX-C4.16 (500 nM) in combination with different doses of sorafenib on Ev-res A498 
RCC cell lines indicates that low dose of C-4.16-OMs sensitize sorafenib for inhibiting growth of 
RCC cell line.   
5.4.7. Mechanism of C4.16 for overcoming drug resistance  
In this study, we determined how induction of apoptosis and inhibition of oncogenic 
survival signaling would reinforce the synergistic cell killing and reversal of drug resistance in 
WT and Evr-res A498 cells when treated with CA IX C4.16+Sor. As shown in Figure 5.7. A, we 
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observed inhibition of AKT activation as indicated by downregulation of pAKT in C4.16 and Sor 
treatment compared to untreated control. We found that Evr-res RCC cells that were treated with 
C4.16 or Sor had a greater loss of AKT activities when compared with their WT cells treated with 
respective agents. Interestingly though, a combination of C4.16 and Sor completely abolished 
AKT activity (pAKT) in both the WT and resistant cells. Therefore, it is likely that superior RCC 
growth inhibition by C4.16 and Sor is in part due to suppression of oncogenic AKT activity.  
Moreover, C4.16 cytotoxicity was mediated by apoptosis induction (Figure 5.7 A) supporting our 
prior studies that have shown activation of apoptosis in C4.16 treated cells. Although, C4.16 or 
Sor induced caspase-3/7 activation, a significant upregulation of caspase-3/7 activity was noted in 
RCC cells treated with C4.16+Sor as compared to control (Figure 5.7 B). This finding was further 
supported by an increment of early and late apoptotic events in both WT and Evr-res A498 cells 
treated with CA IX-C4.16+Sor as compared to untreated control or CA IX-C4.16 (Figure 5.7 C).  
The fraction of cells that stained with Annexin V (+ve) or Annexin V (+ve) and 7-AAD (+ve) was 
higher in combination treatment than singular treatments as shown in Figure 5.7 D. In all the cases; 
combination always worked better than individual drugs in inhibiting RCC cells growth.   
As shown previously, C4.16-dependent loss of RCC cell viability was due in part to 
reduced cyclin B1 levels, activation of pro-apoptotic, stress-activated protein kinases (SAPKs), 
and apoptosis 157. Importantly, we also demonstrated that CARP-1 was a key player in inducing 
apoptosis and cell cycle arrest in the breast, lung and renal cancer cells 139,140. The up-regulation 
of CARP-1 promotes activation of “apoptosis hallmarks,” such as caspase-mediated PARP 
cleavage, downregulation of PI3K/AKT signaling and loss of cyclin B1 in RCC 157. To identify 
potent activators of CARP-1, a library of small molecules, namely CARP-1 functional mimetic 
(CFM) compounds were developed. An NCI-60 screening, as well as high throughput screening 
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using various cancer cell lines, including WT and drug-resistant Evr-res RCC, resulted in the 
identification of several potent analogs. Our current results suggest that C4.16 is a superior 
inhibitor of both WT and drug-resistant RCC even in comparison to the FDA approved drugs, such 
as Ever and Sor. As RCC is highly vascularized, the use of drugs to inhibit RTK, such as VEGFR 
or HGF signaling is used as first-line therapies. Alongside, mTOR inhibitors, such as Evr were 
approved as second-line single agent therapy. All these kinase inhibitors are approved for single 
agent therapy. However, tumors eventually become resistant to therapy including RKT/mTOR 
inhibitors. Our findings suggest that the NPs formulations of the inhibitors will be a worthwhile 
strategy to provide multiple benefits such as (i) amenable for i.v. injection leading to lowering of 
drug dose; (ii) higher stability and bioavailability; (iii) sustain drug release and reduced toxicity. 
Literature reports and clinical experience have revealed that inhibiting RCC proliferation with 
drugs combination specific to different targets is superior to monotherapy approaches 228. 
However, such approaches tend to produce severe on-target and off-target toxicities 229. To achieve 
the maximum therapeutic benefits and reduce the toxicity, we encapsulated anticancer drugs in 
CA IX-C4.16 NPs. This i.v. administrable NPs in combination with currently approved drugs is 
an excellent approach to precisely target the convergent pathways of RCC activity with resistant 
and tumor stroma features 230.  
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Figure 5.7. (A) Western Blot data indicates that C-4.16 stimulates apoptosis in WT and Ev-
resistant RCC cells in part by upregulating pro-apoptotic CARP-1 and activating SAPKs as 
previously shown in [14], and in here P-AKT is indicated as the a protein which is affected much 
by combination of C4.16 and sorafenib. Indicated RCC cells were either untreated (Control, 
denoted as C), treated with C-4.16, Sorafenib, or Everolimus with (+) means presence of the 
combination and (-) indicates use only of single drug for noted dose and time. Cell lysates were 
analyzed by Western blotting (WB) as in Methods for levels activation (phosphorylation) and 
expression of both P-AKT and T-AKT in WT or Ev-res A498 RCC cells. (B) Up-regulation of 
caspase 3/7 with (C-4.16+SOR) treatment in Evr-res A498 cells indicates the C-4.16 mediated 
apoptosis to RCC cells as compared to sorafenib (SOR) treatment or combination (C-4.16+SOR). 
The results support (C-4.16+SOR) combination is more effective for RCC cell lines growth 
inhibition. (C) Free oligomer, CA IX-C-4.16 OMs and CA IX-C-4.16+ sorafenib with an 
increasing apoptosis measured by FACs using staining of Annexin V-FITC and PI in (A) A498 
RCC (WT and Ev-res) cells are shown. Free oligomer (vehicle) were used as negative controls. 
Data represent mean  SD, n=3 per group, **p<0.01 vs. control. (D) Histogram columns of both 
viable cells and apoptotic cells indicates that CA IX-C4.16 + sorafenib has more % apoptotic cell 
than CA IX- C4.16 alone which support our hypothesis of the synergism between these anticancer 
agents. 
5.4.8. Reprogramming macrophages to modulate combination treatment: 
To overcome the critical problem of current RCC treatment, we developed a tumor-penetrating 
nano-sized NP of spherical shape that can localize and penetrate tumor tissues efficiently and target 
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tumor hypoxia to deliver the combination drug cocktail to shut down vital tumorigenic signaling 
while simultaneously reprogramming macrophages for better therapeutic efficacy. Several studies 
have identified the key players that are responsible for drug resistance and immune evasion leading 
to the poor prognosis of RCC. These players are categorized based on their specific roles that 
include (i) RTK-mTOR that regulates critical tumorigenic signaling for tumor survival, immune 
suppression, and stroma formation, (ii) impairment of intrinsic and extrinsic apoptotic signaling is 
an essential player of drug resistance. Induction of CARP-1 protein has been well documented to 
induce apoptosis in cancer cells under the conditions of serum withdrawal or therapy stress. (iii) 
CA IX is a tumor hypoxia marker for the maintenance of extracellular acidosis and cancer 
stemness, thus facilitating tumor growth and metastases. More than seven clinical trials are 
underway to target CA IX in RCC and other solid tumors [NCT00059735, NCT00884520]. The 
delivery system we have engineered here will be a promising addition to clinical translation for 
better RCC treatment. Figure 5.8. A shows a schematic diagram as Raw264.7 cells were placed 
into the insert. Then, cells were polarized to M1-macrophage using IFN- and LPS, and to M2-
macrophage using IL-4 recombinant protein. The change of morphology of Raw264.7 as shown 
in Figure 5.8. B  supports the M1/M2 polarization of naïve Raw264.7 cells231 followed by 
treatment with C4.16 and CA IX-C4.16+Sor for 24 h. The data in Figure 5.8. C clearly demonstrate 
the up-modulation of the tumoricidal M1-macrophage marker (CD86, iNOS) and down-
modulation of the tumorigenic M2-macrophage marker (CD206, Arginase I) compared to 
untreated (UT) control and C4.16. The macrophage reprogramming ability of CA IX-targeting NP 
builds a rational of using (CA IX-C4.16+Sor) as a potent antitumor immune-stimulatory agent of 
RCC. The treatment of CA IX+Sor to Evr-res A498 cells cocultured with M1-macrophage resulted 
in the growth inhibition and change of morphology that could be due to tumoricidal M-1 
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macrophage mediated cell death of RCC cells as shown in Figure 5.8. D. Further to evaluate the 
macrophage induced RCC cell death, we analyzed up-modulation of caspase 3/7 in Evr-res A498 
cell co-cultured with Raw 264.7 cell and treated with CA IX-C4.16+Sor or other treatments. The 
data from Figure 5.8. E clearly confirmed combination is significantly better in inducing apoptosis 
as compared to control or individual treatments. All these results demonstrate hypoxia targeting 
NP in combination with Sor is not only inducing chemotherapeutic effect but also reeducating 
macrophages to function as a tumoricidal agent, which could prove excellent for a combination of 
chemo-immune therapy to inhibit Evr-res RCC.  
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Figure 5.8. Reprogramming macrophages with CA IX-C4.16+Sorafenib treatment. (A) Schematic 
diagram of the procedure. Raw-264.7 cells were placed into the insert. Then, cells were polarized 
to M1-macrophage using IFN-  and LPS, and to M2- macrophage using IL-4 recombinant protein. 
Scheme modified from the original protocol. (B) Change of morphology of M1 and M2 
macrophages supports the polarization of Raw-264.7. (C) RT-PCR data clearly demonstrates the 
up-modulation of the tumoricidal M1-macrophage marker (CD86, iNOS) and down-modulation 
of the tumorigenic M2-macrophage marker (CD206, Arginase I) in CA IX-C4.16+Sor as 
compared to control and C4.16. The macrophage reprogramming ability of CA IX targeting NP 
builds a rational of using (CA IX-C-4.16+Sor) as a potent antitumor immune-stimulatory agent of 
RCC. (D) Change of morphology and reduction of Evr-res A498 density in M1-macrophage and 
Evr-res A498 co-cultured condition, treated with CA XI+Sor suggesting activated M1-
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macrophage mediated RCC cell death. (E) Treatment of CA IX+Sor educate the Raw-264.7 in 
inducing caspase 3/7 mediated apoptosis of Evr-res A498. 
5.4.9. Superior tumor core penetration and high tumor/liver uptake of CA IX oligomers in 
xenograft RCC model.   
After optimizing the anticancer effect of CA IX-C4.16 at the cellular level, we performed NIR 
imaging in animals inoculated with RCC tumor model following administration of CA IX-S0456. 
The idea of performing NIR-imaging with CA IX-oligomer will provide several advantages 
including its use as (i) agent for tumor image guided RCC surgery in the clinic, as well as (ii) 
meaningful insights into the therapeutic outcome and safety of nanoformulation in RCC model. It 
is well known that clinically small molecule NIR imaging agents have excellent ability to 
distinguish the tumor lesion from healthy tissue in imaging-guided surgery as noted in  
NCT02317705 and NCT01778933 232. The results show CA IX-S0456 selectively home to the 
orthotopic subcutaneous Evr-res A498 tumor as compared to control (Figure 5.9. A and C). The 
bio-distribution (Bio-D) study in Figure 5.9. B validates the prominent tumor selectivity of CA 
IX-S0456 as compared other healthy organs such as liver and spleen. Imaging of the patient-
derived RCC tumor xenograft (PDx) (Figure 5.9. C) showed favorable tumor localization of CA 
IX-S0456. The tumor selectivity of CA IX-S0456 in both drug resistant and PDx RCC model 
builds a foundation for widespread applicability of CA IX-S0456 in different RCC tumor model 
that builds a rational platform for further investigation towards clinical translation of this 
technology. In Figure 5.4, 3D spheroid uptake study of CA IX-rhodamine showed high localization 
of rhodamine in the core of the hypoxic Evr-res A498 spheroid. To ascertain core penetrating 
ability of CA IX-S0456 in a drug resistant tumor model, we performed a transverse section of the 
isolated tumor after the bio-D study. Figure 5.9. D confirmed that CA IX-S0446 is very efficient 
in penetrating the core of tumor that predominantly harbors hypoxia and drug resistant features. 
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As shown in Figure 5.9. E, more than 3-fold tumor/liver ROI in CA IX-oligomer compared to 
control demonstrates the feasibility of CA IX-S0456 in clinical translation as an image-guided 
surgery tool. The findings in Figure 5.9. F suggest the ROI is >2 fold in CA IX-S0456 treated 
tumor core as compared to tumor periphery. These results support a high binding affinity and 
specific tumor uptake, faster normal tissue clearance, and low non-specific organ uptake of CA 
IX-oligomer. 
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Figure 5.9. Superior tumor specificity of CA IX-oligomer and antitumor efficacy study of 
combination therapy in Evr-res A498 xenograft and RCC PDx model. (A and C) Superior tumor 
accumulation of CAIX oligomer (CA IX-S0456) as compared to control (S0456) in Evr-res A498 
tumor xenograft model. (B) Bio distribution (Bio-D) study of CA IX-S0456 showed superior 
tumor specificity and low non-specific liver uptake in Evr-res A498 tumor bearing mice. The 
control, S0456 showed poor tumor accumulation with high off-target activity. ((D) Further to 
115 
 
 
 
demonstrate the tumor core penetration of NIR dye, isolated Evr-res A498 tumor was transversely 
sectioned, and brightest fluorescence intensity at the middle section confirmed of CA IX-S0456 
has an excellent hypoxic tumor core penetration ability as compared to control. (E) Significantly 
high tumor/liver accumulation (more than 3-fold) of CA IX-oligomer solve the non-specificity 
effect of the oligomer. (F) Quantification of fluorescent ROI indicates CA IX-oligomer is 
significantly penetrating higher in tumor core contained as compared to its periphery. The results 
suggest the importance of CA IX-oligomer in selective tumor targetability of RCC tumor model. 
(G) Tumor growth inhibition of (CA IX-C4.16+Sor) is significantly higher compared to 
vehicle(control), Sor, and CA IX-C4.16 in Evr-res A498 xenograft tumor. Significant tumor 
growth suppression of combination therapy supports the rationale of using CA IX targeting nano-
formulation as the delivery vehicle of potent drugs, C4.16. The data represented as average values 
from whole four animals in the respective group, bars, SE, significant where *p<0.05 vs. Control. 
(H) Histopathologic (H&E staining) examination to determine the toxicity of therapeutic drugs on 
livers and kidneys at the end of the experiments. Images indicate there is no significant sign of 
necrosis or loss of tissue architectural difference in vehicle control and CA IXC4.16+ Sor treated 
tissues. 
 
5.3.10. Tumor growth inhibition and excellent safety of CA IX-C4.16+Sor in Evr-res tumor. 
After confirming the in vitro anticancer activity, we finally examined the antitumor effect of CA 
IX-C4.16 NP in combination with Sor, to demonstrate the efficacy of combination regimen in 
reversing Evr-resistance in RCC. The CA IX-C4.16 NPs formulation inhibited the viability of WT 
and Evr-res A498 cells in vitro by stimulating various tumoricidal pathways including induction 
of apoptosis, downregulation of pAKT and up-modulation and education of M1-macrophages. As 
shown in Figure 5.9. G, CA IX-C4.16 significantly inhibited highly aggressive Evr-res A498 tumor 
in combination with Sor. The greater tumor growth inhibitory effect of CA IX-C4.16+Sor 
compared to control and individual treatments thus opens an avenue that CA IX-C4.16 nano-
therapy can resurrect Sor as a more efficient anticancer therapeutic agent. Importantly, CA IX-
C4.16+Sor did not cause any necrosis or morphological changes in tissue architecture of normal 
organs such as kidneys and liver (Figure 5.9. J). The superior tumor penetration of CAIX-
oligomer and efficient antitumor effect of CA IX-C4.16+Sor in different RCC tumor model 
underscore a viable strategy for developing a smart therapy against drug resistant tumors 
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with high safety profile. The current findings can support the claim that CA IX-NPs loaded 
with anticancer payload can play a universal role in overcoming drug resistance and repurposing 
current drugs in a more efficient way. 
5.4. Conclusions 
In this study, we have demonstrated elevated expression of CA IX in RCC that qualifies its use as 
an excellent biomarker for targeted therapy and imaging. The combination of C4.16 and Sor have 
a superior synergistic cell killing in Evr-res RCC, which is due in part to activation of caspase 3/7 
protein and complete eradication of oncogenic AKT activation. Combination of CA IX-C4.16 with 
Sor showed targeted delivery of payload in hypoxic tumor resulting in induction of sequential 
anticancer effects including, the resurrection of apoptosis, reversal of drug resistance, and 
reprogramming of malfunction macrophages. This NP could have a direct impact on developing 
newer therapies for treating RCC. We found that CA IX-C4.16 NP is suitable for intravenous 
administration with superior tumor accumulation of CA IX-oligomer as compared to liver and 
demonstrated effective antitumor response in Evr-res A498 tumor. Due to small molecular size 
and ease of chemical functionalization, CA IX-oligomer can potentially be further explored for 
selective CA IX tumor targeting for the diagnostic use and RCC image-guided surgery in the 
clinical setting. The tumor spheroid uptake study has clearly demonstrated excellent tumor core 
penetrating ability of CA IX-targeting oligomer, which is a critical indicator of tumor stromal 
disruption leading to better therapy response and immune modulation. In conclusion, the 
synergistic therapeutic potential of CA IX-C4.16 and Sor combination and selective NIR imaging 
of the CA IX anchored oligomer portend their promising potential towards developing better 
therapeutics and diagnostic tools for clinical translation against deadliest drug resistant RCC. 
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6. CHAPTER 6. SUMMARY AND KEY FINDINGS 
 
6.1. Aim 1  
6.1.1. Summary 
Current treatments for Renal Cell Carcinoma (RCC) include a combination of surgery, targeted 
therapy, and immunotherapy. Emergence of resistant RCCs contributes to failure of drugs and 
poor prognosis, and thus warrants development of new and improved treatment options for RCCs. 
Here we generated and characterized RCC cells that are resistant to Everolimus, a frontline mTOR-
targeted therapy, and tested whether our novel class of CARP-1 functional mimetic (CFM) 
compounds inhibit parental and Everolimus-resistant RCC cells. CFMs inhibited RCC cell 
viability in a dose-dependent manner that was comparable to Everolimus treatments. The GI50 dose 
of Everolimus for parental A498 cells was ~1.2μM while it was <0.02μM for the parental UOK262 
and UOK268 cells. The GI50 dose for Everolimus-resistant A498, UOK262, and UOK268 cells 
were ≥10.0μM, 1.8-7.0μM, and 7.0-≥10.0μM, respectively. CFM-4 and its novel analog CFM-
4.16 inhibited viabilities of Everolimus resistant RCC cells albeit CFM-4.16 was more effective 
than CFM-4. CFM-dependent loos of RCC cell viabilities was due in part to reduced cyclin B1 
levels, activation of pro-apoptotic, stress-activated protein kinases (SAPKs), and apoptosis. CFM-
4.16 suppressed growth of resistant RCC cells in three-dimensional suspension cultures. These 
findings portent promising therapeutic potential of CFM-4.16 in treatment of RCCs. 
6.1.2. Key Findings: 
(1) CARP-1 functional mimetics (CFM 4.16) are a novel small molecule inhibitor of triple-
negative breast cancers, non-small cell lung cancers, and renal cell carcinoma.  
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(2) CFMs induce Apoptosis by activating SAPKs and elevating CARP-1. CARP-1/CCAR1 
interacts with RIPK1, pro-apoptotic adaptor protein FADD, cleaved caspase 8 and is likely a part 
of an intracellular, apoptosis-transducing subcomplex.  
(3) CFMs attenuate biological properties of cancer cell motility, migration, and invasion. 
6.2. Aim 2 
6.2.1.  Summary: 
CFMs are hydrophobic compounds and they have poor aqueous solubility and their dose escalation 
for in-vivo studies remain challenging. In this study, we encapsulated CFM-4.16 in Vitamin-E 
TPGS-based-micellar-nano-formulation that resulted in its higher loading (30% w/w). This CFM-
4.16 nanoformulations inhibited viability of parental and Everolimus-resistant RCC cells in vitro 
and suppressed growth of parental A498 RCC-cell-derived xenografts in part by stimulating 
apoptosis. These findings portent promising therapeutic potential of CFM-4.16 nanoformulations 
in treatment of RCCs. Here we investigated whether the SMA-TPGS nano-formulation of CFM-
4.16 circumvents the solubility concerns of CFM compounds to permit its intravenous 
administration in conducting in vivo studies. Also, the aim is to demonstrate if SMA-TPGS-CFM-
4.16 nanoformulation can produce cancer cells inhibition in different types of cancer. For this 
purpose, we will optimize and characterize novel SMA-TPGS polymeric Nano micelles which 
then will increase water solubility of drug loaded formulation; thus, it will allow intravenous (i.v.) 
administration of the SMA-TPGS-CFM-4.16. Specifically, we aimed to achieve an increased 
serum bioavailability of CFM-4.16 due to administration using nano-formulation, increased nano-
formulation accumulation and retention within the tumor by the EPR effect and therefore an 
increased localized CFM-4.16 concentration in tumor tissues relative to free drug and later 
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producing a marked antitumor response. In this regard, NSCLC, TNBC, and RCC cell lines were 
used to confirm the proof of concept for in-vitro effectiveness of nano micellar formulation of 
CFM analog. The TPGS-based nano-formulation of CFM-4.16 inhibits viability of RCC cells in 
vitro and their growth as xenografted tumors in immunocompromised mice. 
6.2.2. Key Findings 
CARP-1 functional mimetics (CFMs) are novel small molecule inhibitors of RCC. In 
addition, CFMs induce apoptosis by activating SAPKs and elevating CARP-1. In this study, we 
employed a nanotechnology to tackle the poor aqueous solubility of a potent CFM compound 
(CFM-4.16) which restricts its in vivo therapeutic efficacy. This SMA-TPGS-CFM-4.16 
formulation maintained its nanoparticulate nature, homogenous polydispersity and high drug 
encapsulation efficacy. Since free CFM-4.16 or SMA-TPGS-CFM-4.16 elicited similar effects on 
cell viability, and levels of apoptosis would indicate that the anti-cancer effects of CFM-4.16 are 
retained in nanoformulation. Moreover, the physicochemical analyses indicate an optimum release 
of CFM-4.16 from nanoformulation. Together the physicochemical characteristics and biological 
activity of SMA-TPGS-CFM-4.16 seem promising for their use in future pre-clinical in vivo 
studies for the RCC tumor models. 
6.3. Aim 3  
6.3.1. Summary: 
Drug resistance is one of the significant clinical burden in renal cell carcinoma (RCC). The 
development of drug resistance is attributed to many factors, including impairment of apoptosis, 
elevation of carbonic anhydrase IX (CA IX, a marker of tumor hypoxia), and infiltration of 
tumorigenic immune cells. To alleviate the drug resistance, we have used Sorafenib (Sor) in 
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combination with tumor hypoxia directed nanoparticle (NP) loaded with a new class of apoptosis 
inducer, CFM 4.16 (C4.16), namely CA IX-C4.16. The NP is designed to selectively deliver the 
payload to the hypoxic tumor (core), provoke superior cell death in parental (WT) and Everolimus-
resistant (Evr-res) RCC and selectively downmodulate tumorigenic M2-macrophage. Copper-free 
‘click’ chemistry was utilized for conjugating SMA-TPGS with Acetazolamide (ATZ, a CA IX-
specific targeting ligand). The NP was further tagged with a clinically approved NIR dye (S0456) 
for evaluating hypoxic tumor core penetration and organ distribution. Imaging of tumor spheroid 
treated with NIR dye-labeled CA IX-SMA-TPGS revealed remarkable tumor core penetration that 
was modulated by CA IX-mediated targeting in hypoxic-A498 RCC cells. The significant cell 
killing effect with synergistic combination index (CI) of CA IX-C4.16 and Sor for Evr-Resistant 
A498 RCC cells suggests efficient reversal of Evr-resistance. The CA IX directed nanoplatform 
in combination with Sor has shown multiple benefits in overcoming drug resistance through (i) 
inhibition of p-AKT, (ii) upregulation of tumoricidal M1 macrophages resulting in induction of 
caspase 3/7 mediated apoptosis of Evr-res A498 cells in macrophage-RCC co-culturing condition, 
(iii) significant in vitro and in vivo Evr-res A498 tumor growth inhibition as compared to 
individual therapy, and (iv) untraceable liver and kidney toxicity in mice. Near-infrared (NIR) 
imaging of CA IX-SMA-TPGS-S0456 in Evr-res A498 and patient derived tumor xenograft (PDx) 
RCC model exhibited significant accumulation of NP in tumor core with >3-fold higher 
tumor/liver uptake as compared to control. In conclusion, this proof-of-concept study demonstrates 
versatile tumor hypoxia directed nanoplatform that can work in synergy with existing drugs for 
reversing drug-resistance in RCC accompanied with re-education of tumor-associated 
macrophages.   
6.3.2. Key Findings 
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In this study, we have demonstrated elevated expression of CA IX in RCC that qualifies its use as 
an excellent biomarker for targeted therapy and imaging. The combination of C4.16 and Sor have 
a superior synergistic cell killing in Evr-res RCC, which is due in part to activation of caspase 3/7 
protein and complete eradication of oncogenic AKT activation. Combination of CA IX-C4.16 with 
Sor showed targeted delivery of payload in hypoxic tumor resulting in induction of sequential 
anticancer effects including, the resurrection of apoptosis, reversal of drug resistance, and 
reprogramming of malfunction macrophages. This NP could have a direct impact on developing 
newer therapies for treating RCC. We found that CA IX-C4.16 NP is suitable for intravenous 
administration with superior tumor accumulation of CA IX-oligomer as compared to liver and 
demonstrated effective antitumor response in Evr-res A498 tumor. The tumor spheroid uptake 
study has clearly demonstrated excellent tumor core penetrating ability of CA IX-targeting 
oligomer, which is a critical indicator of tumor stromal disruption leading to better therapy 
response and immune modulation against deadliest drug resistant RCC. 
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APPENDIX 
 
 
 
Appendix Figure 7.1. CFMs inhibit RCC cell growth. We treated noted cell lines either with DMSO 
(Control), with various CFMs (A, B) for indicated dose and time. We determined cell viability by MTT 
assay. The data in the histograms represent means of three independent experiments with 4-6 replicates for 
each treatment; bars, S.E. A-D, @,#,&,*, E-F, α,β,γ,δ, statistically significant inhibition (p = <0.05) relative 
to DMSO-treated respective controls. Adapted from 1. 
 
A B 
UOK 262 HLRCC Cells UOK 268 HLRCC Cells 
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Appendix Figure 7.2. CFM-4. 16 stimulates apoptosis in parental and Everolimus-resistant 
RCC cells in part by upregulating pro-apoptotic CARP-1 and activating SAPKs. (A, B) Indicated 
RCC cells were either untreated (Control, denoted as 0), treated with CFM-4, or CFM-4.16 for noted dose 
and time. Cell lysates were analyzed by western blotting (WB) as in Methods for levels of CARP-1, cyclin 
B1, cleaved PARP and caspase-8, and activation (phosphorylation) of pro-apoptotic p38 and JNK1/2 
SAPKs. The western blot membranes were probed with anti-actin antibodies to assess protein loading. 
Adapted from 1. 
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Appendix Figure 7.2. (continued) CFM-4. 16 stimulates apoptosis in parental and Everolimus-
resistant RCC cells in part by upregulating pro-apoptotic CARP-1 and activating SAPKs. (C-E) 
Parental or Everolimus-resistant RCC cells were either untreated (Control), treated with Everolimus, CFM-
4, or CFM-4.16 for noted dose and time. Cell lysates were analyzed by Western blotting (WB) for 
expression and/or activation of Akt, SAPKs, Cyclin B1, PARP, and CARP-1. The western blot membranes 
in panels C-E were probed with anti-actin antibodies to assess protein loading. Adapted from 1. 
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Appendix Figure 7.3. Knockdown of CARP-1 blocks CFM-4.16 effects. (A) Cells were either 
untransfected, transfected with the pcDNA3/Hygro vector plasmid or plasmid expressing CARP-1 
antisense, and stable, hygromycin-resistant cells were generated and characterized as detailed in methods. 
Cell lysates from indicated stable cell lines were subjected to WB analysis as in figure 3 for levels of CARP-
1 and α-tubulin. (B)  The Indicated vector or CARP-1 antisense expressing RCC sublines were either 
untreated (Control) or treated with noted doses of CFM-4, or CFM-4.16 for 24h. Cell viability was 
determined by MTT assay. The histogram columns represent means of three independent experiments; bars, 
S.E. α, β, , , p = <0.05 relative to the vector expressing subline treated with CFM-4.16 only. Adapted 
from 1. 
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Appendix Figure 7.4. Triple negative cancer cells (MDA-MB468), lung cancer cells (A549) and 
renal cancer cells (A 498 and UOK 262) were treated with the indicated doses for 24 hours.  The 
number of viable cells were then determined by MTT assay as described.  
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Appendix Figure 7.5. Scheme 1 and 2 indicate the general procedure for acetazolamide-oligomer 
fragment synthesis. Scheme 3 indicates the preparation of OMs with C-4.16 and mechanism of 
CA IX receptor mediated internalization of OMs in RCC. 
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Appendix Figure 7.6. Oligomicelles formulation and characterization. (A) Hydrodynamic size of 
targeted CA IX-C4.16 OMs and non-targeted SMA-TPGS-C-4.16 OMs and (B) Zeta potential by 
Dynamic Light Scattering (DLS) are shown. (C) The morphology of representative OMs is 
characterized by TEM as shown. Scale bar = 100 nm. (D and E) MALDI-MS analysis of ATZ-
SMA-TPGS and SMA-TPGS are shown. The increment of m/z value in ATZ-SMA-TPGS (m/z 
2239.1) compared to SMA-TPGS(m/z1565.6) oligomers indicates the successful conjugation of 
ATZ to the SMA-TPGS polymers.  
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Appendix Figure 7.7. Overexpression of CA IX protein in A498 RCC cells and xenograft 
model. (A) Immunohistochemistry of CA IX positive A498 renal cell carcinoma tumor xenografts 
collected from tumor tissue section is shown. The intense bright green fluorescence indicates the 
rationale of choosing CA IX as an excellent RCC targeted therapy. (B) Western blot detection of 
CA IX protein in A498 and EV-A498 RCC cells lysates after normoxia (no cobalt chloride 
treatment) and hypoxia (treated with cobalt chloride for 72 hrs to induce hypoxia) are shown. The 
fold up-regulation of CA IX   expression in hypoxic WT and EV-res A498 RCC cells than normoxia 
provides a solid foundation for delivering the payload into oxygen deprived regions and hypoxic 
core of RCC tumor.  
 
IHC FOR CA-IX Expression of A498 Tumor-confocal microscopy  
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Appendix Figure 7.8. 3D spheroid uptake studies of hypoxia targeted-oligomer. Confocal 
microscope images of ATZ-oligomer conjugated with rhodamine B and treated with hypoxic A498 
RCC cells -spheroid indicates tumor matrix penetration of CA IX targeted oligomicelles. The 
untreated and treated spheres were then photographed as noted in methods section. Z-stacking 
of the spheroid (A-D) clearly indicates that fluorescence intensity is superior in 40-60 µm section. 
The highest fluorescence intensity at the center (as indicated by arrow) of 3D- plot (E) suggests 
that CA IX-Rhod oligomer is highly efficient to reach deep into the core of the tumor spheroid. (F) 
Z-stacking of the spheroid at different sections from 10-100 m with CA IX targeted formulations 
also reveals similar findings as noted for the 40-60 µm that had superior fluorescence intensity. 
Figure (G) shows the untreated control experiments in comparison with CA IX-Rhod oligomer and 
Figure (H) shows the overall shape of the spheroid from along the three dimensions (x, y, and z).  
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Appendix Figure 7.9. C-4.16 inhibits growth of RCC cell lines  derived from WT and Everolimus-
resistant cells. Cell cultures studies and in vitro cytotoxicity assay of C-4.16, sorafenib, Everolimus on 
(WT and Evr-Res) A498 and UOK-262 RCC cell lines. (A, B, and C) Cytotoxicity data indicates C-4.16 
was more potent than FDA approved drugs (sorafenib and everolimus) in WT A498 and (D, E, and F) WT 
UOK262. Also, cell cultures studies results on EV-res A498 RCC cell lines (G and H) indicates that C-
4.16 was more effective in inhibiting growth of Evr-res A498 RCC cell lines than sorafenib; however, 
Everolimus is not inhibiting the growth of Evr-res A498 and UOK262 RCC cell lines as previously 
published [14]. The data in the GI50 columns represent mean of three independent experiments. Indicated 
parental and their respective drug resistant RCC cells were either untreated (Control) or treated with noted 
doses of  C-4.16 and sorafenib for 48h.  
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Appendix Figure 7.10. High synergistic CI value of C-4.16 with sorafenib combination 
supports the hypothesis of selecting the combination to RCC treatment using hypoxia 
targeting OMs. (A) Combining very low doses of both drugs will lower the IC50 value significantly 
as in (D) which shows the combination index plot for C-4.16 plus sorafenib in the cells for both 
types A498 RCC cell lines indicates very strong synergism between sorafenib and C-4.16. (B) 
The results also show that CA IX-C-4.16 was more effective in inhibiting growth of A498 (WT and 
Ev-res) and to less extent (C) UOK262 (WT and Ev-res) RCC cell lines than sorafenib and Ev 
and support that C-4.16 was more potent than FDA approved drugs (sorafenib and everolimus). 
(D) We summarized IC50 value table for all drugs with all the above mentioned RCC cell lines. (E) 
In vitro cytotoxicity assay of CA IX-C4.16 (500 nM) in combination with different doses of sorafenib 
on Ev-res A498 RCC cell lines indicates that low dose of C-4.16-OMs sensitize sorafenib for 
inhibiting growth of RCC cell line.   
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Appendix Figure 7.11. Antitumor efficacy study of combination therapy and NIR imaging of CA IX 
targeted oligomer in RCC xenografts tumor. (A) Tumor growth inhibition effect of (CA IX-C-
4.16+SOR) is significantly higher compared to vehicle(control), SOR, and CA IX-C-4.16 in A498 
xenograft tumor. Significant tumor growth suppression of combination therapy supports the rational of 
using CA IX targeting nano-formulation as delivery vehicle of potent drugs, C-4.16. The data represent as 
average values from total four animals in respective group, bars, SE, significant where *p<0.05 vs Control. 
(B) Histopathologic (H&E staining) examination to determine the toxicity of therapeutic drugs on livers 
and kidneys at the end of the experiments. Images indicate there is no significant sign of necrosis, or loss 
of tissue architectural difference in vehicle control and CA IX-C-4.16 treated tissues. (C-F) CA IX negative 
(UOK262) tumor treated with CA IX-S0456 oligomers shows high off-target effect and low tumor 
specificity. (E) UOK 262 and A498 tumor were inoculated on the circled parts. (F-I) CA IX positive (A498) 
tumor treated with hypoxia targeted-NIR oligomer shows high tumor targetability and low non-specific 
healthy organ uptake after 24 hrs of post injection suggesting the importance of CA IX for selective tumor 
imaging for RCC tumor model after 24 hrs indicates high fluorescence intensity at the tumor compared to 
liver and other organs. 
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Appendix Figure 7.12. Compounds were characterized by 1H-NMR to assure chemical identity 
(Supplementary, S1 A-C). SMA-TPGS-PEG-Azid and ATZ-DBCO conjugates indicates the successful 
conjugation of ATZ to the SMA-TPGS polymers. 1H-NMR results confirmed the triazole ring formation as 
some characteristic peaks were found such as H-triazole ring around 7.9 ppm, O-CH2 of triazole ring around 
5.2 ppm, and CH2-N3 peak around 4.2 ppm. 
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Appendix Figure 7.13. In vitro cytotoxicity assay of CA IX-C4.16 (500 nM) in combination with different 
doses of sorafenib on Ev-res A498 RCC cell lines indicates that low dose of CA IX-C4.16 NPs sensitize 
sorafenib for inhibiting growth of RCC cell line. 
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PARTICLE SIZE DISTRIBUTION 
 
Appendix Figure 7.14. Particle size of NFs and the particle size distribution from DLS. 
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Appendix Figure 7.15. M1/M2 Activation procedure. 
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ABSTRACT 
TUMOR MULTICOMPONENT TARGETING POLYMER-LIPID HYBRID 
NANOPARTICLES TO OVERCOME DRUG RESISTANCE IN RENAL CELL 
CARCINOMA 
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Advisor: Dr. Arun K. Iyer 
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Degree: Doctor of Philosophy 
Renal Cell Carcinoma (RCC) contributes to more than 90% of the most common form of 
kidney tumor and remains one of the ten leading causes of cancer death in the United States. 
Although surgery remains an option for operable tumors, high metastatic index and resistance to 
radiation and chemotherapies prompted recent development of therapeutics that target the RCC 
angiogenesis and cell proliferation pathways. Eventually, new strategies with encouraging results 
have emerged that include immunotherapy, such as the programmed death-1 inhibitor 
(Nivolumab), cytokines, and a combination of chemo-immune therapy. Thus, developing 
alternative strategies with effective treatment options remains an urgent unmet need for therapy-
resistant RCC. In this regard, combination treatment targeting different cancer survival pathway 
of tumor microenvironment can be advantageous. Along these lines, we have pursued different 
combination drug regimens, including inhibitors that target mTOR (everolimus) and RTK or 
VEGFR (cabozantinib or sorafenib), as possible treatment strategies. In addition, we explored the 
rational design of nanoparticles to selectively deliver a variety of therapeutic payloads to target 
hypoxic tumor microenvironment overexpressing carbonic anhydrase-IX (CA IX). Our strategy 
involved establishing a library of tumor penetrating nanocarriers carrying combination drug 
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payload of RTK-inhibitor with our own apoptosis inducer/CARP-1 protein functional mimetics 
(CFM-4.16). Nano-carriers were tailored to have varying composition and size that could: (i) 
efficiently reach the tumor core; (ii) target tumor multi-components including cancer epithelial 
cells and tumor-associated macrophages (TAM) for overcoming drug resistance in RCC. 
Specifically, the current work was focused on multimodal approaches, including (a) Optimization 
of hypoxia marker (CA IX) targeted polymer-lipid nano-formulation (PLNP) using copper-free 
‘click’ chemistry; (b) In vitro and in vivo pre-clinical imaging and therapy of PLNP loaded with 
multiple drugs in inhibiting RCCs using mice bearing resistant RCCs and human cancer mimicking 
patient-derived xenografts (PDx). The results of antitumor efficacy and biodistribution of targeted 
PLNPs in animals bearing RCC xenograft and PDx models revealed selective accumulation of 
drugs at tumor sites resulting in greater tumor growth inhibition with reduced side effects. These 
findings portent promising therapeutic potentials for our newly developed hypoxia-targeted-
PLNPs loaded with CFM-4.16 in combination with RTK-inhibitor for effective RCC therapy in 
the clinic. 
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